BindingDB Reactant_set_id Ligand SMILES Ligand InChI Ligand InChI Key BindingDB MonomerID BindingDB Ligand Name Target Name Target Source Organism According to Curator or DataSource Ki (nM) IC50 (nM) Kd (nM) EC50 (nM) kon (M-1-s-1) koff (s-1) pH Temp (C) Curation/DataSource Article DOI BindingDB Entry DOI PMID PubChem AID Patent Number Authors Date of publication Date in BindingDB Institution Link to Ligand in BindingDB Link to Target in BindingDB Link to Ligand-Target Pair in BindingDB Ligand HET ID in PDB PDB ID(s) for Ligand-Target Complex PubChem CID PubChem SID ChEBI ID of Ligand ChEMBL ID of Ligand DrugBank ID of Ligand IUPHAR_GRAC ID of Ligand KEGG ID of Ligand ZINC ID of Ligand Number of Protein Chains in Target (>1 implies a multichain complex) BindingDB Target Chain Sequence 1 PDB ID(s) of Target Chain 1 UniProt (SwissProt) Recommended Name of Target Chain 1 UniProt (SwissProt) Entry Name of Target Chain 1 UniProt (SwissProt) Primary ID of Target Chain 1 UniProt (SwissProt) Secondary ID(s) of Target Chain 1 UniProt (SwissProt) Alternative ID(s) of Target Chain 1 UniProt (TrEMBL) Submitted Name of Target Chain 1 UniProt (TrEMBL) Entry Name of Target Chain 1 UniProt (TrEMBL) Primary ID of Target Chain 1 UniProt (TrEMBL) Secondary ID(s) of Target Chain 1 UniProt (TrEMBL) Alternative ID(s) of Target Chain 1 BindingDB Target Chain Sequence 2 PDB ID(s) of Target Chain 2 UniProt (SwissProt) Recommended Name of Target Chain 2 UniProt (SwissProt) Entry Name of Target Chain 2 UniProt (SwissProt) Primary ID of Target Chain 2 UniProt (SwissProt) Secondary ID(s) of Target Chain 2 UniProt (SwissProt) Alternative ID(s) of Target Chain 2 UniProt (TrEMBL) Submitted Name of Target Chain 2 UniProt (TrEMBL) Entry Name of Target Chain 2 UniProt (TrEMBL) Primary ID of Target Chain 2 UniProt (TrEMBL) Secondary ID(s) of Target Chain 2 UniProt (TrEMBL) Alternative ID(s) of Target Chain 2 BindingDB Target Chain Sequence 3 PDB ID(s) of Target Chain 3 UniProt (SwissProt) Recommended Name of Target Chain 3 UniProt (SwissProt) Entry Name of Target Chain 3 UniProt (SwissProt) Primary ID of Target Chain 3 UniProt (SwissProt) Secondary ID(s) of Target Chain 3 UniProt (SwissProt) Alternative ID(s) of Target Chain 3 UniProt (TrEMBL) Submitted Name of Target Chain 3 UniProt (TrEMBL) Entry Name of Target Chain 3 UniProt (TrEMBL) Primary ID of Target Chain 3 UniProt (TrEMBL) Secondary ID(s) of Target Chain 3 UniProt (TrEMBL) Alternative ID(s) of Target Chain 3 BindingDB Target Chain Sequence 4 PDB ID(s) of Target Chain 4 UniProt (SwissProt) Recommended Name of Target Chain 4 UniProt (SwissProt) Entry Name of Target Chain 4 UniProt (SwissProt) Primary ID of Target Chain 4 UniProt (SwissProt) Secondary ID(s) of Target Chain 4 UniProt (SwissProt) Alternative ID(s) of Target Chain 4 UniProt (TrEMBL) Submitted Name of Target Chain 4 UniProt (TrEMBL) Entry Name of Target Chain 4 UniProt (TrEMBL) Primary ID of Target Chain 4 UniProt (TrEMBL) Secondary ID(s) of Target Chain 4 UniProt (TrEMBL) Alternative ID(s) of Target Chain 4 BindingDB Target Chain Sequence 5 PDB ID(s) of Target Chain 5 UniProt (SwissProt) Recommended Name of Target Chain 5 UniProt (SwissProt) Entry Name of Target Chain 5 UniProt (SwissProt) Primary ID of Target Chain 5 UniProt (SwissProt) Secondary ID(s) of Target Chain 5 UniProt (SwissProt) Alternative ID(s) of Target Chain 5 UniProt (TrEMBL) Submitted Name of Target Chain 5 UniProt (TrEMBL) Entry Name of Target Chain 5 UniProt (TrEMBL) Primary ID of Target Chain 5 UniProt (TrEMBL) Secondary ID(s) of Target Chain 5 UniProt (TrEMBL) Alternative ID(s) of Target Chain 5 BindingDB Target Chain Sequence 6 PDB ID(s) of Target Chain 6 UniProt (SwissProt) Recommended Name of Target Chain 6 UniProt (SwissProt) Entry Name of Target Chain 6 UniProt (SwissProt) Primary ID of Target Chain 6 UniProt (SwissProt) Secondary ID(s) of Target Chain 6 UniProt (SwissProt) Alternative ID(s) of Target Chain 6 UniProt (TrEMBL) Submitted Name of Target Chain 6 UniProt (TrEMBL) Entry Name of Target Chain 6 UniProt (TrEMBL) Primary ID of Target Chain 6 UniProt (TrEMBL) Secondary ID(s) of Target Chain 6 UniProt (TrEMBL) Alternative ID(s) of Target Chain 6 BindingDB Target Chain Sequence 7 PDB ID(s) of Target Chain 7 UniProt (SwissProt) Recommended Name of Target Chain 7 UniProt (SwissProt) Entry Name of Target Chain 7 UniProt (SwissProt) Primary ID of Target Chain 7 UniProt (SwissProt) Secondary ID(s) of Target Chain 7 UniProt (SwissProt) Alternative ID(s) of Target Chain 7 UniProt (TrEMBL) Submitted Name of Target Chain 7 UniProt (TrEMBL) Entry Name of Target Chain 7 UniProt (TrEMBL) Primary ID of Target Chain 7 UniProt (TrEMBL) Secondary ID(s) of Target Chain 7 UniProt (TrEMBL) Alternative ID(s) of Target Chain 7 BindingDB Target Chain Sequence 8 PDB ID(s) of Target Chain 8 UniProt (SwissProt) Recommended Name of Target Chain 8 UniProt (SwissProt) Entry Name of Target Chain 8 UniProt (SwissProt) Primary ID of Target Chain 8 UniProt (SwissProt) Secondary ID(s) of Target Chain 8 UniProt (SwissProt) Alternative ID(s) of Target Chain 8 UniProt (TrEMBL) Submitted Name of Target Chain 8 UniProt (TrEMBL) Entry Name of Target Chain 8 UniProt (TrEMBL) Primary ID of Target Chain 8 UniProt (TrEMBL) Secondary ID(s) of Target Chain 8 UniProt (TrEMBL) Alternative ID(s) of Target Chain 8 BindingDB Target Chain Sequence 9 PDB ID(s) of Target Chain 9 UniProt (SwissProt) Recommended Name of Target Chain 9 UniProt (SwissProt) Entry Name of Target Chain 9 UniProt (SwissProt) Primary ID of Target Chain 9 UniProt (SwissProt) Secondary ID(s) of Target Chain 9 UniProt (SwissProt) Alternative ID(s) of Target Chain 9 UniProt (TrEMBL) Submitted Name of Target Chain 9 UniProt (TrEMBL) Entry Name of Target Chain 9 UniProt (TrEMBL) Primary ID of Target Chain 9 UniProt (TrEMBL) Secondary ID(s) of Target Chain 9 UniProt (TrEMBL) Alternative ID(s) of Target Chain 9 BindingDB Target Chain Sequence 10 PDB ID(s) of Target Chain 10 UniProt (SwissProt) Recommended Name of Target Chain 10 UniProt (SwissProt) Entry Name of Target Chain 10 UniProt (SwissProt) Primary ID of Target Chain 10 UniProt (SwissProt) Secondary ID(s) of Target Chain 10 UniProt (SwissProt) Alternative ID(s) of Target Chain 10 UniProt (TrEMBL) Submitted Name of Target Chain 10 UniProt (TrEMBL) Entry Name of Target Chain 10 UniProt (TrEMBL) Primary ID of Target Chain 10 UniProt (TrEMBL) Secondary ID(s) of Target Chain 10 UniProt (TrEMBL) Alternative ID(s) of Target Chain 10 BindingDB Target Chain Sequence 11 PDB ID(s) of Target Chain 11 UniProt (SwissProt) Recommended Name of Target Chain 11 UniProt (SwissProt) Entry Name of Target Chain 11 UniProt (SwissProt) Primary ID of Target Chain 11 UniProt (SwissProt) Secondary ID(s) of Target Chain 11 UniProt (SwissProt) Alternative ID(s) of Target Chain 11 UniProt (TrEMBL) Submitted Name of Target Chain 11 UniProt (TrEMBL) Entry Name of Target Chain 11 UniProt (TrEMBL) Primary ID of Target Chain 11 UniProt (TrEMBL) Secondary ID(s) of Target Chain 11 UniProt (TrEMBL) Alternative ID(s) of Target Chain 11 BindingDB Target Chain Sequence 12 PDB ID(s) of Target Chain 12 UniProt (SwissProt) Recommended Name of Target Chain 12 UniProt (SwissProt) Entry Name of Target Chain 12 UniProt (SwissProt) Primary ID of Target Chain 12 UniProt (SwissProt) Secondary ID(s) of Target Chain 12 UniProt (SwissProt) Alternative ID(s) of Target Chain 12 UniProt (TrEMBL) Submitted Name of Target Chain 12 UniProt (TrEMBL) Entry Name of Target Chain 12 UniProt (TrEMBL) Primary ID of Target Chain 12 UniProt (TrEMBL) Secondary ID(s) of Target Chain 12 UniProt (TrEMBL) Alternative ID(s) of Target Chain 12 BindingDB Target Chain Sequence 13 PDB ID(s) of Target Chain 13 UniProt (SwissProt) Recommended Name of Target Chain 13 UniProt (SwissProt) Entry Name of Target Chain 13 UniProt (SwissProt) Primary ID of Target Chain 13 UniProt (SwissProt) Secondary ID(s) of Target Chain 13 UniProt (SwissProt) Alternative ID(s) of Target Chain 13 UniProt (TrEMBL) Submitted Name of Target Chain 13 UniProt (TrEMBL) Entry Name of Target Chain 13 UniProt (TrEMBL) Primary ID of Target Chain 13 UniProt (TrEMBL) Secondary ID(s) of Target Chain 13 UniProt (TrEMBL) Alternative ID(s) of Target Chain 13 BindingDB Target Chain Sequence 14 PDB ID(s) of Target Chain 14 UniProt (SwissProt) Recommended Name of Target Chain 14 UniProt (SwissProt) Entry Name of Target Chain 14 UniProt (SwissProt) Primary ID of Target Chain 14 UniProt (SwissProt) Secondary ID(s) of Target Chain 14 UniProt (SwissProt) Alternative ID(s) of Target Chain 14 UniProt (TrEMBL) Submitted Name of Target Chain 14 UniProt (TrEMBL) Entry Name of Target Chain 14 UniProt (TrEMBL) Primary ID of Target Chain 14 UniProt (TrEMBL) Secondary ID(s) of Target Chain 14 UniProt (TrEMBL) Alternative ID(s) of Target Chain 14 BindingDB Target Chain Sequence 15 PDB ID(s) of Target Chain 15 UniProt (SwissProt) Recommended Name of Target Chain 15 UniProt (SwissProt) Entry Name of Target Chain 15 UniProt (SwissProt) Primary ID of Target Chain 15 UniProt (SwissProt) Secondary ID(s) of Target Chain 15 UniProt (SwissProt) Alternative ID(s) of Target Chain 15 UniProt (TrEMBL) Submitted Name of Target Chain 15 UniProt (TrEMBL) Entry Name of Target Chain 15 UniProt (TrEMBL) Primary ID of Target Chain 15 UniProt (TrEMBL) Secondary ID(s) of Target Chain 15 UniProt (TrEMBL) Alternative ID(s) of Target Chain 15 BindingDB Target Chain Sequence 16 PDB ID(s) of Target Chain 16 UniProt (SwissProt) Recommended Name of Target Chain 16 UniProt (SwissProt) Entry Name of Target Chain 16 UniProt (SwissProt) Primary ID of Target Chain 16 UniProt (SwissProt) Secondary ID(s) of Target Chain 16 UniProt (SwissProt) Alternative ID(s) of Target Chain 16 UniProt (TrEMBL) Submitted Name of Target Chain 16 UniProt (TrEMBL) Entry Name of Target Chain 16 UniProt (TrEMBL) Primary ID of Target Chain 16 UniProt (TrEMBL) Secondary ID(s) of Target Chain 16 UniProt (TrEMBL) Alternative ID(s) of Target Chain 16 BindingDB Target Chain Sequence 17 PDB ID(s) of Target Chain 17 UniProt (SwissProt) Recommended Name of Target Chain 17 UniProt (SwissProt) Entry Name of Target Chain 17 UniProt (SwissProt) Primary ID of Target Chain 17 UniProt (SwissProt) Secondary ID(s) of Target Chain 17 UniProt (SwissProt) Alternative ID(s) of Target Chain 17 UniProt (TrEMBL) Submitted Name of Target Chain 17 UniProt (TrEMBL) Entry Name of Target Chain 17 UniProt (TrEMBL) Primary ID of Target Chain 17 UniProt (TrEMBL) Secondary ID(s) of Target Chain 17 UniProt (TrEMBL) Alternative ID(s) of Target Chain 17 BindingDB Target Chain Sequence 18 PDB ID(s) of Target Chain 18 UniProt (SwissProt) Recommended Name of Target Chain 18 UniProt (SwissProt) Entry Name of Target Chain 18 UniProt (SwissProt) Primary ID of Target Chain 18 UniProt (SwissProt) Secondary ID(s) of Target Chain 18 UniProt (SwissProt) Alternative ID(s) of Target Chain 18 UniProt (TrEMBL) Submitted Name of Target Chain 18 UniProt (TrEMBL) Entry Name of Target Chain 18 UniProt (TrEMBL) Primary ID of Target Chain 18 UniProt (TrEMBL) Secondary ID(s) of Target Chain 18 UniProt (TrEMBL) Alternative ID(s) of Target Chain 18 BindingDB Target Chain Sequence 19 PDB ID(s) of Target Chain 19 UniProt (SwissProt) Recommended Name of Target Chain 19 UniProt (SwissProt) Entry Name of Target Chain 19 UniProt (SwissProt) Primary ID of Target Chain 19 UniProt (SwissProt) Secondary ID(s) of Target Chain 19 UniProt (SwissProt) Alternative ID(s) of Target Chain 19 UniProt (TrEMBL) Submitted Name of Target Chain 19 UniProt (TrEMBL) Entry Name of Target Chain 19 UniProt (TrEMBL) Primary ID of Target Chain 19 UniProt (TrEMBL) Secondary ID(s) of Target Chain 19 UniProt (TrEMBL) Alternative ID(s) of Target Chain 19 BindingDB Target Chain Sequence 20 PDB ID(s) of Target Chain 20 UniProt (SwissProt) Recommended Name of Target Chain 20 UniProt (SwissProt) Entry Name of Target Chain 20 UniProt (SwissProt) Primary ID of Target Chain 20 UniProt (SwissProt) Secondary ID(s) of Target Chain 20 UniProt (SwissProt) Alternative ID(s) of Target Chain 20 UniProt (TrEMBL) Submitted Name of Target Chain 20 UniProt (TrEMBL) Entry Name of Target Chain 20 UniProt (TrEMBL) Primary ID of Target Chain 20 UniProt (TrEMBL) Secondary ID(s) of Target Chain 20 UniProt (TrEMBL) Alternative ID(s) of Target Chain 20 BindingDB Target Chain Sequence 21 PDB ID(s) of Target Chain 21 UniProt (SwissProt) Recommended Name of Target Chain 21 UniProt (SwissProt) Entry Name of Target Chain 21 UniProt (SwissProt) Primary ID of Target Chain 21 UniProt (SwissProt) Secondary ID(s) of Target Chain 21 UniProt (SwissProt) Alternative ID(s) of Target Chain 21 UniProt (TrEMBL) Submitted Name of Target Chain 21 UniProt (TrEMBL) Entry Name of Target Chain 21 UniProt (TrEMBL) Primary ID of Target Chain 21 UniProt (TrEMBL) Secondary ID(s) of Target Chain 21 UniProt (TrEMBL) Alternative ID(s) of Target Chain 21 BindingDB Target Chain Sequence 22 PDB ID(s) of Target Chain 22 UniProt (SwissProt) Recommended Name of Target Chain 22 UniProt (SwissProt) Entry Name of Target Chain 22 UniProt (SwissProt) Primary ID of Target Chain 22 UniProt (SwissProt) Secondary ID(s) of Target Chain 22 UniProt (SwissProt) Alternative ID(s) of Target Chain 22 UniProt (TrEMBL) Submitted Name of Target Chain 22 UniProt (TrEMBL) Entry Name of Target Chain 22 UniProt (TrEMBL) Primary ID of Target Chain 22 UniProt (TrEMBL) Secondary ID(s) of Target Chain 22 UniProt (TrEMBL) Alternative ID(s) of Target Chain 22 BindingDB Target Chain Sequence 23 PDB ID(s) of Target Chain 23 UniProt (SwissProt) Recommended Name of Target Chain 23 UniProt (SwissProt) Entry Name of Target Chain 23 UniProt (SwissProt) Primary ID of Target Chain 23 UniProt (SwissProt) Secondary ID(s) of Target Chain 23 UniProt (SwissProt) Alternative ID(s) of Target Chain 23 UniProt (TrEMBL) Submitted Name of Target Chain 23 UniProt (TrEMBL) Entry Name of Target Chain 23 UniProt (TrEMBL) Primary ID of Target Chain 23 UniProt (TrEMBL) Secondary ID(s) of Target Chain 23 UniProt (TrEMBL) Alternative ID(s) of Target Chain 23 BindingDB Target Chain Sequence 24 PDB ID(s) of Target Chain 24 UniProt (SwissProt) Recommended Name of Target Chain 24 UniProt (SwissProt) Entry Name of Target Chain 24 UniProt (SwissProt) Primary ID of Target Chain 24 UniProt (SwissProt) Secondary ID(s) of Target Chain 24 UniProt (SwissProt) Alternative ID(s) of Target Chain 24 UniProt (TrEMBL) Submitted Name of Target Chain 24 UniProt (TrEMBL) Entry Name of Target Chain 24 UniProt (TrEMBL) Primary ID of Target Chain 24 UniProt (TrEMBL) Secondary ID(s) of Target Chain 24 UniProt (TrEMBL) Alternative ID(s) of Target Chain 24 BindingDB Target Chain Sequence 25 PDB ID(s) of Target Chain 25 UniProt (SwissProt) Recommended Name of Target Chain 25 UniProt (SwissProt) Entry Name of Target Chain 25 UniProt (SwissProt) Primary ID of Target Chain 25 UniProt (SwissProt) Secondary ID(s) of Target Chain 25 UniProt (SwissProt) Alternative ID(s) of Target Chain 25 UniProt (TrEMBL) Submitted Name of Target Chain 25 UniProt (TrEMBL) Entry Name of Target Chain 25 UniProt (TrEMBL) Primary ID of Target Chain 25 UniProt (TrEMBL) Secondary ID(s) of Target Chain 25 UniProt (TrEMBL) Alternative ID(s) of Target Chain 25 BindingDB Target Chain Sequence 26 PDB ID(s) of Target Chain 26 UniProt (SwissProt) Recommended Name of Target Chain 26 UniProt (SwissProt) Entry Name of Target Chain 26 UniProt (SwissProt) Primary ID of Target Chain 26 UniProt (SwissProt) Secondary ID(s) of Target Chain 26 UniProt (SwissProt) Alternative ID(s) of Target Chain 26 UniProt (TrEMBL) Submitted Name of Target Chain 26 UniProt (TrEMBL) Entry Name of Target Chain 26 UniProt (TrEMBL) Primary ID of Target Chain 26 UniProt (TrEMBL) Secondary ID(s) of Target Chain 26 UniProt (TrEMBL) Alternative ID(s) of Target Chain 26 BindingDB Target Chain Sequence 27 PDB ID(s) of Target Chain 27 UniProt (SwissProt) Recommended Name of Target Chain 27 UniProt (SwissProt) Entry Name of Target Chain 27 UniProt (SwissProt) Primary ID of Target Chain 27 UniProt (SwissProt) Secondary ID(s) of Target Chain 27 UniProt (SwissProt) Alternative ID(s) of Target Chain 27 UniProt (TrEMBL) Submitted Name of Target Chain 27 UniProt (TrEMBL) Entry Name of Target Chain 27 UniProt (TrEMBL) Primary ID of Target Chain 27 UniProt (TrEMBL) Secondary ID(s) of Target Chain 27 UniProt (TrEMBL) Alternative ID(s) of Target Chain 27 BindingDB Target Chain Sequence 28 PDB ID(s) of Target Chain 28 UniProt (SwissProt) Recommended Name of Target Chain 28 UniProt (SwissProt) Entry Name of Target Chain 28 UniProt (SwissProt) Primary ID of Target Chain 28 UniProt (SwissProt) Secondary ID(s) of Target Chain 28 UniProt (SwissProt) Alternative ID(s) of Target Chain 28 UniProt (TrEMBL) Submitted Name of Target Chain 28 UniProt (TrEMBL) Entry Name of Target Chain 28 UniProt (TrEMBL) Primary ID of Target Chain 28 UniProt (TrEMBL) Secondary ID(s) of Target Chain 28 UniProt (TrEMBL) Alternative ID(s) of Target Chain 28 BindingDB Target Chain Sequence 29 PDB ID(s) of Target Chain 29 UniProt (SwissProt) Recommended Name of Target Chain 29 UniProt (SwissProt) Entry Name of Target Chain 29 UniProt (SwissProt) Primary ID of Target Chain 29 UniProt (SwissProt) Secondary ID(s) of Target Chain 29 UniProt (SwissProt) Alternative ID(s) of Target Chain 29 UniProt (TrEMBL) Submitted Name of Target Chain 29 UniProt (TrEMBL) Entry Name of Target Chain 29 UniProt (TrEMBL) Primary ID of Target Chain 29 UniProt (TrEMBL) Secondary ID(s) of Target Chain 29 UniProt (TrEMBL) Alternative ID(s) of Target Chain 29 BindingDB Target Chain Sequence 30 PDB ID(s) of Target Chain 30 UniProt (SwissProt) Recommended Name of Target Chain 30 UniProt (SwissProt) Entry Name of Target Chain 30 UniProt (SwissProt) Primary ID of Target Chain 30 UniProt (SwissProt) Secondary ID(s) of Target Chain 30 UniProt (SwissProt) Alternative ID(s) of Target Chain 30 UniProt (TrEMBL) Submitted Name of Target Chain 30 UniProt (TrEMBL) Entry Name of Target Chain 30 UniProt (TrEMBL) Primary ID of Target Chain 30 UniProt (TrEMBL) Secondary ID(s) of Target Chain 30 UniProt (TrEMBL) Alternative ID(s) of Target Chain 30 BindingDB Target Chain Sequence 31 PDB ID(s) of Target Chain 31 UniProt (SwissProt) Recommended Name of Target Chain 31 UniProt (SwissProt) Entry Name of Target Chain 31 UniProt (SwissProt) Primary ID of Target Chain 31 UniProt (SwissProt) Secondary ID(s) of Target Chain 31 UniProt (SwissProt) Alternative ID(s) of Target Chain 31 UniProt (TrEMBL) Submitted Name of Target Chain 31 UniProt (TrEMBL) Entry Name of Target Chain 31 UniProt (TrEMBL) Primary ID of Target Chain 31 UniProt (TrEMBL) Secondary ID(s) of Target Chain 31 UniProt (TrEMBL) Alternative ID(s) of Target Chain 31 BindingDB Target Chain Sequence 32 PDB ID(s) of Target Chain 32 UniProt (SwissProt) Recommended Name of Target Chain 32 UniProt (SwissProt) Entry Name of Target Chain 32 UniProt (SwissProt) Primary ID of Target Chain 32 UniProt (SwissProt) Secondary ID(s) of Target Chain 32 UniProt (SwissProt) Alternative ID(s) of Target Chain 32 UniProt (TrEMBL) Submitted Name of Target Chain 32 UniProt (TrEMBL) Entry Name of Target Chain 32 UniProt (TrEMBL) Primary ID of Target Chain 32 UniProt (TrEMBL) Secondary ID(s) of Target Chain 32 UniProt (TrEMBL) Alternative ID(s) of Target Chain 32 BindingDB Target Chain Sequence 33 PDB ID(s) of Target Chain 33 UniProt (SwissProt) Recommended Name of Target Chain 33 UniProt (SwissProt) Entry Name of Target Chain 33 UniProt (SwissProt) Primary ID of Target Chain 33 UniProt (SwissProt) Secondary ID(s) of Target Chain 33 UniProt (SwissProt) Alternative ID(s) of Target Chain 33 UniProt (TrEMBL) Submitted Name of Target Chain 33 UniProt (TrEMBL) Entry Name of Target Chain 33 UniProt (TrEMBL) Primary ID of Target Chain 33 UniProt (TrEMBL) Secondary ID(s) of Target Chain 33 UniProt (TrEMBL) Alternative ID(s) of Target Chain 33 BindingDB Target Chain Sequence 34 PDB ID(s) of Target Chain 34 UniProt (SwissProt) Recommended Name of Target Chain 34 UniProt (SwissProt) Entry Name of Target Chain 34 UniProt (SwissProt) Primary ID of Target Chain 34 UniProt (SwissProt) Secondary ID(s) of Target Chain 34 UniProt (SwissProt) Alternative ID(s) of Target Chain 34 UniProt (TrEMBL) Submitted Name of Target Chain 34 UniProt (TrEMBL) Entry Name of Target Chain 34 UniProt (TrEMBL) Primary ID of Target Chain 34 UniProt (TrEMBL) Secondary ID(s) of Target Chain 34 UniProt (TrEMBL) Alternative ID(s) of Target Chain 34 BindingDB Target Chain Sequence 35 PDB ID(s) of Target Chain 35 UniProt (SwissProt) Recommended Name of Target Chain 35 UniProt (SwissProt) Entry Name of Target Chain 35 UniProt (SwissProt) Primary ID of Target Chain 35 UniProt (SwissProt) Secondary ID(s) of Target Chain 35 UniProt (SwissProt) Alternative ID(s) of Target Chain 35 UniProt (TrEMBL) Submitted Name of Target Chain 35 UniProt (TrEMBL) Entry Name of Target Chain 35 UniProt (TrEMBL) Primary ID of Target Chain 35 UniProt (TrEMBL) Secondary ID(s) of Target Chain 35 UniProt (TrEMBL) Alternative ID(s) of Target Chain 35 BindingDB Target Chain Sequence 36 PDB ID(s) of Target Chain 36 UniProt (SwissProt) Recommended Name of Target Chain 36 UniProt (SwissProt) Entry Name of Target Chain 36 UniProt (SwissProt) Primary ID of Target Chain 36 UniProt (SwissProt) Secondary ID(s) of Target Chain 36 UniProt (SwissProt) Alternative ID(s) of Target Chain 36 UniProt (TrEMBL) Submitted Name of Target Chain 36 UniProt (TrEMBL) Entry Name of Target Chain 36 UniProt (TrEMBL) Primary ID of Target Chain 36 UniProt (TrEMBL) Secondary ID(s) of Target Chain 36 UniProt (TrEMBL) Alternative ID(s) of Target Chain 36 BindingDB Target Chain Sequence 37 PDB ID(s) of Target Chain 37 UniProt (SwissProt) Recommended Name of Target Chain 37 UniProt (SwissProt) Entry Name of Target Chain 37 UniProt (SwissProt) Primary ID of Target Chain 37 UniProt (SwissProt) Secondary ID(s) of Target Chain 37 UniProt (SwissProt) Alternative ID(s) of Target Chain 37 UniProt (TrEMBL) Submitted Name of Target Chain 37 UniProt (TrEMBL) Entry Name of Target Chain 37 UniProt (TrEMBL) Primary ID of Target Chain 37 UniProt (TrEMBL) Secondary ID(s) of Target Chain 37 UniProt (TrEMBL) Alternative ID(s) of Target Chain 37 BindingDB Target Chain Sequence 38 PDB ID(s) of Target Chain 38 UniProt (SwissProt) Recommended Name of Target Chain 38 UniProt (SwissProt) Entry Name of Target Chain 38 UniProt (SwissProt) Primary ID of Target Chain 38 UniProt (SwissProt) Secondary ID(s) of Target Chain 38 UniProt (SwissProt) Alternative ID(s) of Target Chain 38 UniProt (TrEMBL) Submitted Name of Target Chain 38 UniProt (TrEMBL) Entry Name of Target Chain 38 UniProt (TrEMBL) Primary ID of Target Chain 38 UniProt (TrEMBL) Secondary ID(s) of Target Chain 38 UniProt (TrEMBL) Alternative ID(s) of Target Chain 38 BindingDB Target Chain Sequence 39 PDB ID(s) of Target Chain 39 UniProt (SwissProt) Recommended Name of Target Chain 39 UniProt (SwissProt) Entry Name of Target Chain 39 UniProt (SwissProt) Primary ID of Target Chain 39 UniProt (SwissProt) Secondary ID(s) of Target Chain 39 UniProt (SwissProt) Alternative ID(s) of Target Chain 39 UniProt (TrEMBL) Submitted Name of Target Chain 39 UniProt (TrEMBL) Entry Name of Target Chain 39 UniProt (TrEMBL) Primary ID of Target Chain 39 UniProt (TrEMBL) Secondary ID(s) of Target Chain 39 UniProt (TrEMBL) Alternative ID(s) of Target Chain 39 BindingDB Target Chain Sequence 40 PDB ID(s) of Target Chain 40 UniProt (SwissProt) Recommended Name of Target Chain 40 UniProt (SwissProt) Entry Name of Target Chain 40 UniProt (SwissProt) Primary ID of Target Chain 40 UniProt (SwissProt) Secondary ID(s) of Target Chain 40 UniProt (SwissProt) Alternative ID(s) of Target Chain 40 UniProt (TrEMBL) Submitted Name of Target Chain 40 UniProt (TrEMBL) Entry Name of Target Chain 40 UniProt (TrEMBL) Primary ID of Target Chain 40 UniProt (TrEMBL) Secondary ID(s) of Target Chain 40 UniProt (TrEMBL) Alternative ID(s) of Target Chain 40 BindingDB Target Chain Sequence 41 PDB ID(s) of Target Chain 41 UniProt (SwissProt) Recommended Name of Target Chain 41 UniProt (SwissProt) Entry Name of Target Chain 41 UniProt (SwissProt) Primary ID of Target Chain 41 UniProt (SwissProt) Secondary ID(s) of Target Chain 41 UniProt (SwissProt) Alternative ID(s) of Target Chain 41 UniProt (TrEMBL) Submitted Name of Target Chain 41 UniProt (TrEMBL) Entry Name of Target Chain 41 UniProt (TrEMBL) Primary ID of Target Chain 41 UniProt (TrEMBL) Secondary ID(s) of Target Chain 41 UniProt (TrEMBL) Alternative ID(s) of Target Chain 41 BindingDB Target Chain Sequence 42 PDB ID(s) of Target Chain 42 UniProt (SwissProt) Recommended Name of Target Chain 42 UniProt (SwissProt) Entry Name of Target Chain 42 UniProt (SwissProt) Primary ID of Target Chain 42 UniProt (SwissProt) Secondary ID(s) of Target Chain 42 UniProt (SwissProt) Alternative ID(s) of Target Chain 42 UniProt (TrEMBL) Submitted Name of Target Chain 42 UniProt (TrEMBL) Entry Name of Target Chain 42 UniProt (TrEMBL) Primary ID of Target Chain 42 UniProt (TrEMBL) Secondary ID(s) of Target Chain 42 UniProt (TrEMBL) Alternative ID(s) of Target Chain 42 BindingDB Target Chain Sequence 43 PDB ID(s) of Target Chain 43 UniProt (SwissProt) Recommended Name of Target Chain 43 UniProt (SwissProt) Entry Name of Target Chain 43 UniProt (SwissProt) Primary ID of Target Chain 43 UniProt (SwissProt) Secondary ID(s) of Target Chain 43 UniProt (SwissProt) Alternative ID(s) of Target Chain 43 UniProt (TrEMBL) Submitted Name of Target Chain 43 UniProt (TrEMBL) Entry Name of Target Chain 43 UniProt (TrEMBL) Primary ID of Target Chain 43 UniProt (TrEMBL) Secondary ID(s) of Target Chain 43 UniProt (TrEMBL) Alternative ID(s) of Target Chain 43 BindingDB Target Chain Sequence 44 PDB ID(s) of Target Chain 44 UniProt (SwissProt) Recommended Name of Target Chain 44 UniProt (SwissProt) Entry Name of Target Chain 44 UniProt (SwissProt) Primary ID of Target Chain 44 UniProt (SwissProt) Secondary ID(s) of Target Chain 44 UniProt (SwissProt) Alternative ID(s) of Target Chain 44 UniProt (TrEMBL) Submitted Name of Target Chain 44 UniProt (TrEMBL) Entry Name of Target Chain 44 UniProt (TrEMBL) Primary ID of Target Chain 44 UniProt (TrEMBL) Secondary ID(s) of Target Chain 44 UniProt (TrEMBL) Alternative ID(s) of Target Chain 44 BindingDB Target Chain Sequence 45 PDB ID(s) of Target Chain 45 UniProt (SwissProt) Recommended Name of Target Chain 45 UniProt (SwissProt) Entry Name of Target Chain 45 UniProt (SwissProt) Primary ID of Target Chain 45 UniProt (SwissProt) Secondary ID(s) of Target Chain 45 UniProt (SwissProt) Alternative ID(s) of Target Chain 45 UniProt (TrEMBL) Submitted Name of Target Chain 45 UniProt (TrEMBL) Entry Name of Target Chain 45 UniProt (TrEMBL) Primary ID of Target Chain 45 UniProt (TrEMBL) Secondary ID(s) of Target Chain 45 UniProt (TrEMBL) Alternative ID(s) of Target Chain 45 BindingDB Target Chain Sequence 46 PDB ID(s) of Target Chain 46 UniProt (SwissProt) Recommended Name of Target Chain 46 UniProt (SwissProt) Entry Name of Target Chain 46 UniProt (SwissProt) Primary ID of Target Chain 46 UniProt (SwissProt) Secondary ID(s) of Target Chain 46 UniProt (SwissProt) Alternative ID(s) of Target Chain 46 UniProt (TrEMBL) Submitted Name of Target Chain 46 UniProt (TrEMBL) Entry Name of Target Chain 46 UniProt (TrEMBL) Primary ID of Target Chain 46 UniProt (TrEMBL) Secondary ID(s) of Target Chain 46 UniProt (TrEMBL) Alternative ID(s) of Target Chain 46 BindingDB Target Chain Sequence 47 PDB ID(s) of Target Chain 47 UniProt (SwissProt) Recommended Name of Target Chain 47 UniProt (SwissProt) Entry Name of Target Chain 47 UniProt (SwissProt) Primary ID of Target Chain 47 UniProt (SwissProt) Secondary ID(s) of Target Chain 47 UniProt (SwissProt) Alternative ID(s) of Target Chain 47 UniProt (TrEMBL) Submitted Name of Target Chain 47 UniProt (TrEMBL) Entry Name of Target Chain 47 UniProt (TrEMBL) Primary ID of Target Chain 47 UniProt (TrEMBL) Secondary ID(s) of Target Chain 47 UniProt (TrEMBL) Alternative ID(s) of Target Chain 47 BindingDB Target Chain Sequence 48 PDB ID(s) of Target Chain 48 UniProt (SwissProt) Recommended Name of Target Chain 48 UniProt (SwissProt) Entry Name of Target Chain 48 UniProt (SwissProt) Primary ID of Target Chain 48 UniProt (SwissProt) Secondary ID(s) of Target Chain 48 UniProt (SwissProt) Alternative ID(s) of Target Chain 48 UniProt (TrEMBL) Submitted Name of Target Chain 48 UniProt (TrEMBL) Entry Name of Target Chain 48 UniProt (TrEMBL) Primary ID of Target Chain 48 UniProt (TrEMBL) Secondary ID(s) of Target Chain 48 UniProt (TrEMBL) Alternative ID(s) of Target Chain 48 BindingDB Target Chain Sequence 49 PDB ID(s) of Target Chain 49 UniProt (SwissProt) Recommended Name of Target Chain 49 UniProt (SwissProt) Entry Name of Target Chain 49 UniProt (SwissProt) Primary ID of Target Chain 49 UniProt (SwissProt) Secondary ID(s) of Target Chain 49 UniProt (SwissProt) Alternative ID(s) of Target Chain 49 UniProt (TrEMBL) Submitted Name of Target Chain 49 UniProt (TrEMBL) Entry Name of Target Chain 49 UniProt (TrEMBL) Primary ID of Target Chain 49 UniProt (TrEMBL) Secondary ID(s) of Target Chain 49 UniProt (TrEMBL) Alternative ID(s) of Target Chain 49 BindingDB Target Chain Sequence 50 PDB ID(s) of Target Chain 50 UniProt (SwissProt) Recommended Name of Target Chain 50 UniProt (SwissProt) Entry Name of Target Chain 50 UniProt (SwissProt) Primary ID of Target Chain 50 UniProt (SwissProt) Secondary ID(s) of Target Chain 50 UniProt (SwissProt) Alternative ID(s) of Target Chain 50 UniProt (TrEMBL) Submitted Name of Target Chain 50 UniProt (TrEMBL) Entry Name of Target Chain 50 UniProt (TrEMBL) Primary ID of Target Chain 50 UniProt (TrEMBL) Secondary ID(s) of Target Chain 50 UniProt (TrEMBL) Alternative ID(s) of Target Chain 50 570859 O=c1cc(C2CCNCC2)n2ncc(-c3ccccc3)c2[nH]1 InChI=1S/C17H18N4O/c22-16-10-15(13-6-8-18-9-7-13)21-17(20-16)14(11-19-21)12-4-2-1-3-5-12/h1-5,10-11,13,18H,6-9H2,(H,20,22) VKDVYLODEKBFDT-UHFFFAOYSA-N 297776 US10118930, Example 1::3-Phenyl-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 38.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297776 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297776&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529670 381620611 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570860 O=c1cc(C2CCNCC2)n2ncc(-c3ccccn3)c2[nH]1 InChI=1S/C16H17N5O/c22-15-9-14(11-4-7-17-8-5-11)21-16(20-15)12(10-19-21)13-3-1-2-6-18-13/h1-3,6,9-11,17H,4-5,7-8H2,(H,20,22) QEHPDHUFOPTPFK-UHFFFAOYSA-N 297777 US10118930, Example 2::7-(Piperidin-4-yl)-3-(pyridin-2-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one dihydrochloride Tissue-type plasminogen activator Human 39.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297777 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297777&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529671 381620612 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570861 COCc1nn2c(cc(=O)[nH]c2c1-c1ccc(OC)cc1)C1CCNCC1 InChI=1S/C20H24N4O3/c1-26-12-16-19(14-3-5-15(27-2)6-4-14)20-22-18(25)11-17(24(20)23-16)13-7-9-21-10-8-13/h3-6,11,13,21H,7-10,12H2,1-2H3,(H,22,25) LRTZERGADUZTAR-UHFFFAOYSA-N 297778 US10118930, Example 3::2-(Methoxymethyl)-3-(4-methoxyphenyl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 33.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297778 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297778&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529672 381620613 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570862 Fc1ccc(cc1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H17FN4O/c18-13-3-1-11(2-4-13)14-10-20-22-15(9-16(23)21-17(14)22)12-5-7-19-8-6-12/h1-4,9-10,12,19H,5-8H2,(H,21,23) KPCUHILYISJLFT-UHFFFAOYSA-N 297779 US10118930, Example 4::3-(4-Fluorophenyl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 40.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297779 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297779&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529673 381620614 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570863 O=c1cc(C2CCNCC2)n2ncc(-c3cccnc3)c2[nH]1 InChI=1S/C16H17N5O/c22-15-8-14(11-3-6-17-7-4-11)21-16(20-15)13(10-19-21)12-2-1-5-18-9-12/h1-2,5,8-11,17H,3-4,6-7H2,(H,20,22) QWGJWIMGFBFDNZ-UHFFFAOYSA-N 297780 US10118930, Example 5::7-(Piperidin-4-yl)-3-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 32.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297780 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297780&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529674 381620615 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570864 COc1ccccc1-c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 |(-.12,5.71,;-.12,4.17,;1.36,3.77,;2.45,4.86,;3.94,4.46,;4.34,2.97,;3.25,1.88,;1.76,2.28,;.67,1.19,;-.86,1.35,;-1.63,2.69,;-1.48,-.06,;-.34,-1.09,;-.34,-2.63,;.99,-3.4,;2.33,-2.63,;3.66,-3.4,;2.33,-1.09,;.99,-.32,;-1.67,-3.4,;-3.01,-2.63,;-4.34,-3.4,;-4.34,-4.94,;-3.01,-5.71,;-1.67,-4.94,)| InChI=1S/C19H22N4O2/c1-12-18(14-5-3-4-6-16(14)25-2)19-21-17(24)11-15(23(19)22-12)13-7-9-20-10-8-13/h3-6,11,13,20H,7-10H2,1-2H3,(H,21,24) UFDUUTVGGRYBNH-UHFFFAOYSA-N 297781 US10118930, Example 6::3-(2-Methoxyphenyl)-2-methyl-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 170 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297781 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297781&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529675 381620616 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570865 Cc1nn2c(cc(=O)[nH]c2c1-c1cccc(c1)C(F)(F)F)C1CCNCC1 InChI=1S/C19H19F3N4O/c1-11-17(13-3-2-4-14(9-13)19(20,21)22)18-24-16(27)10-15(26(18)25-11)12-5-7-23-8-6-12/h2-4,9-10,12,23H,5-8H2,1H3,(H,24,27) BDQLEFLKGFOQCZ-UHFFFAOYSA-N 297782 2-Methyl-7-(piperidin-4-yl)-3-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride::US10118930, Example 13::US10118930, Example 7 Tissue-type plasminogen activator Human 31.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297782 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297782&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529676 381620617 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570866 Cc1nn2c(cc(=O)[nH]c2c1C#N)C1CCNCC1 InChI=1S/C13H15N5O/c1-8-10(7-14)13-16-12(19)6-11(18(13)17-8)9-2-4-15-5-3-9/h6,9,15H,2-5H2,1H3,(H,16,19) WBQCYWSMIDNAMC-UHFFFAOYSA-N 297783 US10118930, Example 8::2-Methyl-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carbonitrile trifluoroacetate Tissue-type plasminogen activator Human 29.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297783 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297783&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018480 381620618 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570867 CCOC(=O)c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C15H20N4O3/c1-3-22-15(21)13-9(2)18-19-11(8-12(20)17-14(13)19)10-4-6-16-7-5-10/h8,10,16H,3-7H2,1-2H3,(H,17,20) VEMIWYWPSBUQJB-UHFFFAOYSA-N 297784 US10118930, Example 9::Ethyl 2-methyl-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate trifluoroacetate::US10118930, Example 298 Tissue-type plasminogen activator Human 33.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297784 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297784&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137025707 381620619 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570868 Cc1nn2c(cc(=O)[nH]c2c1-c1ccc(Br)cc1)C1CCNCC1 InChI=1S/C18H19BrN4O/c1-11-17(13-2-4-14(19)5-3-13)18-21-16(24)10-15(23(18)22-11)12-6-8-20-9-7-12/h2-5,10,12,20H,6-9H2,1H3,(H,21,24) VHHQTABIWCASIP-UHFFFAOYSA-N 297785 US10118930, Example 10::3-(4-Bromophenyl)-2-methyl-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 110 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297785 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297785&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529677 381620620 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570869 COCc1nn2c(cc(=O)[nH]c2c1-c1ccccc1)C1CCNCC1 InChI=1S/C19H22N4O2/c1-25-12-15-18(14-5-3-2-4-6-14)19-21-17(24)11-16(23(19)22-15)13-7-9-20-10-8-13/h2-6,11,13,20H,7-10,12H2,1H3,(H,21,24) DIADXBWIERWYBM-UHFFFAOYSA-N 297786 US10118930, Example 11::2-(Methoxymethyl)-3-phenyl-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 57.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297786 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297786&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529678 381620621 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570870 O=c1cc(C2CCNCC2)n2ncc(-c3cccc(OCc4ccccc4)c3)c2[nH]1 InChI=1S/C24H24N4O2/c29-23-14-22(18-9-11-25-12-10-18)28-24(27-23)21(15-26-28)19-7-4-8-20(13-19)30-16-17-5-2-1-3-6-17/h1-8,13-15,18,25H,9-12,16H2,(H,27,29) URAPKNQUOLAFNO-UHFFFAOYSA-N 297787 US10118930, Example 12::3-[3-(Benzyloxy)phenyl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 30.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297787 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297787&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529679 381620622 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570871 Cc1nn2c(cc(=O)[nH]c2c1-c1cccc(c1)C(F)(F)F)C1CCNCC1 InChI=1S/C19H19F3N4O/c1-11-17(13-3-2-4-14(9-13)19(20,21)22)18-24-16(27)10-15(26(18)25-11)12-5-7-23-8-6-12/h2-4,9-10,12,23H,5-8H2,1H3,(H,24,27) BDQLEFLKGFOQCZ-UHFFFAOYSA-N 297782 2-Methyl-7-(piperidin-4-yl)-3-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride::US10118930, Example 13::US10118930, Example 7 Tissue-type plasminogen activator Human 21.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297782 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297782&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529676 381620617 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570872 NC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C12H15N5O2/c13-11(19)8-6-15-17-9(5-10(18)16-12(8)17)7-1-3-14-4-2-7/h5-7,14H,1-4H2,(H2,13,19)(H,16,18) QOVXARBEWTTXKD-UHFFFAOYSA-N 297789 US10118930, Example 14::5-Oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxamide hydrochloride Tissue-type plasminogen activator Human 24.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297789 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297789&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018673 381620623 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570873 O=c1cc(C2CCNCC2)n2ncc(C#N)c2[nH]1 InChI=1S/C12H13N5O/c13-6-9-7-15-17-10(5-11(18)16-12(9)17)8-1-3-14-4-2-8/h5,7-8,14H,1-4H2,(H,16,18) UMVCXBCASJRMSR-UHFFFAOYSA-N 297790 US10118930, Example 15::5-Oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carbonitrile Tissue-type plasminogen activator Human 19.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297790 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297790&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018672 381620624 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570874 CCOC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C14H18N4O3/c1-2-21-14(20)10-8-16-18-11(7-12(19)17-13(10)18)9-3-5-15-6-4-9/h7-9,15H,2-6H2,1H3,(H,17,19) MNJZPYSVEVYISE-UHFFFAOYSA-N 297791 US10118930, Example 16::Ethyl 5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate hydrochloride Tissue-type plasminogen activator Human 11.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297791 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297791&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018461 381620625 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570875 OC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C12H14N4O3/c17-10-5-9(7-1-3-13-4-2-7)16-11(15-10)8(6-14-16)12(18)19/h5-7,13H,1-4H2,(H,15,17)(H,18,19) IJCXFBFQAUOFKL-UHFFFAOYSA-N 297792 US10118930, Example 17::5-Oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylic acid hydrochloride Tissue-type plasminogen activator Human 46.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297792 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297792&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018456 381620626 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570876 O=C(OCc1ccccc1)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H20N4O3/c24-17-10-16(14-6-8-20-9-7-14)23-18(22-17)15(11-21-23)19(25)26-12-13-4-2-1-3-5-13/h1-5,10-11,14,20H,6-9,12H2,(H,22,24) DZULWRKDBYTOQG-UHFFFAOYSA-N 297793 US10118930, Example 18::Benzyl 5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate hydrochloride Tissue-type plasminogen activator Human 15.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297793 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297793&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529680 381620627 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570877 CCNC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C14H19N5O2/c1-2-16-14(21)10-8-17-19-11(7-12(20)18-13(10)19)9-3-5-15-6-4-9/h7-9,15H,2-6H2,1H3,(H,16,21)(H,18,20) JQQBEIXDUJZPFB-UHFFFAOYSA-N 297794 US10118930, Example 19::N-Ethyl-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxamide hydrochloride Tissue-type plasminogen activator Human 15.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297794 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297794&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018318 381620628 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570878 FC(F)(F)c1nn2c(cc(=O)[nH]c2c1-c1ccc(Cl)cc1)C1CCNCC1 InChI=1S/C18H16ClF3N4O/c19-12-3-1-11(2-4-12)15-16(18(20,21)22)25-26-13(9-14(27)24-17(15)26)10-5-7-23-8-6-10/h1-4,9-10,23H,5-8H2,(H,24,27) FHVCBDMGTWNACF-UHFFFAOYSA-N 297795 US10118930, Example 20::3-(4-Chlorophenyl)-7-(piperidin-4-yl)-2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 420 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297795 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297795&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529681 381620629 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570879 CC(C)CNC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C16H23N5O2/c1-10(2)8-18-16(23)12-9-19-21-13(7-14(22)20-15(12)21)11-3-5-17-6-4-11/h7,9-11,17H,3-6,8H2,1-2H3,(H,18,23)(H,20,22) NHAIDSPNWGIEEI-UHFFFAOYSA-N 297796 US10118930, Example 21::N-Isobutyl-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxamide hydrochloride Tissue-type plasminogen activator Human 14.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297796 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297796&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018451 381620630 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570880 O=C(NCc1ccccc1)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H21N5O2/c25-17-10-16(14-6-8-20-9-7-14)24-18(23-17)15(12-22-24)19(26)21-11-13-4-2-1-3-5-13/h1-5,10,12,14,20H,6-9,11H2,(H,21,26)(H,23,25) XWUNAQXFAPRYHL-UHFFFAOYSA-N 297797 US10118930, Example 22::N-Benzyl-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxamide hydrochloride Tissue-type plasminogen activator Human 13.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297797 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297797&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529682 381620631 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570881 O=C(N1CCOCC1)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C16H21N5O3/c22-14-9-13(11-1-3-17-4-2-11)21-15(19-14)12(10-18-21)16(23)20-5-7-24-8-6-20/h9-11,17H,1-8H2,(H,19,22) ATCIOTNLQZOMNX-UHFFFAOYSA-N 297798 US10118930, Example 23::3-(Morpholin-4-ylcarbonyl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 14.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297798 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297798&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018513 381620632 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570882 FC(F)(F)c1cc2[nH]c(=O)cc(C3CCNCC3)n2n1 InChI=1S/C12H13F3N4O/c13-12(14,15)9-6-10-17-11(20)5-8(19(10)18-9)7-1-3-16-4-2-7/h5-7,16H,1-4H2,(H,17,20) JJNLBYPGCDWOIJ-UHFFFAOYSA-N 297799 US10118930, Example 24::7-(Piperidin-4-yl)-2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 59.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297799 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297799&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018454 381620633 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570883 O=c1cc(C2CCNCC2)n2nc(cc2[nH]1)-c1cccs1 InChI=1S/C15H16N4OS/c20-15-9-12(10-3-5-16-6-4-10)19-14(17-15)8-11(18-19)13-2-1-7-21-13/h1-2,7-10,16H,3-6H2,(H,17,20) CUUJINITHZLVOQ-UHFFFAOYSA-N 297800 US10118930, Example 25::7-(Piperidin-4-yl)-2-(2-thienyl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 160 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297800 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297800&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018450 381620634 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570884 O=c1cc(C2CCNCC2)n2nc(cc2[nH]1)C1CC1 InChI=1S/C14H18N4O/c19-14-8-12(10-3-5-15-6-4-10)18-13(16-14)7-11(17-18)9-1-2-9/h7-10,15H,1-6H2,(H,16,19) SDOWUCQKCVXTLY-UHFFFAOYSA-N 297801 US10118930, Example 26::2-Cyclopropyl-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 310 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297801 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297801&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018653 381620635 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570885 Fc1ccc(cc1)-c1cc2[nH]c(=O)cc(C3CCNCC3)n2n1 InChI=1S/C17H17FN4O/c18-13-3-1-11(2-4-13)14-9-16-20-17(23)10-15(22(16)21-14)12-5-7-19-8-6-12/h1-4,9-10,12,19H,5-8H2,(H,20,23) RCIDUIFZDYEWSL-UHFFFAOYSA-N 297802 US10118930, Example 27::2-(4-Fluorophenyl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 170 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297802 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297802&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529683 381620636 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570886 COC(=O)c1cc2[nH]c(=O)cc(C3CCNCC3)n2n1 InChI=1S/C13H16N4O3/c1-20-13(19)9-6-11-15-12(18)7-10(17(11)16-9)8-2-4-14-5-3-8/h6-8,14H,2-5H2,1H3,(H,15,18) DKCCRCCYJRDAAU-UHFFFAOYSA-N 297803 US10118930, Example 28::Methyl 5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylate Tissue-type plasminogen activator Human 110 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297803 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297803&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018551 381620637 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570887 Brc1c(nn2c(cc(=O)[nH]c12)C1CCNCC1)-c1ccccc1 InChI=1S/C17H17BrN4O/c18-15-16(12-4-2-1-3-5-12)21-22-13(10-14(23)20-17(15)22)11-6-8-19-9-7-11/h1-5,10-11,19H,6-9H2,(H,20,23) YENFYBHRLNBVPB-UHFFFAOYSA-N 297804 US10118930, Example 29::3-Bromo-2-phenyl-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 20.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297804 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297804&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529684 381620638 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570888 O=c1cc(C2CCNCC2)n2nc3CCCc3c2[nH]1 InChI=1S/C14H18N4O/c19-13-8-12(9-4-6-15-7-5-9)18-14(16-13)10-2-1-3-11(10)17-18/h8-9,15H,1-7H2,(H,16,19) RQUVEDKFKMYZAJ-UHFFFAOYSA-N 297805 US10118930, Example 30::4-(Piperidin-4-yl)-1,7,8,9-tetrahydro-2H-cyclopenta[3,4]pyrazolo[1,5-a]pyrimidin-2-one hydrochloride Tissue-type plasminogen activator Human 200 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297805 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297805&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018250 381620639 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570889 Brc1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C11H13BrN4O/c12-8-6-14-16-9(5-10(17)15-11(8)16)7-1-3-13-4-2-7/h5-7,13H,1-4H2,(H,15,17) HXVUNKLZUFLWAW-UHFFFAOYSA-N 297806 US10118930, Example 31::3-Bromo-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 18.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297806 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297806&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018522 381620640 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570890 Cc1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C14H16N6O2/c1-8-17-14(22-19-8)10-7-16-20-11(6-12(21)18-13(10)20)9-2-4-15-5-3-9/h6-7,9,15H,2-5H2,1H3,(H,18,21) ROIZMIHPWQFLCV-UHFFFAOYSA-N 297807 US10118930, Example 32::3-(3-Methyl-1,2,4-oxadiazol-5-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 15.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297807 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297807&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018682 381620641 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570891 CC(C)c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C16H20N6O2/c1-9(2)14-20-16(24-21-14)11-8-18-22-12(7-13(23)19-15(11)22)10-3-5-17-6-4-10/h7-10,17H,3-6H2,1-2H3,(H,19,23) BKRRWXGDXWXUKK-UHFFFAOYSA-N 297808 US10118930, Example 33::3-(3-Isopropyl-1,2,4-oxadiazol-5-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 13.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297808 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297808&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137026329 381620642 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570892 CCCc1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C16H20N6O2/c1-2-3-13-19-16(24-21-13)11-9-18-22-12(8-14(23)20-15(11)22)10-4-6-17-7-5-10/h8-10,17H,2-7H2,1H3,(H,20,23) UPZCNUFRKDVPPD-UHFFFAOYSA-N 297809 US10118930, Example 34::7-(Piperidin-4-yl)-3-(3-propyl-1,2,4-oxadiazol-5-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 12.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297809 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297809&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018524 381620643 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570893 O=c1cc(C2CCNCC2)n2ncc(-c3nc(no3)-c3ccccc3)c2[nH]1 InChI=1S/C19H18N6O2/c26-16-10-15(12-6-8-20-9-7-12)25-18(22-16)14(11-21-25)19-23-17(24-27-19)13-4-2-1-3-5-13/h1-5,10-12,20H,6-9H2,(H,22,26) XZJJFILYGFPJMT-UHFFFAOYSA-N 297810 US10118930, Example 35::3-(3-Phenyl-1,2,4-oxadiazol-5-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 15.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297810 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297810&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529685 381620644 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570894 Cc1ccc(cc1)S(C)(=O)=NC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H23N5O3S/c1-13-3-5-15(6-4-13)29(2,28)24-20(27)16-12-22-25-17(11-18(26)23-19(16)25)14-7-9-21-10-8-14/h3-6,11-12,14,21H,7-10H2,1-2H3,(H,23,26) DEZKLUTZGZWRIJ-UHFFFAOYSA-N 297811 US10118930, Example 36::N-[Methyl(4-methylphenyl)oxido-lambda6-sulfanylidene]-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxamide hydrochloride Tissue-type plasminogen activator Human 28.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297811 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297811&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529686 381620645 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570895 O=C(N=S1(=O)CCOCC1)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C16H21N5O4S/c22-14-9-13(11-1-3-17-4-2-11)21-15(19-14)12(10-18-21)16(23)20-26(24)7-5-25-6-8-26/h9-11,17H,1-8H2,(H,19,22) VMFSKAAHJWJIDQ-UHFFFAOYSA-N 297812 US10118930, Example 37::N-(4-Oxido-1,4-lambda4-oxathian-4-ylidene)-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxamide hydrochloride Tissue-type plasminogen activator Human 29.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297812 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297812&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018291 381620646 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570896 CCOC(=O)c1c(nn2c(cc(=O)[nH]c12)C1CCNCC1)-c1ccccc1 InChI=1S/C20H22N4O3/c1-2-27-20(26)17-18(14-6-4-3-5-7-14)23-24-15(12-16(25)22-19(17)24)13-8-10-21-11-9-13/h3-7,12-13,21H,2,8-11H2,1H3,(H,22,25) JKWSDWKIRNPTAQ-UHFFFAOYSA-N 297813 US10118930, Example 38::Ethyl 5-oxo-2-phenyl-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate trifluoroacetate Tissue-type plasminogen activator Human 18.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297813 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297813&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529687 381620647 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570897 Cc1ccc(cc1)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H20N6O2/c1-12-2-4-14(5-3-12)18-24-20(28-25-18)15-11-22-26-16(10-17(27)23-19(15)26)13-6-8-21-9-7-13/h2-5,10-11,13,21H,6-9H2,1H3,(H,23,27) AQNHVDRWNQHADK-UHFFFAOYSA-N 297814 US10118930, Example 39::3-[3-(4-Methylphenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-hydrochloride Tissue-type plasminogen activator Human 27.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297814 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297814&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529688 381620648 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570898 CC1CC(CCN1)c1cc(=O)[nH]c2c(Cl)cnn12 InChI=1S/C12H15ClN4O/c1-7-4-8(2-3-14-7)10-5-11(18)16-12-9(13)6-15-17(10)12/h5-8,14H,2-4H2,1H3,(H,16,18) GOQLTCPCGBVLFY-UHFFFAOYSA-N 297815 US10118930, Example 40::(−)-trans-3-Chloro-7-(2-methylpiperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 14.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297815 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297815&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018256 381620649 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570899 NC(=O)c1c(nn2c(cc(=O)[nH]c12)C1CCNCC1)-c1ccccc1 InChI=1S/C18H19N5O2/c19-17(25)15-16(12-4-2-1-3-5-12)22-23-13(10-14(24)21-18(15)23)11-6-8-20-9-7-11/h1-5,10-11,20H,6-9H2,(H2,19,25)(H,21,24) JUSZRKPHEACGLP-UHFFFAOYSA-N 297816 US10118930, Example 41::5-Oxo-2-phenyl-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxamide trifluoroacetate Tissue-type plasminogen activator Human 19.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297816 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297816&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529689 381620650 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570900 O=C(NCc1ccccc1)c1c(nn2c(cc(=O)[nH]c12)C1CCNCC1)-c1ccccc1 InChI=1S/C25H25N5O2/c31-21-15-20(18-11-13-26-14-12-18)30-24(28-21)22(23(29-30)19-9-5-2-6-10-19)25(32)27-16-17-7-3-1-4-8-17/h1-10,15,18,26H,11-14,16H2,(H,27,32)(H,28,31) JABOUDXSXIQXHP-UHFFFAOYSA-N 297817 US10118930, Example 42::N-Benzyl-5-oxo-2-phenyl-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxamide trifluoroacetate Tissue-type plasminogen activator Human 18.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297817 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297817&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529690 381620651 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570901 O=C(N1CCOCC1)c1c(nn2c(cc(=O)[nH]c12)C1CCNCC1)-c1ccccc1 InChI=1S/C22H25N5O3/c28-18-14-17(15-6-8-23-9-7-15)27-21(24-18)19(22(29)26-10-12-30-13-11-26)20(25-27)16-4-2-1-3-5-16/h1-5,14-15,23H,6-13H2,(H,24,28) NCFOYUPGUNTGTE-UHFFFAOYSA-N 297818 US10118930, Example 43::3-(Morpholin-4-ylcarbonyl)-2-phenyl-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one trifluoroacetate Tissue-type plasminogen activator Human 27.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297818 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297818&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529691 381620652 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570902 CC(C)CNC(=O)c1c(nn2c(cc(=O)[nH]c12)C1CCNCC1)-c1ccccc1 InChI=1S/C22H27N5O2/c1-14(2)13-24-22(29)19-20(16-6-4-3-5-7-16)26-27-17(12-18(28)25-21(19)27)15-8-10-23-11-9-15/h3-7,12,14-15,23H,8-11,13H2,1-2H3,(H,24,29)(H,25,28) KIQXSARAZYIRDV-UHFFFAOYSA-N 297819 US10118930, Example 44::N-(3-Methylbutyl)-5-oxo-2-phenyl-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxamide trifluoroacetate Tissue-type plasminogen activator Human 23.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297819 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297819&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529692 381620653 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570903 Cc1ccc(cc1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C18H20N4O/c1-12-2-4-13(5-3-12)15-11-20-22-16(10-17(23)21-18(15)22)14-6-8-19-9-7-14/h2-5,10-11,14,19H,6-9H2,1H3,(H,21,23) BKFONUIXEZMUMS-UHFFFAOYSA-N 297822 US10118930, Example 45::3-(4-Methylphenyl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 23.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297822 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297822&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529695 381620656 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570904 OC(=O)c1cc2[nH]c(=O)cc(C3CCNCC3)n2n1 InChI=1S/C12H14N4O3/c17-11-6-9(7-1-3-13-4-2-7)16-10(14-11)5-8(15-16)12(18)19/h5-7,13H,1-4H2,(H,14,17)(H,18,19) GASHVBQQGUDBSA-UHFFFAOYSA-N 297823 US10118930, Example 46::5-Oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylic acid hydrochloride Tissue-type plasminogen activator Human 69.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297823 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297823&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018471 381620657 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570905 O=c1cc(C2CCNCC2)n2ncc(-c3ccc(cc3)C#N)c2[nH]1 InChI=1S/C18H17N5O/c19-10-12-1-3-13(4-2-12)15-11-21-23-16(9-17(24)22-18(15)23)14-5-7-20-8-6-14/h1-4,9,11,14,20H,5-8H2,(H,22,24) WDSMRZMIMZMACW-UHFFFAOYSA-N 297824 US10118930, Example 47::4-[5-Oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidin-3-yl]benzonitrile trifluoroacetate Tissue-type plasminogen activator Human 13.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297824 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297824&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529696 381620658 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570906 Clc1cccc(c1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H17ClN4O/c18-13-3-1-2-12(8-13)14-10-20-22-15(9-16(23)21-17(14)22)11-4-6-19-7-5-11/h1-3,8-11,19H,4-7H2,(H,21,23) MEHCXKHOTKAHFY-UHFFFAOYSA-N 297825 US10118930, Example 48::3-(3-Chlorophenyl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 14.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297825 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297825&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529697 381620659 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570907 O=c1cc(C2CCNCC2)n2ncc(-c3ccccc3C#N)c2[nH]1 InChI=1S/C18H17N5O/c19-10-13-3-1-2-4-14(13)15-11-21-23-16(9-17(24)22-18(15)23)12-5-7-20-8-6-12/h1-4,9,11-12,20H,5-8H2,(H,22,24) VEASWXVRSXGFBY-UHFFFAOYSA-N 297826 US10118930, Example 49::2-[5-Oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidin-3-yl]benzonitrile trifluoroacetate Tissue-type plasminogen activator Human 16.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297826 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297826&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529698 381620660 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570908 O=c1cc(C2CCNCC2)n2ncc(-c3cccc(c3)C#N)c2[nH]1 InChI=1S/C18H17N5O/c19-10-12-2-1-3-14(8-12)15-11-21-23-16(9-17(24)22-18(15)23)13-4-6-20-7-5-13/h1-3,8-9,11,13,20H,4-7H2,(H,22,24) HPMLEPSQJTUADC-UHFFFAOYSA-N 297827 US10118930, Example 50::3-[5-Oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidin-3-yl]benzonitrile trifluoroacetate Tissue-type plasminogen activator Human 24.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297827 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297827&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529699 381620661 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570909 CC1CC(CCN1)c1cc(=O)[nH]c2c(cnn12)C(N)=O InChI=1S/C13H17N5O2/c1-7-4-8(2-3-15-7)10-5-11(19)17-13-9(12(14)20)6-16-18(10)13/h5-8,15H,2-4H2,1H3,(H2,14,20)(H,17,19) FXAQCGXSNPJCCF-UHFFFAOYSA-N 297828 US10118930, Example 51::(−)-trans-7-(2-Methylpiperidin-4-yl)-5-oxo-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxamide trifluoroacetate Tissue-type plasminogen activator Human 16.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297828 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297828&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018245 381620662 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570910 Fc1cccc(c1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H17FN4O/c18-13-3-1-2-12(8-13)14-10-20-22-15(9-16(23)21-17(14)22)11-4-6-19-7-5-11/h1-3,8-11,19H,4-7H2,(H,21,23) KMVICXXGNITQJQ-UHFFFAOYSA-N 297829 US10118930, Example 52::3-(3-Fluorophenyl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 24.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297829 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297829&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529700 381620663 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570911 COc1ccc(cc1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C18H20N4O2/c1-24-14-4-2-12(3-5-14)15-11-20-22-16(10-17(23)21-18(15)22)13-6-8-19-9-7-13/h2-5,10-11,13,19H,6-9H2,1H3,(H,21,23) SMJRJPDSSCHLEE-UHFFFAOYSA-N 297830 US10118930, Example 53::3-(4-Methoxyphenyl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 15.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297830 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297830&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529701 381620664 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570912 COc1ccc(cc1OC)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H22N4O3/c1-25-16-4-3-13(9-17(16)26-2)14-11-21-23-15(10-18(24)22-19(14)23)12-5-7-20-8-6-12/h3-4,9-12,20H,5-8H2,1-2H3,(H,22,24) RKNPNLUPLRZWLG-UHFFFAOYSA-N 297831 US10118930, Example 54::3-(3,4-Dimethoxyphenyl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 18.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297831 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297831&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529702 381620665 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570913 CS(=O)(=O)c1ccc(cc1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C18H20N4O3S/c1-26(24,25)14-4-2-12(3-5-14)15-11-20-22-16(10-17(23)21-18(15)22)13-6-8-19-9-7-13/h2-5,10-11,13,19H,6-9H2,1H3,(H,21,23) VSOLYBSMEYYVHL-UHFFFAOYSA-N 297832 US10118930, Example 55::3-[4-(Methylsulfonyl)phenyl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 19.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297832 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297832&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529703 381620666 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570914 Fc1ccccc1-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H17FN4O/c18-14-4-2-1-3-12(14)13-10-20-22-15(9-16(23)21-17(13)22)11-5-7-19-8-6-11/h1-4,9-11,19H,5-8H2,(H,21,23) WTBOTPZBSTZDTP-UHFFFAOYSA-N 297833 US10118930, Example 56::3-(2-Fluorophenyl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 770 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297833 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297833&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529704 381620667 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570915 FC(F)(F)c1ccc(cc1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C18H17F3N4O/c19-18(20,21)13-3-1-11(2-4-13)14-10-23-25-15(9-16(26)24-17(14)25)12-5-7-22-8-6-12/h1-4,9-10,12,22H,5-8H2,(H,24,26) MLYMNSGEHOUQJE-UHFFFAOYSA-N 297834 US10118930, Example 57::7-(Piperidin-4-yl)-3-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 21.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297834 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297834&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529705 381620668 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570916 FC(F)(F)c1cccc(c1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C18H17F3N4O/c19-18(20,21)13-3-1-2-12(8-13)14-10-23-25-15(9-16(26)24-17(14)25)11-4-6-22-7-5-11/h1-3,8-11,22H,4-7H2,(H,24,26) QAZGEARLJXDENH-UHFFFAOYSA-N 297835 US10118930, Example 58::7-(Piperidin-4-yl)-3-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 16.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297835 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297835&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529706 381620669 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570917 O=c1cc(C2CCNCC2)n2ncc(-c3cccs3)c2[nH]1 InChI=1S/C15H16N4OS/c20-14-8-12(10-3-5-16-6-4-10)19-15(18-14)11(9-17-19)13-2-1-7-21-13/h1-2,7-10,16H,3-6H2,(H,18,20) OXNMSHURNHMOGT-UHFFFAOYSA-N 297836 US10118930, Example 59::7-(Piperidin-4-yl)-3-(2-thienyl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 15.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297836 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297836&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018249 381620670 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570918 COc1cccc(c1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C18H20N4O2/c1-24-14-4-2-3-13(9-14)15-11-20-22-16(10-17(23)21-18(15)22)12-5-7-19-8-6-12/h2-4,9-12,19H,5-8H2,1H3,(H,21,23) CXVSPZOMCMNQMI-UHFFFAOYSA-N 297837 US10118930, Example 60::3-(3-Methoxyphenyl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 13.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297837 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297837&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529707 381620671 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570919 O=c1cc(C2CCNCC2)n2ncc(-c3ccc4OCCOc4c3)c2[nH]1 InChI=1S/C19H20N4O3/c24-18-10-15(12-3-5-20-6-4-12)23-19(22-18)14(11-21-23)13-1-2-16-17(9-13)26-8-7-25-16/h1-2,9-12,20H,3-8H2,(H,22,24) ZXPUHPQOTWAAPQ-UHFFFAOYSA-N 297838 US10118930, Example 61::3-(2,3-Dihydro-1,4-benzodioxin-6-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297838 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297838&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529708 381620672 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570920 COc1ccc(OC)c(c1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H22N4O3/c1-25-13-3-4-17(26-2)14(9-13)15-11-21-23-16(10-18(24)22-19(15)23)12-5-7-20-8-6-12/h3-4,9-12,20H,5-8H2,1-2H3,(H,22,24) CVFYJVBTUWEDFO-UHFFFAOYSA-N 297839 US10118930, Example 62::3-(2,5-Dimethoxyphenyl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297839 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297839&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529709 381620673 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570921 FC(F)(F)c1ccccc1-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C18H17F3N4O/c19-18(20,21)14-4-2-1-3-12(14)13-10-23-25-15(9-16(26)24-17(13)25)11-5-7-22-8-6-11/h1-4,9-11,22H,5-8H2,(H,24,26) BVAIILKADYTHMT-UHFFFAOYSA-N 297840 US10118930, Example 63::7-(Piperidin-4-yl)-3-[2-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 40.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297840 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297840&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529710 381620674 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570922 Fc1ccc(cc1)-c1c(nn2c(cc(=O)[nH]c12)C1CCNCC1)-c1ccccc1 InChI=1S/C23H21FN4O/c24-18-8-6-16(7-9-18)21-22(17-4-2-1-3-5-17)27-28-19(14-20(29)26-23(21)28)15-10-12-25-13-11-15/h1-9,14-15,25H,10-13H2,(H,26,29) BELPYJXVOJPPDW-UHFFFAOYSA-N 297841 US10118930, Example 64::3-(4-Fluorophenyl)-2-phenyl-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 39.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297841 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297841&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529711 381620675 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570923 CC1CC(CCN1)c1cc(=O)[nH]c2c(cnn12)C#N InChI=1S/C13H15N5O/c1-8-4-9(2-3-15-8)11-5-12(19)17-13-10(6-14)7-16-18(11)13/h5,7-9,15H,2-4H2,1H3,(H,17,19) RVXFYHDUCASLKN-UHFFFAOYSA-N 297842 US10118930, Example 65::(−)-trans-7-(2-Methylpiperidin-4-yl)-5-oxo-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carbonitrile trifluoroacetate Tissue-type plasminogen activator Human 12.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297842 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297842&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018334 381620676 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570924 Cc1csc(c1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C16H18N4OS/c1-10-6-14(22-9-10)12-8-18-20-13(7-15(21)19-16(12)20)11-2-4-17-5-3-11/h6-9,11,17H,2-5H2,1H3,(H,19,21) GJYZNNPHVASOEL-UHFFFAOYSA-N 297843 US10118930, Example 66::3-(4-Methyl-2-thienyl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 17.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297843 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297843&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018486 381620677 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570925 COc1ccccc1-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C18H20N4O2/c1-24-16-5-3-2-4-13(16)14-11-20-22-15(10-17(23)21-18(14)22)12-6-8-19-9-7-12/h2-5,10-12,19H,6-9H2,1H3,(H,21,23) NNAHEUNPDFJTKY-UHFFFAOYSA-N 297844 US10118930, Example 67::3-(2-Methoxyphenyl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 97.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297844 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297844&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529712 381620678 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570926 O=c1cc(C2CCNCC2)n2ncc(-c3cc(cs3)C#N)c2[nH]1 InChI=1S/C16H15N5OS/c17-7-10-5-14(23-9-10)12-8-19-21-13(6-15(22)20-16(12)21)11-1-3-18-4-2-11/h5-6,8-9,11,18H,1-4H2,(H,20,22) QTJGEGYBQOVETK-UHFFFAOYSA-N 297845 US10118930, Example 68::5-[5-Oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidin-3-yl]thiophene-3-carbonitrile trifluoroacetate Tissue-type plasminogen activator Human 11.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297845 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297845&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018655 381620679 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570927 COc1ccc(cn1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H19N5O2/c1-24-16-3-2-12(9-19-16)13-10-20-22-14(8-15(23)21-17(13)22)11-4-6-18-7-5-11/h2-3,8-11,18H,4-7H2,1H3,(H,21,23) MXWFPEGHAYCUPJ-UHFFFAOYSA-N 297846 US10118930, Example 69::3-(6-Methoxypyridin-3-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one Tissue-type plasminogen activator Human 19.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297846 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297846&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529713 381620680 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570928 FC(F)(F)Oc1cccc(c1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C18H17F3N4O2/c19-18(20,21)27-13-3-1-2-12(8-13)14-10-23-25-15(9-16(26)24-17(14)25)11-4-6-22-7-5-11/h1-3,8-11,22H,4-7H2,(H,24,26) FTJDIYWWXDGBPC-UHFFFAOYSA-N 297847 US10118930, Example 70::7-(Piperidin-4-yl)-3-[3-(trifluoromethoxy)phenyl]pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 14.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297847 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297847&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529714 381620681 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570929 FC(F)(F)Oc1ccccc1-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C18H17F3N4O2/c19-18(20,21)27-15-4-2-1-3-12(15)13-10-23-25-14(9-16(26)24-17(13)25)11-5-7-22-8-6-11/h1-4,9-11,22H,5-8H2,(H,24,26) YMCGLKLUZWCBQM-UHFFFAOYSA-N 297848 US10118930, Example 71::7-(Piperidin-4-yl)-3-[2-(trifluoromethoxy)phenyl]pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297848 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297848&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529715 381620682 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570930 Fc1ccc(cc1Cl)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H16ClFN4O/c18-13-7-11(1-2-14(13)19)12-9-21-23-15(8-16(24)22-17(12)23)10-3-5-20-6-4-10/h1-2,7-10,20H,3-6H2,(H,22,24) NFUIOKNDIGZXCK-UHFFFAOYSA-N 297849 US10118930, Example 72::3-(3-Chloro-4-fluorophenyl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 64.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297849 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297849&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529716 381620683 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570931 O=c1cc(C2CCNCC2)n2ncc(c2[nH]1)S(=O)(=O)c1ccccc1 InChI=1S/C17H18N4O3S/c22-16-10-14(12-6-8-18-9-7-12)21-17(20-16)15(11-19-21)25(23,24)13-4-2-1-3-5-13/h1-5,10-12,18H,6-9H2,(H,20,22) YSEWTNSEOGEJRC-UHFFFAOYSA-N 297850 US10118930, Example 73::3-(Phenylsulfonyl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 12.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297850 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297850&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529717 381620684 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570932 Clc1ccc(c(Cl)c1)S(=O)(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H16Cl2N4O3S/c18-11-1-2-14(12(19)7-11)27(25,26)15-9-21-23-13(8-16(24)22-17(15)23)10-3-5-20-6-4-10/h1-2,7-10,20H,3-6H2,(H,22,24) SVHBAFVITGVGPB-UHFFFAOYSA-N 297851 US10118930, Example 74::3-[(2,4-Dichlorophenyl)sulfonyl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 18.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297851 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297851&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529718 381620685 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570933 O=C(Nc1cccc2ccccc12)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C22H21N5O2/c28-20-12-19(15-8-10-23-11-9-15)27-21(26-20)17(13-24-27)22(29)25-18-7-3-5-14-4-1-2-6-16(14)18/h1-7,12-13,15,23H,8-11H2,(H,25,29)(H,26,28) RVHSHGYKNGPYAM-UHFFFAOYSA-N 297852 US10118930, Example 75::N-(naphthalen-1-yl)-5- oxo-7-(piperidin-4-yl)- 4,5- dihydropyrazolo[1,5- a]pyrimidine-3- carboxamide Tissue-type plasminogen activator Human 40.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297852 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297852&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529719 381620686 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570934 Cc1ccc(F)cc1NC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H20FN5O2/c1-11-2-3-13(20)8-15(11)23-19(27)14-10-22-25-16(9-17(26)24-18(14)25)12-4-6-21-7-5-12/h2-3,8-10,12,21H,4-7H2,1H3,(H,23,27)(H,24,26) ZGIDNTUMYJRCSH-UHFFFAOYSA-N 297853 US10118930, Example 76::N-(5-fluoro-2- methylphenyl)-5-oxo-7- (piperidin-4-yl)-4,5- dihydropyrazolo[1,5- a]pyrimidine-3- carboxamide Tissue-type plasminogen activator Human 29.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297853 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297853&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529720 381620687 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570935 O=C(NCC1CCCC1)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C18H25N5O2/c24-16-9-15(13-5-7-19-8-6-13)23-17(22-16)14(11-21-23)18(25)20-10-12-3-1-2-4-12/h9,11-13,19H,1-8,10H2,(H,20,25)(H,22,24) HLKXRAPOEKHNAM-UHFFFAOYSA-N 297854 US10118930, Example 77::N-cyclopentylmethyl)- 5-oxo-7-(piperidin-4-yl)- 4,5- dihydropyrazolo[1,5- a]pyrimidine-3- carboxamide Tissue-type plasminogen activator Human 62.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297854 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297854&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018552 381620688 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570936 CN(CC1CC1)C(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H23N5O2/c1-21(10-11-2-3-11)17(24)13-9-19-22-14(8-15(23)20-16(13)22)12-4-6-18-7-5-12/h8-9,11-12,18H,2-7,10H2,1H3,(H,20,23) PYUMXKYRKMGFQD-UHFFFAOYSA-N 297855 US10118930, Example 78::N-(cyclopropylmethyl)- N-methyl-5-oxo-7- (piperidin-4-yl)-4,5- dihydropyrazolo[1,5- a]pyrimidine-3- carboxamide Tissue-type plasminogen activator Human 48.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297855 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297855&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137251677 381620689 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570937 CCc1cccc(NC(=O)c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)c1 InChI=1S/C20H23N5O2/c1-2-13-4-3-5-15(10-13)23-20(27)16-12-22-25-17(11-18(26)24-19(16)25)14-6-8-21-9-7-14/h3-5,10-12,14,21H,2,6-9H2,1H3,(H,23,27)(H,24,26) DRTADACUPKQHSQ-UHFFFAOYSA-N 297856 US10118930, Example 80::N-(3-ethylphenyl)-5- oxo-7-(piperidin-4-yl)- 4,5- dihydropyrazolo[1,5- a]pyrimidine-3- carboxamide Tissue-type plasminogen activator Human 33.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297856 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297856&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529721 381620690 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570938 Cc1cc(F)ccc1NC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H20FN5O2/c1-11-8-13(20)2-3-15(11)23-19(27)14-10-22-25-16(9-17(26)24-18(14)25)12-4-6-21-7-5-12/h2-3,8-10,12,21H,4-7H2,1H3,(H,23,27)(H,24,26) IJTFJQVVAGYWIQ-UHFFFAOYSA-N 297857 US10118930, Example 81::N-(4-fluoro-2- methylphenyl)-5-oxo-7- (piperidin-4-yl)-4,5- dihydropyrazolo[1,5- a]pyrimidine-3- carboxamide Tissue-type plasminogen activator Human 81.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297857 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297857&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529722 381620691 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570939 O=C(NC1CCOC1)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C16H21N5O3/c22-14-7-13(10-1-4-17-5-2-10)21-15(20-14)12(8-18-21)16(23)19-11-3-6-24-9-11/h7-8,10-11,17H,1-6,9H2,(H,19,23)(H,20,22) QHLDZELPDGJNGJ-UHFFFAOYSA-N 297858 US10118930, Example 82::5-oxo-7-(piperidin-4-yl)- N-(tetrahydrofuran-3- yl)-4,5- dihydropyrazolo[1,5- a]pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 29.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297858 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297858&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018277 381620692 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570940 O=C(NCCN1CCNC1=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H23N7O3/c25-14-9-13(11-1-3-18-4-2-11)24-15(22-14)12(10-21-24)16(26)19-5-7-23-8-6-20-17(23)27/h9-11,18H,1-8H2,(H,19,26)(H,20,27)(H,22,25) OCRZIQOIFLUBOO-UHFFFAOYSA-N 297859 US10118930, Example 83::5-oxo-N-[2-(2- oxoimidazolidin-1- yl)ethyl]-7-(piperidin-4- yl)-4,5- dihydropyrazolo[1,5- a]pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 30.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297859 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297859&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018276 381620693 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570941 CCCn1ccnc1CNC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H25N7O2/c1-2-8-25-9-7-21-16(25)12-22-19(28)14-11-23-26-15(10-17(27)24-18(14)26)13-3-5-20-6-4-13/h7,9-11,13,20H,2-6,8,12H2,1H3,(H,22,28)(H,24,27) SBDNLCQWMPJPBT-UHFFFAOYSA-N 297860 US10118930, Example 84::5-oxo-7-(piperidin-4-yl)- N-[(1-propyl-1H- imidazol-2-yl)methyl]- 4,5- dihydropyrazolo[1,5- a]pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297860 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297860&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137251821 381620694 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570942 Cc1ccc(NC(=O)c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)cc1C InChI=1S/C20H23N5O2/c1-12-3-4-15(9-13(12)2)23-20(27)16-11-22-25-17(10-18(26)24-19(16)25)14-5-7-21-8-6-14/h3-4,9-11,14,21H,5-8H2,1-2H3,(H,23,27)(H,24,26) GVBGTGJHVRGRQC-UHFFFAOYSA-N 297861 US10118930, Example 85::N-(3,4-dimethylphenyl)- 5-oxo-7-(piperidin-4-yl)- 4,5- dihydropyrazolo[1,5- a]pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 32.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297861 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297861&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529723 381620695 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570943 Cc1ccccc1CNC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H23N5O2/c1-13-4-2-3-5-15(13)11-22-20(27)16-12-23-25-17(10-18(26)24-19(16)25)14-6-8-21-9-7-14/h2-5,10,12,14,21H,6-9,11H2,1H3,(H,22,27)(H,24,26) LGRCCHMMCJYLHI-UHFFFAOYSA-N 297862 US10118930, Example 86::N-(2-methylbenzyl)-5- oxo-7-(piperidin-4-yl)- 4,5- dihydropyrazolo[1,5- a]pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 17.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297862 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297862&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529724 381620696 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570944 Fc1c(Cl)cccc1NC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C18H17ClFN5O2/c19-12-2-1-3-13(16(12)20)23-18(27)11-9-22-25-14(8-15(26)24-17(11)25)10-4-6-21-7-5-10/h1-3,8-10,21H,4-7H2,(H,23,27)(H,24,26) BPDZGATUAUMHCK-UHFFFAOYSA-N 297863 US10118930, Example 87::N-(3-chloro-2- fluorophenyl)-5-oxo-7- (piperidin-4-yl)-4,5- dihydropyrazolo[1,5- a]pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 30.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297863 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297863&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529725 381620697 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570945 COCCCNC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C16H23N5O3/c1-24-8-2-5-18-16(23)12-10-19-21-13(9-14(22)20-15(12)21)11-3-6-17-7-4-11/h9-11,17H,2-8H2,1H3,(H,18,23)(H,20,22) WLGLQWYEORAZPG-UHFFFAOYSA-N 297864 US10118930, Example 88::N-(3-methoxypropyl)-5- oxo-7-(piperidin-4-yl)- 4,5- dihydropyrazolo[1,5- a]pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 49.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297864 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297864&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018701 381620698 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570946 NC(=O)CCNC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C15H20N6O3/c16-12(22)3-6-18-15(24)10-8-19-21-11(7-13(23)20-14(10)21)9-1-4-17-5-2-9/h7-9,17H,1-6H2,(H2,16,22)(H,18,24)(H,20,23) MACFBOAMWDTNMM-UHFFFAOYSA-N 297865 US10118930, Example 89::N-(3-amino-3- oxopropyl)-5-oxo-7- (piperidin-4-yl)-4,5- dihydropyrazolo[1,5- a]pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 140 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297865 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297865&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018707 381620699 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570947 O=C(NCCC1CCCC1)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H27N5O2/c25-17-11-16(14-6-8-20-9-7-14)24-18(23-17)15(12-22-24)19(26)21-10-5-13-3-1-2-4-13/h11-14,20H,1-10H2,(H,21,26)(H,23,25) NBNLLWBHDSNJNK-UHFFFAOYSA-N 297866 US10118930, Example 90::N-(2-cyclopentylethyl)- 5-oxo-7-(piperidin-4-yl)- 4,5- dihydropyrazolo[1,5- a]pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 28.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297866 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297866&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018700 381620700 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570948 CC1(CCC1)NC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H23N5O2/c1-17(5-2-6-17)21-16(24)12-10-19-22-13(9-14(23)20-15(12)22)11-3-7-18-8-4-11/h9-11,18H,2-8H2,1H3,(H,20,23)(H,21,24) IFAQZJGHXHJABB-UHFFFAOYSA-N 297867 US10118930, Example 91::N-(1-methylcyclobutyl)- 5-oxo-7-(piperidin-4-yl)- 4,5- dihydropyrazolo[1,5- a]pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 19.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297867 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297867&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018337 381620701 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570949 O=C(NCCN1CCOC1=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H22N6O4/c24-14-9-13(11-1-3-18-4-2-11)23-15(21-14)12(10-20-23)16(25)19-5-6-22-7-8-27-17(22)26/h9-11,18H,1-8H2,(H,19,25)(H,21,24) COEWPPLLSZGLIH-UHFFFAOYSA-N 297868 US10118930, Example 92::5-oxo-N-[2-(2-oxo-1,3- oxazolidin-3-yl)ethyl]-7- (piperidin-4-yl)-4,5- dihydropyrazolo[1,5- a]pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 33.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297868 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297868&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018339 381620702 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570950 CC(C)(C)CNC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H25N5O2/c1-17(2,3)10-19-16(24)12-9-20-22-13(8-14(23)21-15(12)22)11-4-6-18-7-5-11/h8-9,11,18H,4-7,10H2,1-3H3,(H,19,24)(H,21,23) BCIZEXWHUYUFDO-UHFFFAOYSA-N 297869 US10118930, Example 93::N-(2,2-dimethylpropyl)- 5-oxo-7-(piperidin-4-yl)- 4,5- dihydropyrazolo[1,5- a]pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 22.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297869 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297869&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018341 381620703 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570951 O=C(NC1(Cc2ccccc2)CC1)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C22H25N5O2/c28-19-12-18(16-6-10-23-11-7-16)27-20(25-19)17(14-24-27)21(29)26-22(8-9-22)13-15-4-2-1-3-5-15/h1-5,12,14,16,23H,6-11,13H2,(H,25,28)(H,26,29) KCXZPJFFHVNNNF-UHFFFAOYSA-N 297870 US10118930, Example 94::N-(1- benzylcyclopropyl)-5- oxo-7-(piperidin-4-yl)- 4,5- dihydropyrazolo[1,5- a]pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 30.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297870 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297870&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529726 381620704 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570952 OC1CCN(CC1)C(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H23N5O3/c23-12-3-7-21(8-4-12)17(25)13-10-19-22-14(9-15(24)20-16(13)22)11-1-5-18-6-2-11/h9-12,18,23H,1-8H2,(H,20,24) OEQZTCJMZAWERG-UHFFFAOYSA-N 297871 US10118930, Example 95::3-[(4-hydroxypiperidin- 1-yl)carbonyl]-7- (piperidin-4- yl)pyrazolo[1,5- a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 43.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297871 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297871&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018340 381620705 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570953 CCCN(CC)C(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H25N5O2/c1-3-9-21(4-2)17(24)13-11-19-22-14(10-15(23)20-16(13)22)12-5-7-18-8-6-12/h10-12,18H,3-9H2,1-2H3,(H,20,23) DJYASZPIFZQORC-UHFFFAOYSA-N 297872 US10118930, Example 96::N-ethyl-5-oxo-7- (piperidin-4-yl)-N- propyl-4,5- dihydropyrazolo[1,5- a]pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 33.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297872 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297872&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018343 381620706 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570954 CN(Cc1ccccc1)C(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H23N5O2/c1-24(13-14-5-3-2-4-6-14)20(27)16-12-22-25-17(11-18(26)23-19(16)25)15-7-9-21-10-8-15/h2-6,11-12,15,21H,7-10,13H2,1H3,(H,23,26) FYWBAWSMBNHJMS-UHFFFAOYSA-N 297873 US10118930, Example 97::N-benzyl-N-methyl-5- oxo-7-(piperidin-4-yl)- 4,5- dihydropyrazolo[1,5- a]pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 24.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297873 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297873&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529727 381620707 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570955 CCC(=O)N1CCN(CC1)C(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H26N6O3/c1-2-17(27)23-7-9-24(10-8-23)19(28)14-12-21-25-15(11-16(26)22-18(14)25)13-3-5-20-6-4-13/h11-13,20H,2-10H2,1H3,(H,22,26) NTCLOERJWILOEI-UHFFFAOYSA-N 297874 US10118930, Example 98::7-(piperidin-4-yl)-3-[(4- propanoylpiperazin-1- yl)carbonyl]pyrazolo[1,5- a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 90.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297874 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297874&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018284 381620708 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570956 CN(CCC(N)=O)C(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C16H22N6O3/c1-21(7-4-13(17)23)16(25)11-9-19-22-12(8-14(24)20-15(11)22)10-2-5-18-6-3-10/h8-10,18H,2-7H2,1H3,(H2,17,23)(H,20,24) GKAFVKBCWJGPDS-UHFFFAOYSA-N 297875 US10118930, Example 99::N-(3-amino-3- oxopropyl)-N-methyl-5- oxo-7-(piperidin-4-yl)- 4,5- dihydropyrazolo[1,5- a]pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 49.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297875 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297875&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018285 381620709 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570957 O=C(N1CCNC(=O)CC1)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H22N6O3/c24-14-3-7-22(8-6-19-14)17(26)12-10-20-23-13(9-15(25)21-16(12)23)11-1-4-18-5-2-11/h9-11,18H,1-8H2,(H,19,24)(H,21,25) HTGZVUUGVXTXAR-UHFFFAOYSA-N 297876 US10118930, Example 100::3-[(5-oxo-1,4-diazepan- 1-yl)carbonyl]-7- (piperidin-4- yl)pyrazolo[1,5- a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 110 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297876 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297876&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018279 381620710 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570958 FC1(F)CCN(C1)C(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C16H19F2N5O2/c17-16(18)3-6-22(9-16)15(25)11-8-20-23-12(7-13(24)21-14(11)23)10-1-4-19-5-2-10/h7-8,10,19H,1-6,9H2,(H,21,24) RFUZBKZLZVDICO-UHFFFAOYSA-N 297877 US10118930, Example 101::3-[(3,3- difluoropyrrolidin-1- yl)carbonyl]-7- (piperidin-4- yl)pyrazolo[1,5- a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297877 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297877&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018280 381620711 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570959 CN(CC(F)(F)F)C(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C15H18F3N5O2/c1-22(8-15(16,17)18)14(25)10-7-20-23-11(6-12(24)21-13(10)23)9-2-4-19-5-3-9/h6-7,9,19H,2-5,8H2,1H3,(H,21,24) KEAKCRGXDSWJEB-UHFFFAOYSA-N 297878 US10118930, Example 103::N-methyl-5-oxo-7- (piperidin-4-yl)-N- (2,2,2-trifluoroethyl)- 4,5- dihydropyrazolo[1,5- a]pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 35.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297878 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297878&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018571 381620712 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570960 CC1CCCN(C1C)C(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H27N5O2/c1-12-4-3-9-23(13(12)2)19(26)15-11-21-24-16(10-17(25)22-18(15)24)14-5-7-20-8-6-14/h10-14,20H,3-9H2,1-2H3,(H,22,25) VIABHBWVBIQSSR-UHFFFAOYSA-N 297879 US10118930, Example 104::3-[(2,3- dimethylpiperidin-1- yl)carbonyl]-7- (piperidin-4- yl)pyrazolo[1,5- a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 31.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297879 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297879&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018569 381620713 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570961 COCC(C)(C)c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C18H24N6O3/c1-18(2,10-26-3)17-22-16(27-23-17)12-9-20-24-13(8-14(25)21-15(12)24)11-4-6-19-7-5-11/h8-9,11,19H,4-7,10H2,1-3H3,(H,21,25) KJKJXSMCXYQVCB-UHFFFAOYSA-N 297880 US10118930, Example 105::3-[3-(1-methoxy-2- methylpropan-2-yl)- 1,2,4-oxadiazol-5-yl]-7- (piperidin-4- yl)pyrazolo[1,5- a]pyrimidin-5(4H)-one Tissue-type plasminogen activator Human 95.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297880 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297880&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018264 381620714 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570962 O=c1cc(C2CCNCC2)n2ncc(-c3nc(Cc4ccccc4)no3)c2[nH]1 InChI=1S/C20H20N6O2/c27-18-11-16(14-6-8-21-9-7-14)26-19(24-18)15(12-22-26)20-23-17(25-28-20)10-13-4-2-1-3-5-13/h1-5,11-12,14,21H,6-10H2,(H,24,27) ODQPVJLCOCITLE-UHFFFAOYSA-N 297881 US10118930, Example 106::US10118930, Example 114::3-(3-benzyl-1,2,4- oxadiazol-5-yl)-7- (piperidin-4- yl)pyrazolo[1,5- a]pyrimidin-5(4H)-one Tissue-type plasminogen activator Human 63.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297881 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297881&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529728 381620715 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570963 CCc1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C15H18N6O2/c1-2-12-18-15(23-20-12)10-8-17-21-11(7-13(22)19-14(10)21)9-3-5-16-6-4-9/h7-9,16H,2-6H2,1H3,(H,19,22) RHEMDTHEFXFTFX-UHFFFAOYSA-N 297882 US10118930, Example 107::3-(3-ethyl-1,2,4- oxadiazol-5-yl)-7- (piperidin-4- yl)pyrazolo[1,5- a]pyrimidin-5(4H)-one::US10118930, Example 199 Tissue-type plasminogen activator Human 49.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297882 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297882&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018266 381620716 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570964 O=c1cc(C2CCNCC2)n2ncc(-c3nc(no3)C3CCC3)c2[nH]1 InChI=1S/C17H20N6O2/c24-14-8-13(10-4-6-18-7-5-10)23-16(20-14)12(9-19-23)17-21-15(22-25-17)11-2-1-3-11/h8-11,18H,1-7H2,(H,20,24) FIENSVVDZRVWER-UHFFFAOYSA-N 297883 US10118930, Example 108::3-(3-cyclobutyl-1,2,4- oxadiazol-5-yl)-7- (piperidin-4- yl)pyrazolo[1,5- a]pyrimidin-5(4H)-one Tissue-type plasminogen activator Human 76.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297883 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297883&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018269 381620717 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570965 Fc1ccc(s1)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H15FN6O2S/c18-13-2-1-12(27-13)15-22-17(26-23-15)10-8-20-24-11(7-14(25)21-16(10)24)9-3-5-19-6-4-9/h1-2,7-9,19H,3-6H2,(H,21,25) VKJVSEXKIZLUER-UHFFFAOYSA-N 297884 US10118930, Example 109::3-[3-(5-fluorothiophen- 2-yl)-1,2,4-oxadiazol-5- yl]-7-(piperidin-4- yl)pyrazolo[1,5- a]pyrimidin-5(4H)-one Tissue-type plasminogen activator Human 120 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297884 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297884&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018268 381620718 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570966 O=c1cc(C2CCNCC2)n2ncc(-c3nc(no3)-c3ccco3)c2[nH]1 InChI=1S/C17H16N6O3/c24-14-8-12(10-3-5-18-6-4-10)23-16(20-14)11(9-19-23)17-21-15(22-26-17)13-2-1-7-25-13/h1-2,7-10,18H,3-6H2,(H,20,24) KHXKIWCURSVUHP-UHFFFAOYSA-N 297885 US10118930, Example 110::3-[3-(furan-2-yl)-1,2,4- oxadiazol-5-yl]-7- (piperidin-4- yl)pyrazolo[1,5- a]pyrimidin-5(4H-one Tissue-type plasminogen activator Human 82.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297885 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297885&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018272 381620719 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570967 FC(F)(F)c1cccc(c1)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H17F3N6O2/c21-20(22,23)13-3-1-2-12(8-13)17-27-19(31-28-17)14-10-25-29-15(9-16(30)26-18(14)29)11-4-6-24-7-5-11/h1-3,8-11,24H,4-7H2,(H,26,30) JDUUYXQKKLPUCY-UHFFFAOYSA-N 297886 US10118930, Example 111::7-(Piperidin-4-yl)-3-{3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 32.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297886 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297886&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529729 381620720 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570968 Fc1cccc(c1)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H17FN6O2/c20-13-3-1-2-12(8-13)17-24-19(28-25-17)14-10-22-26-15(9-16(27)23-18(14)26)11-4-6-21-7-5-11/h1-3,8-11,21H,4-7H2,(H,23,27) PSVASFUERMDWNX-UHFFFAOYSA-N 297887 US10118930, Example 112::3-[3-(3-Fluorophenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 29.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297887 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297887&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529730 381620721 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570969 FC(F)(F)c1ccc(cc1)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H17F3N6O2/c21-20(22,23)13-3-1-12(2-4-13)17-27-19(31-28-17)14-10-25-29-15(9-16(30)26-18(14)29)11-5-7-24-8-6-11/h1-4,9-11,24H,5-8H2,(H,26,30) SQLFOJDHWGHYJT-UHFFFAOYSA-N 297888 US10118930, Example 113::7-(Piperidin-4-yl)-3-{3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 44.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297888 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297888&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529731 381620722 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570970 O=c1cc(C2CCNCC2)n2ncc(-c3nc(Cc4ccccc4)no3)c2[nH]1 InChI=1S/C20H20N6O2/c27-18-11-16(14-6-8-21-9-7-14)26-19(24-18)15(12-22-26)20-23-17(25-28-20)10-13-4-2-1-3-5-13/h1-5,11-12,14,21H,6-10H2,(H,24,27) ODQPVJLCOCITLE-UHFFFAOYSA-N 297881 US10118930, Example 106::US10118930, Example 114::3-(3-benzyl-1,2,4- oxadiazol-5-yl)-7- (piperidin-4- yl)pyrazolo[1,5- a]pyrimidin-5(4H)-one Tissue-type plasminogen activator Human 23.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297881 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297881&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529728 381620715 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570971 FC(F)(F)Oc1ccc(cc1)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H17F3N6O3/c21-20(22,23)31-13-3-1-12(2-4-13)17-27-19(32-28-17)14-10-25-29-15(9-16(30)26-18(14)29)11-5-7-24-8-6-11/h1-4,9-11,24H,5-8H2,(H,26,30) RSIXWJKDEAHFIQ-UHFFFAOYSA-N 297890 US10118930, Example 115::7-(Piperidin-4-yl)-3-{3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 27.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297890 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297890&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529732 381620723 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570972 COc1cc(ccc1C)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C21H22N6O3/c1-12-3-4-14(9-17(12)29-2)19-25-21(30-26-19)15-11-23-27-16(10-18(28)24-20(15)27)13-5-7-22-8-6-13/h3-4,9-11,13,22H,5-8H2,1-2H3,(H,24,28) FSGDNPRRYDEXAS-UHFFFAOYSA-N 297891 US10118930, Example 116::3-[3-(3-Methoxy-4-methylphenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 39.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297891 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297891&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529733 381620724 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570973 Cc1ccc(cc1F)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H19FN6O2/c1-11-2-3-13(8-15(11)21)18-25-20(29-26-18)14-10-23-27-16(9-17(28)24-19(14)27)12-4-6-22-7-5-12/h2-3,8-10,12,22H,4-7H2,1H3,(H,24,28) KEOWCSZIWIYQIQ-UHFFFAOYSA-N 297892 US10118930, Example 117::3-[3-(3-Fluoro-4-methylphenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 38.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297892 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297892&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529734 381620725 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570974 Cc1ccc(cc1C(F)(F)F)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C21H19F3N6O2/c1-11-2-3-13(8-15(11)21(22,23)24)18-28-20(32-29-18)14-10-26-30-16(9-17(31)27-19(14)30)12-4-6-25-7-5-12/h2-3,8-10,12,25H,4-7H2,1H3,(H,27,31) LWJKCYUXUJTITG-UHFFFAOYSA-N 297893 US10118930, Example 118::3-{3-[4-Methyl-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 45.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297893 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297893&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529735 381620726 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570975 Cc1ccccc1-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H20N6O2/c1-12-4-2-3-5-14(12)18-24-20(28-25-18)15-11-22-26-16(10-17(27)23-19(15)26)13-6-8-21-9-7-13/h2-5,10-11,13,21H,6-9H2,1H3,(H,23,27) LFXGPTRJZGBYJR-UHFFFAOYSA-N 297894 US10118930, Example 119::3-[3-(2-Methylphenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 79.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297894 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297894&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529736 381620727 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570976 Cc1cccc(c1)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H20N6O2/c1-12-3-2-4-14(9-12)18-24-20(28-25-18)15-11-22-26-16(10-17(27)23-19(15)26)13-5-7-21-8-6-13/h2-4,9-11,13,21H,5-8H2,1H3,(H,23,27) UFIRQUBOTCNIEH-UHFFFAOYSA-N 297895 US10118930, Example 120::3-[3-(3-Methylphenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 35.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297895 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297895&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529737 381620728 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570977 Clc1ccccc1-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H17ClN6O2/c20-14-4-2-1-3-12(14)17-24-19(28-25-17)13-10-22-26-15(9-16(27)23-18(13)26)11-5-7-21-8-6-11/h1-4,9-11,21H,5-8H2,(H,23,27) NIPJLAWOQRQHNR-UHFFFAOYSA-N 297896 US10118930, Example 121::3-[3-(2-Chlorophenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 40.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297896 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297896&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529738 381620729 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570978 COc1ccc(cc1F)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H19FN6O3/c1-29-16-3-2-12(8-14(16)21)18-25-20(30-26-18)13-10-23-27-15(9-17(28)24-19(13)27)11-4-6-22-7-5-11/h2-3,8-11,22H,4-7H2,1H3,(H,24,28) DHEVTYHGSKNSRU-UHFFFAOYSA-N 297897 US10118930, Example 122::3-[3-(3-Fluoro-4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 35.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297897 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297897&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529739 381620730 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570979 Cc1ccc(cc1Cl)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H19ClN6O2/c1-11-2-3-13(8-15(11)21)18-25-20(29-26-18)14-10-23-27-16(9-17(28)24-19(14)27)12-4-6-22-7-5-12/h2-3,8-10,12,22H,4-7H2,1H3,(H,24,28) PIHZBEUOWWFWMT-UHFFFAOYSA-N 297898 US10118930, Example 123::3-[3-(3-Chloro-4-methylphenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 47.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297898 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297898&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529740 381620731 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570980 FC(F)(F)Oc1cccc(c1)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H17F3N6O3/c21-20(22,23)31-13-3-1-2-12(8-13)17-27-19(32-28-17)14-10-25-29-15(9-16(30)26-18(14)29)11-4-6-24-7-5-11/h1-3,8-11,24H,4-7H2,(H,26,30) XTRXHEILLBLCTQ-UHFFFAOYSA-N 297901 US10118930, Example 124::7-(Piperidin-4-yl)-3-{3-[3-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 38.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297901 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297901&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529743 381620734 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570981 COc1cccc(c1)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H20N6O3/c1-28-14-4-2-3-13(9-14)18-24-20(29-25-18)15-11-22-26-16(10-17(27)23-19(15)26)12-5-7-21-8-6-12/h2-4,9-12,21H,5-8H2,1H3,(H,23,27) NSXAKAFHCIRGKC-UHFFFAOYSA-N 297902 US10118930, Example 125::3-[3-(3-Methoxyphenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 40.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297902 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297902&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529744 381620735 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570982 Fc1ccc(cc1)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H17FN6O2/c20-13-3-1-12(2-4-13)17-24-19(28-25-17)14-10-22-26-15(9-16(27)23-18(14)26)11-5-7-21-8-6-11/h1-4,9-11,21H,5-8H2,(H,23,27) WMXGDVVPQQPXOM-UHFFFAOYSA-N 297904 US10118930, Example 126::3-[3-(4-Fluorophenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 47.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297904 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297904&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529746 381620737 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570983 Cc1ccc(-c2noc(n2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)c(C)c1 InChI=1S/C21H22N6O2/c1-12-3-4-15(13(2)9-12)19-25-21(29-26-19)16-11-23-27-17(10-18(28)24-20(16)27)14-5-7-22-8-6-14/h3-4,9-11,14,22H,5-8H2,1-2H3,(H,24,28) GEUGYEPUESNRCS-UHFFFAOYSA-N 297905 US10118930, Example 127::3-[3-(2,4-Dimethylphenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 62.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297905 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297905&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529747 381620738 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570984 Cc1ccc(-c2noc(n2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)c(c1)C(F)(F)F InChI=1S/C21H19F3N6O2/c1-11-2-3-13(15(8-11)21(22,23)24)18-28-20(32-29-18)14-10-26-30-16(9-17(31)27-19(14)30)12-4-6-25-7-5-12/h2-3,8-10,12,25H,4-7H2,1H3,(H,27,31) LYTLLDWQMFQALD-UHFFFAOYSA-N 297906 US10118930, Example 128::3-{3-[4-Methyl-2-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 110 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297906 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297906&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529748 381620739 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570985 Cc1ccc(cc1C)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C21H22N6O2/c1-12-3-4-15(9-13(12)2)19-25-21(29-26-19)16-11-23-27-17(10-18(28)24-20(16)27)14-5-7-22-8-6-14/h3-4,9-11,14,22H,5-8H2,1-2H3,(H,24,28) KMORXFUEIHGEJC-UHFFFAOYSA-N 297907 US10118930, Example 129::3-[3-(3,4-Dimethylphenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 38.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297907 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297907&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529749 381620740 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570986 Cc1ccc(-c2noc(n2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)c(Cl)c1 InChI=1S/C20H19ClN6O2/c1-11-2-3-13(15(21)8-11)18-25-20(29-26-18)14-10-23-27-16(9-17(28)24-19(14)27)12-4-6-22-7-5-12/h2-3,8-10,12,22H,4-7H2,1H3,(H,24,28) URKIHZNAZYYHPL-UHFFFAOYSA-N 297909 US10118930, Example 130::3-[3-(2-Chloro-4-methylphenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 41.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297909 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297909&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529750 381620742 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570987 Cc1ccc(-c2noc(n2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)c(F)c1 InChI=1S/C20H19FN6O2/c1-11-2-3-13(15(21)8-11)18-25-20(29-26-18)14-10-23-27-16(9-17(28)24-19(14)27)12-4-6-22-7-5-12/h2-3,8-10,12,22H,4-7H2,1H3,(H,24,28) JEOVKKHWSZGNDM-UHFFFAOYSA-N 297910 US10118930, Example 131::3-[3-(2-Fluoro-4-methylphenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 63.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297910 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297910&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529751 381620743 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570988 Fc1c(Cl)cccc1-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H16ClFN6O2/c20-13-3-1-2-11(16(13)21)17-25-19(29-26-17)12-9-23-27-14(8-15(28)24-18(12)27)10-4-6-22-7-5-10/h1-3,8-10,22H,4-7H2,(H,24,28) YCQPRGKBOUTENT-UHFFFAOYSA-N 297911 US10118930, Example 132::3-[3-(3-Chloro-2-fluorophenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 35.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297911 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297911&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529752 381620744 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570989 Clc1cccc(n1)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C18H16ClN7O2/c19-14-3-1-2-12(22-14)16-24-18(28-25-16)11-9-21-26-13(8-15(27)23-17(11)26)10-4-6-20-7-5-10/h1-3,8-10,20H,4-7H2,(H,23,27) IJTVKBXUNWOONW-UHFFFAOYSA-N 297913 US10118930, Example 133::3-[3-(6-Chloropyridin-2-yl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 39.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297913 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297913&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529753 381620746 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570990 Fc1cc(ccc1C(F)(F)F)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H16F4N6O2/c21-14-7-11(1-2-13(14)20(22,23)24)17-28-19(32-29-17)12-9-26-30-15(8-16(31)27-18(12)30)10-3-5-25-6-4-10/h1-2,7-10,25H,3-6H2,(H,27,31) WJAVMQUSGXCXAO-UHFFFAOYSA-N 297914 US10118930, Example 134::3-{3-[3-Fluoro-4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 43.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297914 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297914&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529754 381620747 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570991 Fc1cc(ccc1-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1)C(F)(F)F InChI=1S/C20H16F4N6O2/c21-14-7-11(20(22,23)24)1-2-12(14)17-28-19(32-29-17)13-9-26-30-15(8-16(31)27-18(13)30)10-3-5-25-6-4-10/h1-2,7-10,25H,3-6H2,(H,27,31) BGCKRVKJSLCAEG-UHFFFAOYSA-N 297917 US10118930, Example 135::3-{3-[2-Fluoro-4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 40.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297917 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297917&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529757 381620750 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570992 FC(F)(F)c1ccc(-c2noc(n2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)c(Cl)c1 InChI=1S/C20H16ClF3N6O2/c21-14-7-11(20(22,23)24)1-2-12(14)17-28-19(32-29-17)13-9-26-30-15(8-16(31)27-18(13)30)10-3-5-25-6-4-10/h1-2,7-10,25H,3-6H2,(H,27,31) AJLKYWSJOYTADB-UHFFFAOYSA-N 297918 US10118930, Example 136::3-{3-[2-Chloro-4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 43.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297918 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297918&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529758 381620751 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570993 Fc1ccc(Cl)cc1-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H16ClFN6O2/c20-11-1-2-14(21)12(7-11)17-25-19(29-26-17)13-9-23-27-15(8-16(28)24-18(13)27)10-3-5-22-6-4-10/h1-2,7-10,22H,3-6H2,(H,24,28) BLSWRJCVNOZXNN-UHFFFAOYSA-N 297921 US10118930, Example 137::3-[3-(5-Chloro-2-fluorophenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 31.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297921 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297921&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529760 381620754 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570994 Fc1cc(Cl)cc(c1)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H16ClFN6O2/c20-12-5-11(6-13(21)7-12)17-25-19(29-26-17)14-9-23-27-15(8-16(28)24-18(14)27)10-1-3-22-4-2-10/h5-10,22H,1-4H2,(H,24,28) UEORUIKXTHRAGO-UHFFFAOYSA-N 297922 US10118930, Example 138::3-[3-(3-Chloro-5-fluorophenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 39.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297922 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297922&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529761 381620755 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570995 Cc1cc(ccc1-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1)C(F)(F)F InChI=1S/C21H19F3N6O2/c1-11-8-13(21(22,23)24)2-3-14(11)18-28-20(32-29-18)15-10-26-30-16(9-17(31)27-19(15)30)12-4-6-25-7-5-12/h2-3,8-10,12,25H,4-7H2,1H3,(H,27,31) AKNMVXRNQVFYAP-UHFFFAOYSA-N 297923 US10118930, Example 139::3-{3-[2-Methyl-4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 41.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297923 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297923&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529762 381620756 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570996 Cc1c(Cl)cccc1-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H19ClN6O2/c1-11-13(3-2-4-15(11)21)18-25-20(29-26-18)14-10-23-27-16(9-17(28)24-19(14)27)12-5-7-22-8-6-12/h2-4,9-10,12,22H,5-8H2,1H3,(H,24,28) MNHDRASKYDWIJM-UHFFFAOYSA-N 297924 US10118930, Example 140::3-[3-(3-Chloro-2-methylphenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 130 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297924 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297924&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529763 381620757 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570997 Cc1ccc(Cl)cc1-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H19ClN6O2/c1-11-2-3-13(21)8-14(11)18-25-20(29-26-18)15-10-23-27-16(9-17(28)24-19(15)27)12-4-6-22-7-5-12/h2-3,8-10,12,22H,4-7H2,1H3,(H,24,28) GFHRFGWWYJGVEO-UHFFFAOYSA-N 297925 US10118930, Example 141::3-[3-(5-Chloro-2-methylphenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 74.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297925 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297925&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529764 381620758 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570998 COc1ccc(cc1Cl)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H19ClN6O3/c1-29-16-3-2-12(8-14(16)21)18-25-20(30-26-18)13-10-23-27-15(9-17(28)24-19(13)27)11-4-6-22-7-5-11/h2-3,8-11,22H,4-7H2,1H3,(H,24,28) HHGYZKFBUXBWCQ-UHFFFAOYSA-N 297926 US10118930, Example 142::3-[3-(3-Chloro-4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 41.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297926 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297926&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529765 381620759 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 570999 Clc1cccc(-c2noc(n2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)c1Cl InChI=1S/C19H16Cl2N6O2/c20-13-3-1-2-11(16(13)21)17-25-19(29-26-17)12-9-23-27-14(8-15(28)24-18(12)27)10-4-6-22-7-5-10/h1-3,8-10,22H,4-7H2,(H,24,28) LFSPZRYXPWAARO-UHFFFAOYSA-N 297927 US10118930, Example 143::3-[3-(2,3-Dichlorophenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 41.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297927 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297927&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529766 381620760 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571000 Fc1ccc(cc1Cl)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H16ClFN6O2/c20-13-7-11(1-2-14(13)21)17-25-19(29-26-17)12-9-23-27-15(8-16(28)24-18(12)27)10-3-5-22-6-4-10/h1-2,7-10,22H,3-6H2,(H,24,28) XGQFHPZQOCPQEL-UHFFFAOYSA-N 297928 US10118930, Example 144::3-[3-(3-Chloro-4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 87.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297928 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297928&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529767 381620761 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571001 FC(F)(F)c1ccc(Cl)cc1-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H16ClF3N6O2/c21-11-1-2-14(20(22,23)24)12(7-11)17-28-19(32-29-17)13-9-26-30-15(8-16(31)27-18(13)30)10-3-5-25-6-4-10/h1-2,7-10,25H,3-6H2,(H,27,31) VHHLGFYOYCKISS-UHFFFAOYSA-N 297929 US10118930, Example 145::3-{3-[5-Chloro-2-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 28.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297929 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297929&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529768 381620762 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571002 FC(F)(F)c1cccc(n1)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H16F3N7O2/c20-19(21,22)14-3-1-2-12(25-14)16-27-18(31-28-16)11-9-24-29-13(8-15(30)26-17(11)29)10-4-6-23-7-5-10/h1-3,8-10,23H,4-7H2,(H,26,30) ZYCGCBPBCMLVJG-UHFFFAOYSA-N 297930 US10118930, Example 146::7-(Piperidin-4-yl)-3-{3-[6-(trifluoromethyl)pyridin-2-yl]-1,2,4-oxadiazol-5-yl}pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 35.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297930 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297930&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529769 381620763 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571003 FC(F)(F)c1ccnc(c1)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H16F3N7O2/c20-19(21,22)11-3-6-24-13(7-11)16-27-18(31-28-16)12-9-25-29-14(8-15(30)26-17(12)29)10-1-4-23-5-2-10/h3,6-10,23H,1-2,4-5H2,(H,26,30) RCPDIJOZDOCZOW-UHFFFAOYSA-N 297931 US10118930, Example 147::7-(piperidin-4-yl)-3-{3-[4-(trifluoromethyl)pyridin-2-yl]-1,2,4-oxadiazol-5-yl}pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 38.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297931 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297931&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529770 381620764 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571004 Clc1ncccc1-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C18H16ClN7O2/c19-15-11(2-1-5-21-15)16-24-18(28-25-16)12-9-22-26-13(8-14(27)23-17(12)26)10-3-6-20-7-4-10/h1-2,5,8-10,20H,3-4,6-7H2,(H,23,27) HISHPHLWAYBXER-UHFFFAOYSA-N 297932 US10118930, Example 148::3-[3-(2-Chloropyridin-3-yl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 43.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297932 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297932&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529771 381620765 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571005 FC(F)(F)Oc1ccc(cc1Cl)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H16ClF3N6O3/c21-13-7-11(1-2-15(13)32-20(22,23)24)17-28-19(33-29-17)12-9-26-30-14(8-16(31)27-18(12)30)10-3-5-25-6-4-10/h1-2,7-10,25H,3-6H2,(H,27,31) GTWLHGJERNPBBU-UHFFFAOYSA-N 297933 US10118930, Example 149::3-{3-[3-Chloro-4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 100.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297933 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297933&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529772 381620766 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571006 FC(F)(F)c1cc(Cl)c(-c2noc(n2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)c(Cl)c1 InChI=1S/C20H15Cl2F3N6O2/c21-12-5-10(20(23,24)25)6-13(22)16(12)17-29-19(33-30-17)11-8-27-31-14(7-15(32)28-18(11)31)9-1-3-26-4-2-9/h5-9,26H,1-4H2,(H,28,32) TUJPAXZNWYJVBH-UHFFFAOYSA-N 297934 US10118930, Example 150::3-{3-[2,6-Dichloro-4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 45.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297934 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297934&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529773 381620767 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571007 Clc1cc(Cl)cc(c1)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H16Cl2N6O2/c20-12-5-11(6-13(21)7-12)17-25-19(29-26-17)14-9-23-27-15(8-16(28)24-18(14)27)10-1-3-22-4-2-10/h5-10,22H,1-4H2,(H,24,28) CSYMZFVCXUEARK-UHFFFAOYSA-N 297935 US10118930, Example 151::3-[3-(3,5-Dichlorophenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 44.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297935 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297935&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529774 381620768 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571008 FC(F)(F)c1ccc(-c2noc(n2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)c(c1)C(F)(F)F InChI=1S/C21H16F6N6O2/c22-20(23,24)11-1-2-12(14(7-11)21(25,26)27)17-31-19(35-32-17)13-9-29-33-15(8-16(34)30-18(13)33)10-3-5-28-6-4-10/h1-2,7-10,28H,3-6H2,(H,30,34) DGSJDVIXKUFOSB-UHFFFAOYSA-N 297936 US10118930, Example 152::3-{3-[2,4-Bis(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 43.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297936 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297936&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529775 381620769 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571009 Clc1cccc(c1)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H17ClN6O2/c20-13-3-1-2-12(8-13)17-24-19(28-25-17)14-10-22-26-15(9-16(27)23-18(14)26)11-4-6-21-7-5-11/h1-3,8-11,21H,4-7H2,(H,23,27) IOIQBJFZAFFHID-UHFFFAOYSA-N 297937 US10118930, Example 153::3-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 31.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297937 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297937&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529776 381620770 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571010 COc1ccc(-c2noc(n2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)c(C)c1 InChI=1S/C21H22N6O3/c1-12-9-14(29-2)3-4-15(12)19-25-21(30-26-19)16-11-23-27-17(10-18(28)24-20(16)27)13-5-7-22-8-6-13/h3-4,9-11,13,22H,5-8H2,1-2H3,(H,24,28) ZPYLPWTXJKEZOT-UHFFFAOYSA-N 297938 US10118930, Example 154::3-[3-(4-methoxy-2-methylphenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 24.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297938 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297938&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529777 381620771 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571011 FC(F)(F)Oc1ccccc1-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H17F3N6O3/c21-20(22,23)31-15-4-2-1-3-12(15)17-27-19(32-28-17)13-10-25-29-14(9-16(30)26-18(13)29)11-5-7-24-8-6-11/h1-4,9-11,24H,5-8H2,(H,26,30) WBOHCZXWXROFLL-UHFFFAOYSA-N 297939 US10118930, Example 155::7-(piperidin-4-yl)-3-{3-[2-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 14.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297939 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297939&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529778 381620772 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571012 COc1ccc(cc1)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H20N6O3/c1-28-14-4-2-13(3-5-14)18-24-20(29-25-18)15-11-22-26-16(10-17(27)23-19(15)26)12-6-8-21-9-7-12/h2-5,10-12,21H,6-9H2,1H3,(H,23,27) VPSGTMQUETWCML-UHFFFAOYSA-N 297940 US10118930, Example 156::3-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 16.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297940 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297940&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529779 381620773 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571013 Clc1ccc(cc1)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H17ClN6O2/c20-13-3-1-12(2-4-13)17-24-19(28-25-17)14-10-22-26-15(9-16(27)23-18(14)26)11-5-7-21-8-6-11/h1-4,9-11,21H,5-8H2,(H,23,27) VDZFZYZEWKPVIL-UHFFFAOYSA-N 297941 US10118930, Example 157::3-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 56.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297941 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297941&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529780 381620774 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571014 Fc1ccc(-c2noc(n2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)c(F)c1 InChI=1S/C19H16F2N6O2/c20-11-1-2-12(14(21)7-11)17-25-19(29-26-17)13-9-23-27-15(8-16(28)24-18(13)27)10-3-5-22-6-4-10/h1-2,7-10,22H,3-6H2,(H,24,28) GLMBSARSBYRJOH-UHFFFAOYSA-N 297943 US10118930, Example 158::3-[3-(2,4-difluorophenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 38.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297943 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297943&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529781 381620776 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571015 Fc1ccccc1-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H17FN6O2/c20-14-4-2-1-3-12(14)17-24-19(28-25-17)13-10-22-26-15(9-16(27)23-18(13)26)11-5-7-21-8-6-11/h1-4,9-11,21H,5-8H2,(H,23,27) VJPUVKKOBOECNG-UHFFFAOYSA-N 297944 US10118930, Example 159::3-[3-(2-fluorophenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 23.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297944 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297944&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529782 381620777 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571016 COc1ccccc1-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H20N6O3/c1-28-16-5-3-2-4-13(16)18-24-20(29-25-18)14-11-22-26-15(10-17(27)23-19(14)26)12-6-8-21-9-7-12/h2-5,10-12,21H,6-9H2,1H3,(H,23,27) URPSRANORMFQQJ-UHFFFAOYSA-N 297945 US10118930, Example 160::3-[3-(2-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 73.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297945 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297945&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529783 381620778 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571017 FC(F)(F)c1ccc(cc1)-c1ccc(cc1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C24H21F3N4O/c25-24(26,27)19-7-5-16(6-8-19)15-1-3-17(4-2-15)20-14-29-31-21(13-22(32)30-23(20)31)18-9-11-28-12-10-18/h1-8,13-14,18,28H,9-12H2,(H,30,32) FDHQMBSDZIBSOT-UHFFFAOYSA-N 297946 US10118930, Example 161::7-(piperidin-4-yl)-3-[4′-(trifluoromethyl)biphenyl-4-yl]pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 330 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297946 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297946&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529784 381620779 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571018 FC(F)(F)c1ccc(cc1)-c1cccc(c1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C24H21F3N4O/c25-24(26,27)19-6-4-15(5-7-19)17-2-1-3-18(12-17)20-14-29-31-21(13-22(32)30-23(20)31)16-8-10-28-11-9-16/h1-7,12-14,16,28H,8-11H2,(H,30,32) KYEIYAJOJKXCJV-UHFFFAOYSA-N 297947 US10118930, Example 162::7-(piperidin-4-yl)-3-[4′-(trifluoromethyl)biphenyl-3-yl]pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 140 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297947 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297947&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529785 381620780 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571019 Clc1cccc(c1)-c1csc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H18ClN5OS/c21-14-3-1-2-13(8-14)16-11-28-20(24-16)15-10-23-26-17(9-18(27)25-19(15)26)12-4-6-22-7-5-12/h1-3,8-12,22H,4-7H2,(H,25,27) HXIABNXMQAITJF-UHFFFAOYSA-N 297948 US10118930, Example 163::3-[4-(3-chlorophenyl)-1,3-thiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 40.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297948 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297948&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529786 381620781 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571020 CC(C)(C)c1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H22N6O2/c1-17(2,3)16-22-21-15(25-16)11-9-19-23-12(8-13(24)20-14(11)23)10-4-6-18-7-5-10/h8-10,18H,4-7H2,1-3H3,(H,20,24) NAPGLBNNFRKFLG-UHFFFAOYSA-N 297949 US10118930, Example 165::3-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297949 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297949&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018489 381620782 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571021 FC(F)(F)c1ccc(cc1)-c1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H17F3N6O2/c21-20(22,23)13-3-1-12(2-4-13)18-27-28-19(31-18)14-10-25-29-15(9-16(30)26-17(14)29)11-5-7-24-8-6-11/h1-4,9-11,24H,5-8H2,(H,26,30) NMWIFJFXIRYMJV-UHFFFAOYSA-N 297950 US10118930, Example 166::7-(piperidin-4-yl)-3-{5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-yl}pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 8.70 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297950 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297950&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529787 381620783 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571022 O=c1cc(C2CCNCC2)n2ncc(-c3nnc(o3)-c3ccc(cc3)C#N)c2[nH]1 InChI=1S/C20H17N7O2/c21-10-12-1-3-14(4-2-12)19-25-26-20(29-19)15-11-23-27-16(9-17(28)24-18(15)27)13-5-7-22-8-6-13/h1-4,9,11,13,22H,5-8H2,(H,24,28) DTDWZPZZQSRJGA-UHFFFAOYSA-N 297951 US10118930, Example 167::4-{5-[5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidin-3-yl]-1,3,4-oxadiazol-2-yl}benzonitrile hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297951 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297951&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529788 381620784 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571023 Cn1cncc1-c1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H18N8O2/c1-24-9-19-8-13(24)17-23-22-16(27-17)11-7-20-25-12(6-14(26)21-15(11)25)10-2-4-18-5-3-10/h6-10,18H,2-5H2,1H3,(H,21,26) UFOZQCZDQSAQON-UHFFFAOYSA-N 297952 US10118930, Example 168::3-[5-(1-methyl-1H-imidazol-5-yl)-1,3,4-oxadiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 33.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297952 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297952&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018196 381620785 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571024 Clc1cccc(c1)-c1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H17ClN6O2/c20-13-3-1-2-12(8-13)18-24-25-19(28-18)14-10-22-26-15(9-16(27)23-17(14)26)11-4-6-21-7-5-11/h1-3,8-11,21H,4-7H2,(H,23,27) IFCVPXFOBNEAGL-UHFFFAOYSA-N 297953 US10118930, Example 169::3-[5-(3-chlorophenyl)-1,3,4-oxadiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297953 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297953&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529789 381620786 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571025 Cc1ccc(cc1)-c1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H20N6O2/c1-12-2-4-14(5-3-12)19-24-25-20(28-19)15-11-22-26-16(10-17(27)23-18(15)26)13-6-8-21-9-7-13/h2-5,10-11,13,21H,6-9H2,1H3,(H,23,27) BZMFMXHIZOLNAT-UHFFFAOYSA-N 297954 US10118930, Example 170::3-[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297954 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297954&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529790 381620787 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571026 Cc1ccccc1-c1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H20N6O2/c1-12-4-2-3-5-14(12)19-24-25-20(28-19)15-11-22-26-16(10-17(27)23-18(15)26)13-6-8-21-9-7-13/h2-5,10-11,13,21H,6-9H2,1H3,(H,23,27) UYCJXTNGTDGZDL-UHFFFAOYSA-N 297955 US10118930, Example 171::3-[5-(2-methylphenyl)-1,3,4-oxadiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 35.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297955 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297955&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529791 381620788 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571027 FC(F)(F)c1ccccc1-c1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H17F3N6O2/c21-20(22,23)14-4-2-1-3-12(14)18-27-28-19(31-18)13-10-25-29-15(9-16(30)26-17(13)29)11-5-7-24-8-6-11/h1-4,9-11,24H,5-8H2,(H,26,30) DPSQYLCPJYBERU-UHFFFAOYSA-N 297956 US10118930, Example 172::7-(piperidin-4-yl)-3-{5-[2-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-yl}pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 59.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297956 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297956&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529792 381620789 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571028 COCc1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C15H18N6O3/c1-23-8-13-19-20-15(24-13)10-7-17-21-11(6-12(22)18-14(10)21)9-2-4-16-5-3-9/h6-7,9,16H,2-5,8H2,1H3,(H,18,22) DFCGTEPACNRJTD-UHFFFAOYSA-N 297957 US10118930, Example 173::3-[5-(methoxymethyl)-1,3,4-oxadiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297957 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297957&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018525 381620790 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571029 O=c1cc(C2CCNCC2)n2ncc(-c3nnc(o3)C3CC3)c2[nH]1 InChI=1S/C16H18N6O2/c23-13-7-12(9-3-5-17-6-4-9)22-14(19-13)11(8-18-22)16-21-20-15(24-16)10-1-2-10/h7-10,17H,1-6H2,(H,19,23) OXICPWPWKWYJSM-UHFFFAOYSA-N 297958 US10118930, Example 174::3-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297958 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297958&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018603 381620791 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571030 FC(F)(F)c1cccc(c1)-c1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H17F3N6O2/c21-20(22,23)13-3-1-2-12(8-13)18-27-28-19(31-18)14-10-25-29-15(9-16(30)26-17(14)29)11-4-6-24-7-5-11/h1-3,8-11,24H,4-7H2,(H,26,30) OELAWAIFBNNSNC-UHFFFAOYSA-N 297959 US10118930, Example 175::7-(piperidin-4-yl)-3-{5-[3-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-yl}pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 35.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297959 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297959&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529793 381620792 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571031 COc1ccc(Cc2nnc(o2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)cc1 InChI=1S/C21H22N6O3/c1-29-15-4-2-13(3-5-15)10-19-25-26-21(30-19)16-12-23-27-17(11-18(28)24-20(16)27)14-6-8-22-9-7-14/h2-5,11-12,14,22H,6-10H2,1H3,(H,24,28) KABXXTGEFNZATL-UHFFFAOYSA-N 297960 US10118930, Example 176::3-[5-(4-methoxybenzyl)-1,3,4-oxadiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 38.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297960 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297960&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529794 381620793 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571032 O=c1cc(C2CCNCC2)n2ncc(-c3nnc(o3)C3CCCC3)c2[nH]1 InChI=1S/C18H22N6O2/c25-15-9-14(11-5-7-19-8-6-11)24-16(21-15)13(10-20-24)18-23-22-17(26-18)12-3-1-2-4-12/h9-12,19H,1-8H2,(H,21,25) FYIYYGHCAJNXAC-UHFFFAOYSA-N 297961 US10118930, Example 177::3-(5-cyclopentyl-1,3,4-oxadiazol-2-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 40.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297961 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297961&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018722 381620794 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571033 O=c1cc(C2CCNCC2)n2ncc(-c3nnc(o3)-c3ccco3)c2[nH]1 InChI=1S/C17H16N6O3/c24-14-8-12(10-3-5-18-6-4-10)23-15(20-14)11(9-19-23)16-21-22-17(26-16)13-2-1-7-25-13/h1-2,7-10,18H,3-6H2,(H,20,24) UDESHNLZFSOKEM-UHFFFAOYSA-N 297962 US10118930, Example 178::3-[5-(2-furyl)-1,3,4-oxadiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297962 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297962&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137026276 381620795 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571034 CC(C)(C)c1ccc(cc1)-c1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C23H26N6O2/c1-23(2,3)16-6-4-15(5-7-16)21-27-28-22(31-21)17-13-25-29-18(12-19(30)26-20(17)29)14-8-10-24-11-9-14/h4-7,12-14,24H,8-11H2,1-3H3,(H,26,30) AKSCLPWTSQRGNB-UHFFFAOYSA-N 297963 US10118930, Example 179::3-[5-(4-tert-butylphenyl)-1,3,4-oxadiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 37.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297963 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297963&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529795 381620796 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571035 O=c1cc(C2CCNCC2)n2ncc(-c3nnc(Cc4ccccc4)o3)c2[nH]1 InChI=1S/C20H20N6O2/c27-17-11-16(14-6-8-21-9-7-14)26-19(23-17)15(12-22-26)20-25-24-18(28-20)10-13-4-2-1-3-5-13/h1-5,11-12,14,21H,6-10H2,(H,23,27) DICLJDHOHWVCES-UHFFFAOYSA-N 297964 US10118930, Example 180::3-(5-benzyl-1,3,4-oxadiazol-2-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 35.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297964 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297964&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529796 381620797 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571036 Clc1ccc(cc1)-c1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H17ClN6O2/c20-13-3-1-12(2-4-13)18-24-25-19(28-18)14-10-22-26-15(9-16(27)23-17(14)26)11-5-7-21-8-6-11/h1-4,9-11,21H,5-8H2,(H,23,27) JBFGJMDFUBMEJN-UHFFFAOYSA-N 297965 US10118930, Example 181::3-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 28.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297965 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297965&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529797 381620798 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571037 O=c1cc(C2CCNCC2)n2ncc(-c3nnc(CC4CCCCC4)o3)c2[nH]1 InChI=1S/C20H26N6O2/c27-17-11-16(14-6-8-21-9-7-14)26-19(23-17)15(12-22-26)20-25-24-18(28-20)10-13-4-2-1-3-5-13/h11-14,21H,1-10H2,(H,23,27) MLUBSSFPSYNYQP-UHFFFAOYSA-N 297966 US10118930, Example 182::3-[5-(cyclohexylmethyl)-1,3,4-oxadiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 35.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297966 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297966&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018699 381620799 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571038 Cc1cc(ccn1)-c1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H19N7O2/c1-11-8-13(4-7-21-11)18-24-25-19(28-18)14-10-22-26-15(9-16(27)23-17(14)26)12-2-5-20-6-3-12/h4,7-10,12,20H,2-3,5-6H2,1H3,(H,23,27) JTSSCOFPGZFUBS-UHFFFAOYSA-N 297967 US10118930, Example 183::3-[5-(2-methylpyridin-4-yl)-1,3,4-oxadiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 50.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297967 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297967&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529798 381620800 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571039 COc1ccccc1-c1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H20N6O3/c1-28-16-5-3-2-4-13(16)19-24-25-20(29-19)14-11-22-26-15(10-17(27)23-18(14)26)12-6-8-21-9-7-12/h2-5,10-12,21H,6-9H2,1H3,(H,23,27) WIBNUTOMEJFAPG-UHFFFAOYSA-N 297968 US10118930, Example 184::3-[5-(2-methoxyphenyl)-1,3,4-oxadiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 36.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297968 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297968&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529799 381620801 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571040 O=c1cc(C2CCNCC2)n2ncc(-c3nnc(o3)-c3ccncc3)c2[nH]1 InChI=1S/C18H17N7O2/c26-15-9-14(11-1-5-19-6-2-11)25-16(22-15)13(10-21-25)18-24-23-17(27-18)12-3-7-20-8-4-12/h3-4,7-11,19H,1-2,5-6H2,(H,22,26) OSEYWTRMTGOBFT-UHFFFAOYSA-N 297969 US10118930, Example 185::7-(piperidin-4-yl)-3-[5-(pyridin-4-yl)-1,3,4-oxadiazol-2-yl]pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 38.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297969 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297969&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529800 381620802 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571041 Fc1ccccc1-c1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H17FN6O2/c20-14-4-2-1-3-12(14)18-24-25-19(28-18)13-10-22-26-15(9-16(27)23-17(13)26)11-5-7-21-8-6-11/h1-4,9-11,21H,5-8H2,(H,23,27) CVLIFBIYEJQUTE-UHFFFAOYSA-N 297970 US10118930, Example 186::3-[5-(2-fluorophenyl)-1,3,4-oxadiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297970 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297970&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529801 381620803 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571042 Cc1nc(sc1-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1)-c1ccccc1 InChI=1S/C21H21N5OS/c1-13-19(28-21(24-13)15-5-3-2-4-6-15)16-12-23-26-17(11-18(27)25-20(16)26)14-7-9-22-10-8-14/h2-6,11-12,14,22H,7-10H2,1H3,(H,25,27) SAJZVEHJXBSEPH-UHFFFAOYSA-N 297971 US10118930, Example 187::3-(4-methyl-2-phenyl-1,3-thiazol-5-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 35.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297971 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297971&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529802 381620804 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571043 FC(F)(F)c1ccc(cn1)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H16F3N7O2/c20-19(21,22)14-2-1-11(8-24-14)16-27-18(31-28-16)12-9-25-29-13(7-15(30)26-17(12)29)10-3-5-23-6-4-10/h1-2,7-10,23H,3-6H2,(H,26,30) DWKNTWYYWDWARD-UHFFFAOYSA-N 297972 US10118930, Example 188::7-(piperidin-4-yl)-3-{3-[6-(trifluoromethyl)pyridin-3-yl]-1,2,4-oxadiazol-5-yl}pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 35.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297972 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297972&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529803 381620805 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571044 FC(F)(F)c1ccncc1-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H16F3N7O2/c20-19(21,22)13-3-6-24-8-11(13)16-27-18(31-28-16)12-9-25-29-14(7-15(30)26-17(12)29)10-1-4-23-5-2-10/h3,6-10,23H,1-2,4-5H2,(H,26,30) AJIDLFMNKVHZQE-UHFFFAOYSA-N 297973 US10118930, Example 189::7-(piperidin-4-yl)-3-{3-[4-(trifluoromethyl)pyridin-3-yl]-1,2,4-oxadiazol-5-yl}pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 38.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297973 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297973&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529804 381620806 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571045 Fc1cc(F)c(cc1F)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H15F3N6O2/c20-12-6-14(22)13(21)5-10(12)17-26-19(30-27-17)11-8-24-28-15(7-16(29)25-18(11)28)9-1-3-23-4-2-9/h5-9,23H,1-4H2,(H,25,29) NGLPHFOVEGJNPQ-UHFFFAOYSA-N 297974 US10118930, Example 190::7-(piperidin-4-yl)-3-[3-(2,4,5-trifluorophenyl)-1,2,4-oxadiazol-5-yl]pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297974 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297974&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529805 381620807 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571046 CS(=O)(=O)Cc1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C15H18N6O4S/c1-26(23,24)8-12-18-15(25-20-12)10-7-17-21-11(6-13(22)19-14(10)21)9-2-4-16-5-3-9/h6-7,9,16H,2-5,8H2,1H3,(H,19,22) YCMCBRZXQCAQLO-UHFFFAOYSA-N 297975 US10118930, Example 191::3-{3-[(methylsulfonyl)methyl]-1,2,4-oxadiazol-5-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297975 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297975&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018281 381620808 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571047 FC(F)(F)CCCc1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H19F3N6O2/c18-17(19,20)5-1-2-13-23-16(28-25-13)11-9-22-26-12(8-14(27)24-15(11)26)10-3-6-21-7-4-10/h8-10,21H,1-7H2,(H,24,27) BMBCYKCOLSQSBM-UHFFFAOYSA-N 297976 US10118930, Example 192::7-(piperidin-4-yl)-3-[3-(4,4,4-trifluorobutyl)-1,2,4-oxadiazol-5-yl]pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297976 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297976&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018727 381620809 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571048 O=c1cc(C2CCNCC2)n2ncc(-c3nc(no3)C3CCN(CC3)C3CC3)c2[nH]1 InChI=1S/C21H27N7O2/c29-18-11-17(13-3-7-22-8-4-13)28-20(24-18)16(12-23-28)21-25-19(26-30-21)14-5-9-27(10-6-14)15-1-2-15/h11-15,22H,1-10H2,(H,24,29) STIBAIGWOPPOJQ-UHFFFAOYSA-N 297977 US10118930, Example 193::3-[3-(1-cyclopropylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 32.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297977 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297977&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018375 381620810 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571049 CC(C)(C)c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H22N6O2/c1-17(2,3)16-21-15(25-22-16)11-9-19-23-12(8-13(24)20-14(11)23)10-4-6-18-7-5-10/h8-10,18H,4-7H2,1-3H3,(H,20,24) APERGOQHHIDZNR-UHFFFAOYSA-N 297978 US10118930, Example 194::3-(3-tert-butyl-1,2,4-oxadiazol-5-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 29.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297978 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297978&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137026198 381620811 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571050 Fc1ccc(Cc2noc(n2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)c(Cl)c1 InChI=1S/C20H18ClFN6O2/c21-15-8-13(22)2-1-12(15)7-17-25-20(30-27-17)14-10-24-28-16(9-18(29)26-19(14)28)11-3-5-23-6-4-11/h1-2,8-11,23H,3-7H2,(H,26,29) CFCVHQCXYRSRPX-UHFFFAOYSA-N 297979 US10118930, Example 195::3-[3-(2-chloro-4-fluorobenzyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 35.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297979 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297979&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529806 381620812 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571051 CC(C)(C)c1ccc(cc1)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C23H26N6O2/c1-23(2,3)16-6-4-15(5-7-16)20-27-22(31-28-20)17-13-25-29-18(12-19(30)26-21(17)29)14-8-10-24-11-9-14/h4-7,12-14,24H,8-11H2,1-3H3,(H,26,30) NPTDAFSPBCZBOF-UHFFFAOYSA-N 297980 US10118930, Example 196::3-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 75.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297980 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297980&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529807 381620813 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571052 CN(C)c1ccc(cc1F)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C21H22FN7O2/c1-28(2)16-4-3-13(9-15(16)22)19-26-21(31-27-19)14-11-24-29-17(10-18(30)25-20(14)29)12-5-7-23-8-6-12/h3-4,9-12,23H,5-8H2,1-2H3,(H,25,30) OWTDGHPDDIBLIX-UHFFFAOYSA-N 297981 US10118930, Example 197::3-{3-[4-(dimethylamino)-3-fluorophenyl]-1,2,4-oxadiazol-5-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 35.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297981 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297981&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529808 381620814 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571053 Cc1ccccc1Cc1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C21H22N6O2/c1-13-4-2-3-5-15(13)10-18-24-21(29-26-18)16-12-23-27-17(11-19(28)25-20(16)27)14-6-8-22-9-7-14/h2-5,11-12,14,22H,6-10H2,1H3,(H,25,28) UZYBWXDENGFFTA-UHFFFAOYSA-N 297982 US10118930, Example 198::3-[3-(2-methylbenzyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297982 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297982&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529809 381620815 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571054 CCc1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C15H18N6O2/c1-2-12-18-15(23-20-12)10-8-17-21-11(7-13(22)19-14(10)21)9-3-5-16-6-4-9/h7-9,16H,2-6H2,1H3,(H,19,22) RHEMDTHEFXFTFX-UHFFFAOYSA-N 297882 US10118930, Example 107::3-(3-ethyl-1,2,4- oxadiazol-5-yl)-7- (piperidin-4- yl)pyrazolo[1,5- a]pyrimidin-5(4H)-one::US10118930, Example 199 Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297882 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297882&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018266 381620716 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571055 NC(=O)c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C14H15N7O3/c15-11(23)12-19-14(24-20-12)8-6-17-21-9(5-10(22)18-13(8)21)7-1-3-16-4-2-7/h5-7,16H,1-4H2,(H2,15,23)(H,18,22) OTZVSUARBGGEDT-UHFFFAOYSA-N 297984 US10118930, Example 200::5-[5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidin-3-yl]-1,2,4-oxadiazole-3-carboxamide hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297984 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297984&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018584 381620816 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571056 CC(C)S(=O)(=O)Cc1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H22N6O4S/c1-10(2)28(25,26)9-14-20-17(27-22-14)12-8-19-23-13(7-15(24)21-16(12)23)11-3-5-18-6-4-11/h7-8,10-11,18H,3-6,9H2,1-2H3,(H,21,24) WKQWEIFRIKIHJU-UHFFFAOYSA-N 297985 US10118930, Example 201::3-{3-[(isopropylsulfonyl)methyl]-1,2,4-oxadiazol-5-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297985 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297985&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018380 381620817 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571057 Fc1cnc(-c2noc(n2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)c(F)c1 InChI=1S/C18H15F2N7O2/c19-10-5-12(20)15(22-7-10)16-25-18(29-26-16)11-8-23-27-13(6-14(28)24-17(11)27)9-1-3-21-4-2-9/h5-9,21H,1-4H2,(H,24,28) GUTNSEZZMBJXQI-UHFFFAOYSA-N 297986 US10118930, Example 202::3-[3-(3,5-difluoropyridin-2-yl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 37.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297986 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297986&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529810 381620818 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571058 CN1CCC(Cc2noc(n2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)CC1 InChI=1S/C20H27N7O2/c1-26-8-4-13(5-9-26)10-17-23-20(29-25-17)15-12-22-27-16(11-18(28)24-19(15)27)14-2-6-21-7-3-14/h11-14,21H,2-10H2,1H3,(H,24,28) JLKJNCYJUNIDSJ-UHFFFAOYSA-N 297987 US10118930, Example 203::3-{3-[(1-methylpiperidin-4-yl)methyl]-1,2,4-oxadiazol-5-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297987 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297987&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137025695 381620819 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571059 COC(=O)c1ccc(cc1)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C21H20N6O4/c1-30-21(29)14-4-2-13(3-5-14)18-25-20(31-26-18)15-11-23-27-16(10-17(28)24-19(15)27)12-6-8-22-9-7-12/h2-5,10-12,22H,6-9H2,1H3,(H,24,28) VJFHCBJBFLNZIP-UHFFFAOYSA-N 297988 US10118930, Example 204::Methyl 4-{5-[5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidin-3-yl]-1,2,4-oxadiazol-3-yl}benzoate hydrochloride Tissue-type plasminogen activator Human 35.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297988 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297988&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529811 381620820 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571060 [O-][N+](=O)c1cccc(c1)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H17N7O4/c27-16-9-15(11-4-6-20-7-5-11)25-18(22-16)14(10-21-25)19-23-17(24-30-19)12-2-1-3-13(8-12)26(28)29/h1-3,8-11,20H,4-7H2,(H,22,27) VHHIHOHRODFJHC-UHFFFAOYSA-N 297989 US10118930, Example 205::3-[3-(3-nitrophenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 35.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297989 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297989&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529812 381620821 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571061 COCCc1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C16H20N6O3/c1-24-7-4-13-19-16(25-21-13)11-9-18-22-12(8-14(23)20-15(11)22)10-2-5-17-6-3-10/h8-10,17H,2-7H2,1H3,(H,20,23) JZBTTYGFLVIZCM-UHFFFAOYSA-N 297990 US10118930, Example 206::3-[3-(2-methoxyethyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 20.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297990 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297990&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018458 381620822 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571062 O=c1cc(C2CCNCC2)n2ncc(-c3nc(no3)-c3ccncc3)c2[nH]1 InChI=1S/C18H17N7O2/c26-15-9-14(11-1-5-19-6-2-11)25-17(22-15)13(10-21-25)18-23-16(24-27-18)12-3-7-20-8-4-12/h3-4,7-11,19H,1-2,5-6H2,(H,22,26) QEMNLHZRWQHYSC-UHFFFAOYSA-N 297991 US10118930, Example 207::7-(piperidin-4-yl)-3-[3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl]pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 93.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297991 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297991&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529813 381620823 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571063 Nc1cccc(c1)-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H19N7O2/c20-13-3-1-2-12(8-13)17-24-19(28-25-17)14-10-22-26-15(9-16(27)23-18(14)26)11-4-6-21-7-5-11/h1-3,8-11,21H,4-7,20H2,(H,23,27) QXCLUMXVPICOQO-UHFFFAOYSA-N 297992 US10118930, Example 208::3-[3-(3-aminophenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 55.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297992 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297992&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529814 381620824 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571064 Clc1ccccc1Cc1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H19ClN6O2/c21-15-4-2-1-3-13(15)9-17-24-20(29-26-17)14-11-23-27-16(10-18(28)25-19(14)27)12-5-7-22-8-6-12/h1-4,10-12,22H,5-9H2,(H,25,28) PVEVNVKLKDUKPH-UHFFFAOYSA-N 297993 US10118930, Example 209::3-[3-(2-chlorobenzyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 36.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297993 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297993&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529815 381620825 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571065 Clc1ccc(Cc2noc(n2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)cc1 InChI=1S/C20H19ClN6O2/c21-14-3-1-12(2-4-14)9-17-24-20(29-26-17)15-11-23-27-16(10-18(28)25-19(15)27)13-5-7-22-8-6-13/h1-4,10-11,13,22H,5-9H2,(H,25,28) IBBWPKLBNLFTFO-UHFFFAOYSA-N 297994 US10118930, Example 210::3-[3-(4-chlorobenzyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297994 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297994&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529816 381620826 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571066 CCOC(=O)c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C16H18N6O4/c1-2-25-16(24)13-20-15(26-21-13)10-8-18-22-11(7-12(23)19-14(10)22)9-3-5-17-6-4-9/h7-9,17H,2-6H2,1H3,(H,19,23) SLEJDTZIDDZFED-UHFFFAOYSA-N 297996 US10118930, Example 211::Ethyl 5-[5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidin-3-yl]-1,2,4-oxadiazole-3-carboxylate hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297996 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297996&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018368 381620828 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571067 NCc1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C14H17N7O2/c15-6-11-18-14(23-20-11)9-7-17-21-10(5-12(22)19-13(9)21)8-1-3-16-4-2-8/h5,7-8,16H,1-4,6,15H2,(H,19,22) IVQOWNCRNAIPCZ-UHFFFAOYSA-N 297997 US10118930, Example 212::3-[3-(aminomethyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 58.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297997 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297997&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018352 381620829 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571068 Clc1ccc(Cc2noc(n2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)cc1Cl InChI=1S/C20H18Cl2N6O2/c21-14-2-1-11(7-15(14)22)8-17-25-20(30-27-17)13-10-24-28-16(9-18(29)26-19(13)28)12-3-5-23-6-4-12/h1-2,7,9-10,12,23H,3-6,8H2,(H,26,29) UBBLXOBHXXPJFQ-UHFFFAOYSA-N 297998 US10118930, Example 213::3-[3-(3,4-dichlorobenzyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 30.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297998 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297998&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529817 381620830 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571069 Cc1ccc(Cc2noc(n2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)cc1 InChI=1S/C21H22N6O2/c1-13-2-4-14(5-3-13)10-18-24-21(29-26-18)16-12-23-27-17(11-19(28)25-20(16)27)15-6-8-22-9-7-15/h2-5,11-12,15,22H,6-10H2,1H3,(H,25,28) XMVLWOPGRIWJBM-UHFFFAOYSA-N 297999 US10118930, Example 214::3-[3-(4-methylbenzyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 32.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297999 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297999&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529818 381620831 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571070 CC(c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1)c1ccccc1 InChI=1S/C21H22N6O2/c1-13(14-5-3-2-4-6-14)19-25-21(29-26-19)16-12-23-27-17(11-18(28)24-20(16)27)15-7-9-22-10-8-15/h2-6,11-13,15,22H,7-10H2,1H3,(H,24,28) RRWQDRDTQSCGTC-UHFFFAOYSA-N 298000 US10118930, Example 215::3-[3-(1-phenylethyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298000 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298000&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529819 381620832 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571071 Fc1ccccc1-c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H17FN6O2/c20-14-4-2-1-3-12(14)19-24-17(25-28-19)13-10-22-26-15(9-16(27)23-18(13)26)11-5-7-21-8-6-11/h1-4,9-11,21H,5-8H2,(H,23,27) JQVIYFNPZJZJPY-UHFFFAOYSA-N 298001 US10118930, Example 216::3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298001 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298001&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529820 381620833 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571072 Clc1cccc(Cc2nc(no2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)c1 InChI=1S/C20H19ClN6O2/c21-14-3-1-2-12(8-14)9-18-25-19(26-29-18)15-11-23-27-16(10-17(28)24-20(15)27)13-4-6-22-7-5-13/h1-3,8,10-11,13,22H,4-7,9H2,(H,24,28) UHBXRNXDUZKCQC-UHFFFAOYSA-N 298002 US10118930, Example 217::3-[5-(3-chlorobenzyl)-1,2,4-oxadiazol-3-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 36.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298002 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298002&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529821 381620834 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571073 Fc1c(Cl)cccc1-c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H16ClFN6O2/c20-13-3-1-2-11(16(13)21)19-25-17(26-29-19)12-9-23-27-14(8-15(28)24-18(12)27)10-4-6-22-7-5-10/h1-3,8-10,22H,4-7H2,(H,24,28) UHWBZTLGIFGPGY-UHFFFAOYSA-N 298003 US10118930, Example 218::3-[5-(3-chloro-2-fluorophenyl)-1,2,4-oxadiazol-3-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 54.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298003 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298003&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529822 381620835 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571074 COc1ccccc1-c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H20N6O3/c1-28-16-5-3-2-4-13(16)20-24-18(25-29-20)14-11-22-26-15(10-17(27)23-19(14)26)12-6-8-21-9-7-12/h2-5,10-12,21H,6-9H2,1H3,(H,23,27) SHVKQGZDBKURDU-UHFFFAOYSA-N 298004 US10118930, Example 219::3-[5-(2-methoxyphenyl)-1,2,4-oxadiazol-3-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 35.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298004 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298004&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529823 381620836 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571075 Cc1ccc(cc1)-c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H20N6O2/c1-12-2-4-14(5-3-12)20-24-18(25-28-20)15-11-22-26-16(10-17(27)23-19(15)26)13-6-8-21-9-7-13/h2-5,10-11,13,21H,6-9H2,1H3,(H,23,27) ISHKWVBAFRRPMO-UHFFFAOYSA-N 298005 US10118930, Example 220::3-[5-(4-methylphenyl)-1,2,4-oxadiazol-3-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 15.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298005 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298005&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529824 381620837 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571076 OC(=O)c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C14H14N6O4/c21-10-5-9(7-1-3-15-4-2-7)20-12(17-10)8(6-16-20)13-18-11(14(22)23)19-24-13/h5-7,15H,1-4H2,(H,17,21)(H,22,23) RDPTZPOQGDSOIE-UHFFFAOYSA-N 298006 US10118930, Example 221::5-[5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidin-3-yl]-1,2,4-oxadiazole-3-carboxylic acid hydrochloride Tissue-type plasminogen activator Human 48.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298006 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298006&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018382 381620838 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571077 FC(F)(F)c1cccc(Cc2noc(n2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)c1 InChI=1S/C21H19F3N6O2/c22-21(23,24)14-3-1-2-12(8-14)9-17-27-20(32-29-17)15-11-26-30-16(10-18(31)28-19(15)30)13-4-6-25-7-5-13/h1-3,8,10-11,13,25H,4-7,9H2,(H,28,31) URINGQNXAIDVCC-UHFFFAOYSA-N 298007 US10118930, Example 222::7-(piperidin-4-yl)-3-{3-[3-(trifluoromethyl)benzyl]-1,2,4-oxadiazol-5-yl}pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 37.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298007 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298007&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529825 381620839 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571078 CC(C)(c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1)c1ccccc1 InChI=1S/C22H24N6O2/c1-22(2,15-6-4-3-5-7-15)21-26-20(30-27-21)16-13-24-28-17(12-18(29)25-19(16)28)14-8-10-23-11-9-14/h3-7,12-14,23H,8-11H2,1-2H3,(H,25,29) SNZQUPRVNIOUDB-UHFFFAOYSA-N 298008 US10118930, Example 223::3-[3-(2-phenylpropan-2-yl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 31.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298008 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298008&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529826 381620840 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571079 Fc1ccc(Cc2noc(n2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)cc1 InChI=1S/C20H19FN6O2/c21-14-3-1-12(2-4-14)9-17-24-20(29-26-17)15-11-23-27-16(10-18(28)25-19(15)27)13-5-7-22-8-6-13/h1-4,10-11,13,22H,5-9H2,(H,25,28) IDHKLCNOKFWPNX-UHFFFAOYSA-N 298009 US10118930, Example 224::3-[3-(4-fluorobenzyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 9.70 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298009 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298009&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529827 381620841 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571080 Cc1ccccc1-c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H20N6O2/c1-12-4-2-3-5-14(12)20-24-18(25-28-20)15-11-22-26-16(10-17(27)23-19(15)26)13-6-8-21-9-7-13/h2-5,10-11,13,21H,6-9H2,1H3,(H,23,27) TWRGOBWQERMKSH-UHFFFAOYSA-N 298012 US10118930, Example 225::3-[5-(2-methylphenyl)-1,2,4-oxadiazol-3-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298012 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298012&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529829 381620844 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571081 Clc1cccc(c1)-c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H17ClN6O2/c20-13-3-1-2-12(8-13)19-24-17(25-28-19)14-10-22-26-15(9-16(27)23-18(14)26)11-4-6-21-7-5-11/h1-3,8-11,21H,4-7H2,(H,23,27) CFQBJRQCUANRSA-UHFFFAOYSA-N 298013 US10118930, Example 226::3-[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 35.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298013 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298013&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529830 381620845 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571082 FC(F)(F)c1cccc(c1)-c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H17F3N6O2/c21-20(22,23)13-3-1-2-12(8-13)19-27-17(28-31-19)14-10-25-29-15(9-16(30)26-18(14)29)11-4-6-24-7-5-11/h1-3,8-11,24H,4-7H2,(H,26,30) WMWWHFCIGJOEEB-UHFFFAOYSA-N 298014 US10118930, Example 227::7-(piperidin-4-yl)-3-{5-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl}pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298014 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298014&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529831 381620846 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571083 O=c1cc(C2CCNCC2)n2ncc(-c3noc(Cc4ccccc4)n3)c2[nH]1 InChI=1S/C20H20N6O2/c27-17-11-16(14-6-8-21-9-7-14)26-20(23-17)15(12-22-26)19-24-18(28-25-19)10-13-4-2-1-3-5-13/h1-5,11-12,14,21H,6-10H2,(H,23,27) NNCQQDJGJADEKD-UHFFFAOYSA-N 298015 US10118930, Example 228::3-(5-benzyl-1,2,4-oxadiazol-3-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 33.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298015 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298015&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529832 381620847 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571084 Cc1c(Cl)cccc1-c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H19ClN6O2/c1-11-13(3-2-4-15(11)21)20-25-18(26-29-20)14-10-23-27-16(9-17(28)24-19(14)27)12-5-7-22-8-6-12/h2-4,9-10,12,22H,5-8H2,1H3,(H,24,28) TVKPBEXSSXETJD-UHFFFAOYSA-N 298016 US10118930, Example 229::3-[5-(3-chloro-2-methylphenyl)-1,2,4-oxadiazol-3-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 36.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298016 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298016&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529833 381620848 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571085 Cc1ccc(Cl)cc1-c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H19ClN6O2/c1-11-2-3-13(21)8-14(11)20-25-18(26-29-20)15-10-23-27-16(9-17(28)24-19(15)27)12-4-6-22-7-5-12/h2-3,8-10,12,22H,4-7H2,1H3,(H,24,28) CPJJVDRXGLUXAY-UHFFFAOYSA-N 298017 US10118930, Example 230::3-[5-(5-chloro-2-methylphenyl)-1,2,4-oxadiazol-3-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 36.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298017 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298017&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529834 381620849 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571086 FC(F)(F)c1ccc(cc1)-c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H17F3N6O2/c21-20(22,23)13-3-1-12(2-4-13)19-27-17(28-31-19)14-10-25-29-15(9-16(30)26-18(14)29)11-5-7-24-8-6-11/h1-4,9-11,24H,5-8H2,(H,26,30) RCMMSEQKXKQJHG-UHFFFAOYSA-N 298018 US10118930, Example 231::7-(piperidin-4-yl)-3-{5-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl}pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298018 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298018&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529835 381620850 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571087 FC(F)(F)c1ccc(-c2nc(no2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)c(Cl)c1 InChI=1S/C20H16ClF3N6O2/c21-14-7-11(20(22,23)24)1-2-12(14)19-28-17(29-32-19)13-9-26-30-15(8-16(31)27-18(13)30)10-3-5-25-6-4-10/h1-2,7-10,25H,3-6H2,(H,27,31) GPGMALFRPKXBJM-UHFFFAOYSA-N 298019 US10118930, Example 232::3-{5-[2-chloro-4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 71.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298019 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298019&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529836 381620851 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571088 Clc1ccc(cc1)-c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H17ClN6O2/c20-13-3-1-12(2-4-13)19-24-17(25-28-19)14-10-22-26-15(9-16(27)23-18(14)26)11-5-7-21-8-6-11/h1-4,9-11,21H,5-8H2,(H,23,27) LMAJBIVBSKQXKX-UHFFFAOYSA-N 298020 US10118930, Example 233::3-[5-(4-chlorophenyl)-1,2,4-oxadiazol-3-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 36.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298020 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298020&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529837 381620852 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571089 Clc1cc(Cl)cc(c1)-c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H16Cl2N6O2/c20-12-5-11(6-13(21)7-12)19-25-17(26-29-19)14-9-23-27-15(8-16(28)24-18(14)27)10-1-3-22-4-2-10/h5-10,22H,1-4H2,(H,24,28) ATCUZYNKABSYOI-UHFFFAOYSA-N 298021 US10118930, Example 234::3-[5-(3,5-dichlorophenyl)-1,2,4-oxadiazol-3-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 35.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298021 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298021&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529838 381620853 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571090 Fc1ccc(Cl)cc1-c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H16ClFN6O2/c20-11-1-2-14(21)12(7-11)19-25-17(26-29-19)13-9-23-27-15(8-16(28)24-18(13)27)10-3-5-22-6-4-10/h1-2,7-10,22H,3-6H2,(H,24,28) VPTUYHLOYCZVHG-UHFFFAOYSA-N 298022 US10118930, Example 235::3-[5-(5-chloro-2-fluorophenyl)-1,2,4-oxadiazol-3-yl]-7-(piperidin-4-yl)pyrazolo[1,5-c]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 30.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298022 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298022&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529839 381620854 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571091 FC(F)(F)Oc1ccccc1-c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H17F3N6O3/c21-20(22,23)31-15-4-2-1-3-12(15)19-27-17(28-32-19)13-10-25-29-14(9-16(30)26-18(13)29)11-5-7-24-8-6-11/h1-4,9-11,24H,5-8H2,(H,26,30) QHAPJAZVNHARHU-UHFFFAOYSA-N 298023 US10118930, Example 236::7-(piperidin-4-yl)-3-{5-[2-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-3-yl}pyrazolo[1,5-c]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 27.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298023 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298023&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529840 381620855 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571092 COc1ccc(cc1Cl)-c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H19ClN6O3/c1-29-16-3-2-12(8-14(16)21)20-25-18(26-30-20)13-10-23-27-15(9-17(28)24-19(13)27)11-4-6-22-7-5-11/h2-3,8-11,22H,4-7H2,1H3,(H,24,28) SHABLKGZPMKBSI-UHFFFAOYSA-N 298024 US10118930, Example 237::3-[5-(3-chloro-4-methoxyphenyl)-1,2,4-oxadiazol-3-yl]-7-(piperidin-4-yl)pyrazolo[1,5-c]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 20.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298024 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298024&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529841 381620856 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571093 OC(c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1)c1ccccc1 InChI=1S/C20H20N6O3/c27-16-10-15(12-6-8-21-9-7-12)26-19(23-16)14(11-22-26)20-24-18(25-29-20)17(28)13-4-2-1-3-5-13/h1-5,10-12,17,21,28H,6-9H2,(H,23,27) GESSANPMSPZHOV-UHFFFAOYSA-N 298025 US10118930, Example 238::3-{3-[hydroxy(phenyl)methyl]-1,2,4-oxadiazol-5-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 28.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298025 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298025&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529842 381620857 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571094 FC(F)(F)Oc1ccc(Cc2nc(no2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)cc1 InChI=1S/C21H19F3N6O3/c22-21(23,24)32-14-3-1-12(2-4-14)9-18-28-19(29-33-18)15-11-26-30-16(10-17(31)27-20(15)30)13-5-7-25-8-6-13/h1-4,10-11,13,25H,5-9H2,(H,27,31) FGNUIKZIDHUNJH-UHFFFAOYSA-N 298026 US10118930, Example 239::7-(piperidin-4-yl)-3-{5-[4-(trifluoromethoxy)benzyl]-1,2,4-oxadiazol-3-yl}pyrazolo[1,5-c]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 30.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298026 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298026&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529843 381620858 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571095 COc1c(F)cc(Cc2nc(no2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)cc1F InChI=1S/C21H20F2N6O3/c1-31-19-14(22)6-11(7-15(19)23)8-18-27-20(28-32-18)13-10-25-29-16(9-17(30)26-21(13)29)12-2-4-24-5-3-12/h6-7,9-10,12,24H,2-5,8H2,1H3,(H,26,30) IYUIUFSVXQTNRK-UHFFFAOYSA-N 298027 US10118930, Example 240::3-[5-(3,5-difluoro-4-methoxybenzyl)-1,2,4-oxadiazol-3-yl]-7-(piperidin-4-yl)pyrazolo[1,5-c]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 20.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298027 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298027&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529844 381620859 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571096 CCC(c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1)c1ccc(OC)cc1 InChI=1S/C23H26N6O3/c1-3-17(14-4-6-16(31-2)7-5-14)23-27-21(28-32-23)18-13-25-29-19(12-20(30)26-22(18)29)15-8-10-24-11-9-15/h4-7,12-13,15,17,24H,3,8-11H2,1-2H3,(H,26,30) XHEDVFBGZKRQCC-UHFFFAOYSA-N 298028 US10118930, Example 241::3-{5-[rac-1-(4-methoxyphenyl)propyl]-1,2,4-oxadiazol-3-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 21.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298028 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298028&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529845 381620860 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571097 COc1ccc(cc1)C(C)(C)c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C23H26N6O3/c1-23(2,15-4-6-16(31-3)7-5-15)22-27-20(28-32-22)17-13-25-29-18(12-19(30)26-21(17)29)14-8-10-24-11-9-14/h4-7,12-14,24H,8-11H2,1-3H3,(H,26,30) VVCFFPXEZDWPSY-UHFFFAOYSA-N 298029 US10118930, Example 242::3-{5-[2-(4-methoxyphenyl)propan-2-yl]-1,2,4-oxadiazol-3-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 20.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298029 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298029&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529846 381620861 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571098 O=c1cc(C2CCNCC2)n2ncc(-c3noc(n3)C3CCOCC3)c2[nH]1 InChI=1S/C18H22N6O3/c25-15-9-14(11-1-5-19-6-2-11)24-17(21-15)13(10-20-24)16-22-18(27-23-16)12-3-7-26-8-4-12/h9-12,19H,1-8H2,(H,21,25) TUVYDOFFNZLKAT-UHFFFAOYSA-N 298030 US10118930, Example 243::7-(piperidin-4-yl)-3-[5-(tetrahydro-2H-pyran-4-yl)-1,2,4-oxadiazol-3-yl]pyrazolo[1,5-c]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 29.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298030 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298030&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018600 381620862 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571099 FC(F)Oc1ccc(Cc2nc(no2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)cc1 InChI=1S/C21H20F2N6O3/c22-21(23)31-14-3-1-12(2-4-14)9-18-27-19(28-32-18)15-11-25-29-16(10-17(30)26-20(15)29)13-5-7-24-8-6-13/h1-4,10-11,13,21,24H,5-9H2,(H,26,30) LGXSBOUNZGGJAS-UHFFFAOYSA-N 298031 US10118930, Example 244::3-{5-[4-(difluoromethoxy)benzyl]-1,2,4-oxadiazol-3-yl}-7-(piperidin-4-yl)pyrazolo[1,5-c]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 21.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298031 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298031&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529847 381620863 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571100 COc1ccc(cc1)C1(CC1)c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C23H24N6O3/c1-31-16-4-2-15(3-5-16)23(8-9-23)22-27-20(28-32-22)17-13-25-29-18(12-19(30)26-21(17)29)14-6-10-24-11-7-14/h2-5,12-14,24H,6-11H2,1H3,(H,26,30) DABLGOWQNDNSDP-UHFFFAOYSA-N 298032 US10118930, Example 245::3-{5-[1-(4-methoxyphenyl)cyclopropyl]-1,2,4-oxadiazol-3-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 29.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298032 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298032&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529848 381620864 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571101 COc1ccc(Cc2nc(no2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)c(F)c1 InChI=1S/C21H21FN6O3/c1-30-14-3-2-13(16(22)9-14)8-19-26-20(27-31-19)15-11-24-28-17(10-18(29)25-21(15)28)12-4-6-23-7-5-12/h2-3,9-12,23H,4-8H2,1H3,(H,25,29) VXNWDOOIPRYGFO-UHFFFAOYSA-N 298033 US10118930, Example 246::3-[5-(2-fluoro-4-methoxybenzyl)-1,2,4-oxadiazol-3-yl]-7-(piperidin-4-yl)pyrazolo[1,5-c]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 28.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298033 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298033&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529849 381620865 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571102 COc1ccc(Cc2nc(no2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)cc1F InChI=1S/C21H21FN6O3/c1-30-17-3-2-12(8-15(17)22)9-19-26-20(27-31-19)14-11-24-28-16(10-18(29)25-21(14)28)13-4-6-23-7-5-13/h2-3,8,10-11,13,23H,4-7,9H2,1H3,(H,25,29) WQFPQXLSNQVZFY-UHFFFAOYSA-N 298034 US10118930, Example 247::3-[5-(3-fluoro-4-methoxybenzyl)-1,2,4-oxadiazol-3-yl]-7-(piperidin-4-yl)pyrazolo[1,5-c]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 28.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298034 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298034&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529850 381620866 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571103 Cc1ccc(cc1Cl)-c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H19ClN6O2/c1-11-2-3-13(8-15(11)21)20-25-18(26-29-20)14-10-23-27-16(9-17(28)24-19(14)27)12-4-6-22-7-5-12/h2-3,8-10,12,22H,4-7H2,1H3,(H,24,28) RHLDIFSFLLXRHB-UHFFFAOYSA-N 298036 US10118930, Example 248::3-[5-(3-chloro-4-methylphenyl)-1,2,4-oxadiazol-3-yl]-7-(piperidin-4-yl)pyrazolo[1,5-c]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 47.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298036 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298036&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529852 381620868 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571104 Cc1ccc(-c2nc(no2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)c(c1)C(F)(F)F InChI=1S/C21H19F3N6O2/c1-11-2-3-13(15(8-11)21(22,23)24)20-28-18(29-32-20)14-10-26-30-16(9-17(31)27-19(14)30)12-4-6-25-7-5-12/h2-3,8-10,12,25H,4-7H2,1H3,(H,27,31) CEBYMMAYEXZHDX-UHFFFAOYSA-N 298037 US10118930, Example 249::3-{5-[4-methyl-2-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl}-7-(piperidin-4-yl)pyrazolo[1,5-c]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 12.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298037 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298037&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529853 381620869 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571105 Cc1nc(C)c(s1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C16H19N5OS/c1-9-15(23-10(2)19-9)12-8-18-21-13(7-14(22)20-16(12)21)11-3-5-17-6-4-11/h7-8,11,17H,3-6H2,1-2H3,(H,20,22) XMBRTUSJHHGAJB-UHFFFAOYSA-N 298038 US10118930, Example 250::3-(2,4-dimethyl-1,3-thiazol-5-yl)-7-(piperidin-4-yl)pyrazolo[1,5-c]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298038 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298038&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018627 381620870 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571106 COc1ccc(Cc2nc(no2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)cn1 InChI=1S/C20H21N7O3/c1-29-17-3-2-12(10-22-17)8-18-25-19(26-30-18)14-11-23-27-15(9-16(28)24-20(14)27)13-4-6-21-7-5-13/h2-3,9-11,13,21H,4-8H2,1H3,(H,24,28) XVIGJMIRKDYSEO-UHFFFAOYSA-N 298039 US10118930, Example 251::3-{5-[(6-methoxypyridin-3-yl)methyl]-1,2,4-oxadiazol-3-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 31.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298039 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298039&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529854 381620871 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571107 CC(C)Oc1ccc(Cc2nc(no2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)cc1 InChI=1S/C23H26N6O3/c1-14(2)31-17-5-3-15(4-6-17)11-21-27-22(28-32-21)18-13-25-29-19(12-20(30)26-23(18)29)16-7-9-24-10-8-16/h3-6,12-14,16,24H,7-11H2,1-2H3,(H,26,30) OYNIWDRIRQHJNI-UHFFFAOYSA-N 298040 US10118930, Example 252::7-(piperidin-4-yl)-3-{5-[4-(propan-2-yloxy)benzyl]-1,2,4-oxadiazol-3-yl}pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 24.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298040 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298040&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529855 381620872 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571108 Cc1ncc(s1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C15H17N5OS/c1-9-17-8-13(22-9)11-7-18-20-12(6-14(21)19-15(11)20)10-2-4-16-5-3-10/h6-8,10,16H,2-5H2,1H3,(H,19,21) CVBIMFBJMCNIFK-UHFFFAOYSA-N 298041 US10118930, Example 253::3-(2-methyl-1,3-thiazol-5-yl)-7-(piperidin-4-yl)pyrazolo[1,5-c]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 8.20 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298041 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298041&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018260 381620873 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571109 O=C(Nc1cnn2c(cc(=O)[nH]c12)C1CCNCC1)c1ccccc1 InChI=1S/C18H19N5O2/c24-16-10-15(12-6-8-19-9-7-12)23-17(22-16)14(11-20-23)21-18(25)13-4-2-1-3-5-13/h1-5,10-12,19H,6-9H2,(H,21,25)(H,22,24) PXTWWIQBYUHOFR-UHFFFAOYSA-N 298042 US10118930, Example 254::N-[5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-c]pyrimidin-3-yl]benzamide hydrochloride Tissue-type plasminogen activator Human 100.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298042 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298042&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018515 381620874 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571110 CC(C)(c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1)c1ccc(F)cc1 InChI=1S/C22H23FN6O2/c1-22(2,14-3-5-15(23)6-4-14)21-27-20(31-28-21)16-12-25-29-17(11-18(30)26-19(16)29)13-7-9-24-10-8-13/h3-6,11-13,24H,7-10H2,1-2H3,(H,26,30) DUDAJOOHQPBCNG-UHFFFAOYSA-N 298043 US10118930, Example 255::3-{3-[2-(4-fluorophenyl)propan-2-yl]-1,2,4-oxadiazol-5-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 17.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298043 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298043&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529856 381620875 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571111 CC(C)c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C16H20N6O2/c1-9(2)16-20-14(21-24-16)11-8-18-22-12(7-13(23)19-15(11)22)10-3-5-17-6-4-10/h7-10,17H,3-6H2,1-2H3,(H,19,23) WKHIPOMJAIDZPX-UHFFFAOYSA-N 298044 US10118930, Example 256::7-(piperidin-4-yl)-3-[5-(propan-2-yl)-1,2,4-oxadiazol-3-yl]pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 28.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298044 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298044&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018391 381620876 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571112 CC(C)(C)c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H22N6O2/c1-17(2,3)16-21-14(22-25-16)11-9-19-23-12(8-13(24)20-15(11)23)10-4-6-18-7-5-10/h8-10,18H,4-7H2,1-3H3,(H,20,24) MXEQLEUWLJMBHC-UHFFFAOYSA-N 298045 US10118930, Example 257::3-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298045 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298045&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018314 381620877 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571113 CCC1=[S]C(=C(C)N1)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 |t:2,4| InChI=1S/C17H22N5OS/c1-3-15-20-10(2)16(24-15)12-9-19-22-13(8-14(23)21-17(12)22)11-4-6-18-7-5-11/h8-9,11,18,20H,3-7H2,1-2H3,(H,21,23) QZOVCVDBLQCZQE-UHFFFAOYSA-N 298046 US10118930, Example 258::3-(2-ethyl-4-methyl-1,3-thiazol-5-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 21.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298046 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298046&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018306 381620878 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571114 CC(C)C1=[S]C(=C(C)N1)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 |t:3,5| InChI=1S/C18H24N5OS/c1-10(2)18-21-11(3)16(25-18)13-9-20-23-14(8-15(24)22-17(13)23)12-4-6-19-7-5-12/h8-10,12,19,21H,4-7H2,1-3H3,(H,22,24) CZTIGXSYVZKYAN-UHFFFAOYSA-N 298047 US10118930, Example 259::3-[4-methyl-2-(propan-2-yl)-1,3-thiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 19.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298047 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298047&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018420 381620879 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571115 FC(F)(F)c1ccccc1-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H17F3N6O2/c21-20(22,23)14-4-2-1-3-12(14)17-27-19(31-28-17)13-10-25-29-15(9-16(30)26-18(13)29)11-5-7-24-8-6-11/h1-4,9-11,24H,5-8H2,(H,26,30) LYSNUEFEKCYJPV-UHFFFAOYSA-N 298048 US10118930, Example 260::7-(piperidin-4-yl)-3-{3-[2-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}pyrazolo[1,5-c]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 31.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298048 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298048&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529857 381620880 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571116 O=c1cc(C2CCNCC2)n2ncc(-c3noc(n3)C34CCC(CC3)CC4)c2[nH]1 InChI=1S/C21H26N6O2/c28-17-11-16(14-4-9-22-10-5-14)27-19(24-17)15(12-23-27)18-25-20(29-26-18)21-6-1-13(2-7-21)3-8-21/h11-14,22H,1-10H2,(H,24,28) HYIPJYGZEVSUPT-UHFFFAOYSA-N 298049 US10118930, Example 261::3-[5-(bicyclo[2.2.2]oct-1-yl)-1,2,4-oxadiazol-3-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 24.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298049 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298049&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018633 381620881 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571117 CCc1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C15H18N6O2/c1-2-13-19-14(20-23-13)10-8-17-21-11(7-12(22)18-15(10)21)9-3-5-16-6-4-9/h7-9,16H,2-6H2,1H3,(H,18,22) CAFMNXCEKXCWKA-UHFFFAOYSA-N 298050 US10118930, Example 262::3-(5-ethyl-1,2,4-oxadiazol-3-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 23.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298050 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298050&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018310 381620882 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571118 O=c1cc(C2CCNCC2)n2ncc(-c3cc(no3)-c3ccccc3)c2[nH]1 InChI=1S/C20H19N5O2/c26-19-11-17(14-6-8-21-9-7-14)25-20(23-19)15(12-22-25)18-10-16(24-27-18)13-4-2-1-3-5-13/h1-5,10-12,14,21H,6-9H2,(H,23,26) QJYKLUQPWHLAFZ-UHFFFAOYSA-N 298051 US10118930, Example 263::3-(3-phenyl-1,2-oxazol-5-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 28.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298051 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298051&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529858 381620883 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571119 CC(C)N1CCC(CC1)c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C21H29N7O2/c1-13(2)27-9-5-15(6-10-27)19-25-21(30-26-19)16-12-23-28-17(11-18(29)24-20(16)28)14-3-7-22-8-4-14/h11-15,22H,3-10H2,1-2H3,(H,24,29) LBTOZUUOIIQSSE-UHFFFAOYSA-N 298052 US10118930, Example 264::7-(piperidin-4-yl)-3-{3-[1-(propan-2-yl)piperidin-4-yl]-1,2,4-oxadiazol-5-yl}pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 200 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298052 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298052&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018737 381620884 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571120 CCc1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C13H18N4O/c1-2-9-8-15-17-11(7-12(18)16-13(9)17)10-3-5-14-6-4-10/h7-8,10,14H,2-6H2,1H3,(H,16,18) GLVLCVWNQDONLH-UHFFFAOYSA-N 298053 US10118930, Example 265::3-ethyl-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 340 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298053 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298053&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018641 381620885 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571121 O=c1cc(C2CCNCC2)n2ncc(-c3nc(cs3)-c3ccccc3)c2[nH]1 InChI=1S/C20H19N5OS/c26-18-10-17(14-6-8-21-9-7-14)25-19(24-18)15(11-22-25)20-23-16(12-27-20)13-4-2-1-3-5-13/h1-5,10-12,14,21H,6-9H2,(H,24,26) SMFCPQXISSHFKX-UHFFFAOYSA-N 298054 US10118930, Example 266::3-(4-phenyl-1,3-thiazol-2-yl)-7-(piperidin-4-yl)pyrazolo[1,5-c]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 29.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298054 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298054&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529859 381620886 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571122 Fc1ccccc1-c1csc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H18FN5OS/c21-15-4-2-1-3-13(15)16-11-28-20(24-16)14-10-23-26-17(9-18(27)25-19(14)26)12-5-7-22-8-6-12/h1-4,9-12,22H,5-8H2,(H,25,27) GSDBCUXSOHRFLB-UHFFFAOYSA-N 298055 US10118930, Example 267::3-[4-(2-fluorophenyl)-1,3-thiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-c]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 15.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298055 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298055&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529860 381620887 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571123 Fc1c(Cl)cccc1-c1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H16ClFN6O2/c20-13-3-1-2-11(16(13)21)18-25-26-19(29-18)12-9-23-27-14(8-15(28)24-17(12)27)10-4-6-22-7-5-10/h1-3,8-10,22H,4-7H2,(H,24,28) ULKRAIWMBMMQRN-UHFFFAOYSA-N 298056 US10118930, Example 268::3-[5-(3-chloro-2-fluorophenyl)-1,3,4-oxadiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-c]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 24.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298056 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298056&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529861 381620888 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571124 FC(F)Oc1ccc(Cc2nnc(o2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)cc1 InChI=1S/C21H20F2N6O3/c22-21(23)31-14-3-1-12(2-4-14)9-18-27-28-20(32-18)15-11-25-29-16(10-17(30)26-19(15)29)13-5-7-24-8-6-13/h1-4,10-11,13,21,24H,5-9H2,(H,26,30) DKNILJFAMFMTLW-UHFFFAOYSA-N 298057 US10118930, Example 269::3-{5-[4-(difluoromethoxy)benzyl]-1,3,4-oxadiazol-2-yl}-7-(piperidin-4-yl)pyrazolo[1,5-c]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 33.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298057 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298057&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529862 381620889 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571125 FC(F)(F)Oc1ccc(Cc2nnc(o2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)cc1 InChI=1S/C21H19F3N6O3/c22-21(23,24)33-14-3-1-12(2-4-14)9-18-28-29-20(32-18)15-11-26-30-16(10-17(31)27-19(15)30)13-5-7-25-8-6-13/h1-4,10-11,13,25H,5-9H2,(H,27,31) YPIUBJLGSUXUJR-UHFFFAOYSA-N 298058 US10118930, Example 270::7-(piperidin-4-yl)-3-{5-[4-(trifluoromethoxy)benzyl]-1,3,4-oxadiazol-2-yl}pyrazolo[1,5-c]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 24.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298058 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298058&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529863 381620890 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571126 CC(C)(C)c1csc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C18H23N5OS/c1-18(2,3)14-10-25-17(21-14)12-9-20-23-13(8-15(24)22-16(12)23)11-4-6-19-7-5-11/h8-11,19H,4-7H2,1-3H3,(H,22,24) ZWEYBQLLNIUZNE-UHFFFAOYSA-N 298060 US10118930, Example 271::3-(4-tert-butyl-1,3-thiazol-2-yl)-7-(piperidin-4-yl)pyrazolo[1,5-c]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 25.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298060 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298060&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018526 381620892 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571127 Cc1sc(nc1-c1ccccc1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C21H21N5OS/c1-13-19(15-5-3-2-4-6-15)25-21(28-13)16-12-23-26-17(11-18(27)24-20(16)26)14-7-9-22-10-8-14/h2-6,11-12,14,22H,7-10H2,1H3,(H,24,27) FXQRRJUAEFIBPY-UHFFFAOYSA-N 298061 US10118930, Example 272::3-(5-methyl-4-phenyl-1,3-thiazol-2-yl)-7-(piperidin-4-yl)pyrazolo[1,5-c]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 13.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298061 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298061&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529865 381620893 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571128 Cc1ccccc1-c1csc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C21H21N5OS/c1-13-4-2-3-5-15(13)17-12-28-21(24-17)16-11-23-26-18(10-19(27)25-20(16)26)14-6-8-22-9-7-14/h2-5,10-12,14,22H,6-9H2,1H3,(H,25,27) PVFFPOQOEANRPV-UHFFFAOYSA-N 298062 US10118930, Example 448::3-[4-(2-methylphenyl)-1,3-thiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-c]pyrimidin-5(4H)-one hydrochloride::US10118930, Example 273 Tissue-type plasminogen activator Human 27.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298062 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298062&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529866 381620894 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571129 Clc1cccc(Cc2nnc(o2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)c1 InChI=1S/C20H19ClN6O2/c21-14-3-1-2-12(8-14)9-18-25-26-20(29-18)15-11-23-27-16(10-17(28)24-19(15)27)13-4-6-22-7-5-13/h1-3,8,10-11,13,22H,4-7,9H2,(H,24,28) NXPQOEBUTOUHCW-UHFFFAOYSA-N 298063 US10118930, Example 274::3-[5-(3-chlorobenzyl)-1,3,4-oxadiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-c]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 11.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298063 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298063&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529867 381620895 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571130 CC(C)(c1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1)n1cncn1 InChI=1S/C18H21N9O2/c1-18(2,26-10-20-9-22-26)17-25-24-16(29-17)12-8-21-27-13(7-14(28)23-15(12)27)11-3-5-19-6-4-11/h7-11,19H,3-6H2,1-2H3,(H,23,28) ZYDPFXPFPFCXTA-UHFFFAOYSA-N 298064 US10118930, Example 275::7-(piperidin-4-yl)-3-{5-[2-(1H-1,2,4-triazol-1-yl)propan-2-yl]-1,3,4-oxadiazol-2-yl}pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 20.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298064 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298064&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018637 381620896 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571131 Clc1ccccc1Cc1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H19ClN6O2/c21-15-4-2-1-3-13(15)9-18-25-26-20(29-18)14-11-23-27-16(10-17(28)24-19(14)27)12-5-7-22-8-6-12/h1-4,10-12,22H,5-9H2,(H,24,28) TWDNXLAEXJJVEG-UHFFFAOYSA-N 298065 US10118930, Example 276::3-[5-(2-chlorobenzyl)-1,3,4-oxadiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 14.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298065 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298065&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529868 381620897 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571132 Cc1cnc(Cc2nnc(o2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)s1 InChI=1S/C18H19N7O2S/c1-10-8-20-16(28-10)7-15-23-24-18(27-15)12-9-21-25-13(6-14(26)22-17(12)25)11-2-4-19-5-3-11/h6,8-9,11,19H,2-5,7H2,1H3,(H,22,26) GEMOGYQCYVWMGJ-UHFFFAOYSA-N 298066 US10118930, Example 277::3-{5-[(5-methyl-1,3-thiazol-2-yl)methyl]-1,3,4-oxadiazol-2-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 17.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298066 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298066&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018298 381620898 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571133 Clc1ccc(cc1)C1(CC1)c1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C22H21ClN6O2/c23-15-3-1-14(2-4-15)22(7-8-22)21-28-27-20(31-21)16-12-25-29-17(11-18(30)26-19(16)29)13-5-9-24-10-6-13/h1-4,11-13,24H,5-10H2,(H,26,30) UZFMQAZOORSFKH-UHFFFAOYSA-N 298067 US10118930, Example 278::3-{5-[1-(4-chlorophenyl)cyclopropyl]-1,3,4-oxadiazol-2-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 19.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298067 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298067&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529869 381620899 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571134 Fc1cccc(Cl)c1Cc1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H18ClFN6O2/c21-14-2-1-3-15(22)12(14)8-18-26-27-20(30-18)13-10-24-28-16(9-17(29)25-19(13)28)11-4-6-23-7-5-11/h1-3,9-11,23H,4-8H2,(H,25,29) BIIMCOHLBBOPMF-UHFFFAOYSA-N 298068 US10118930, Example 279::3-[5-(2-chloro-6-fluorobenzyl)-1,3,4-oxadiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 25.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298068 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298068&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529870 381620900 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571135 COc1ccccc1Cc1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C21H22N6O3/c1-29-17-5-3-2-4-14(17)10-19-25-26-21(30-19)15-12-23-27-16(11-18(28)24-20(15)27)13-6-8-22-9-7-13/h2-5,11-13,22H,6-10H2,1H3,(H,24,28) RDTSNSVIKMJLPW-UHFFFAOYSA-N 298069 US10118930, Example 280::3-[5-(2-methoxybenzyl)-1,3,4-oxadiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 29.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298069 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298069&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529871 381620901 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571136 CC(CN1CCOCC1)c1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H27N7O3/c1-13(12-26-6-8-29-9-7-26)19-24-25-20(30-19)15-11-22-27-16(10-17(28)23-18(15)27)14-2-4-21-5-3-14/h10-11,13-14,21H,2-9,12H2,1H3,(H,23,28) GNUOQBHHYYTDBX-UHFFFAOYSA-N 298070 US10118930, Example 281::3-{5-[1-(morpholin-4-yl)propan-2-yl]-1,3,4-oxadiazol-2-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 90.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298070 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298070&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018733 381620902 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571137 O=c1cc(C2CCNCC2)n2ncc(-c3nnc(CCN4CCOCC4)o3)c2[nH]1 InChI=1S/C19H25N7O3/c27-16-11-15(13-1-4-20-5-2-13)26-18(22-16)14(12-21-26)19-24-23-17(29-19)3-6-25-7-9-28-10-8-25/h11-13,20H,1-10H2,(H,22,27) NHUCFMPZAMRTKB-UHFFFAOYSA-N 298071 US10118930, Example 282::3-{5-[2-(morpholin-4-yl)ethyl]-1,3,4-oxadiazol-2-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298071 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298071&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018426 381620903 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571138 O=c1cc(C2CCNCC2)n2ncc(-c3nnc(CCc4ccccc4)o3)c2[nH]1 InChI=1S/C21H22N6O2/c28-18-12-17(15-8-10-22-11-9-15)27-20(24-18)16(13-23-27)21-26-25-19(29-21)7-6-14-4-2-1-3-5-14/h1-5,12-13,15,22H,6-11H2,(H,24,28) ITPYUSSKAZWCFH-UHFFFAOYSA-N 298073 US10118930, Example 283::3-[5-(2-phenylethyl)-1,3,4-oxadiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 10.00 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298073 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298073&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529873 381620905 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571139 Clc1ccc(Cc2nnc(o2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)cc1 InChI=1S/C20H19ClN6O2/c21-14-3-1-12(2-4-14)9-18-25-26-20(29-18)15-11-23-27-16(10-17(28)24-19(15)27)13-5-7-22-8-6-13/h1-4,10-11,13,22H,5-9H2,(H,24,28) AIXJJZNICJWPOE-UHFFFAOYSA-N 298074 US10118930, Example 284::3-[5-(4-chlorobenzyl)-1,3,4-oxadiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 20.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298074 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298074&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529874 381620906 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571140 O=c1cc(C2CCNCC2)n2ncc(-c3nnc(Cc4ccccn4)o3)c2[nH]1 InChI=1S/C19H19N7O2/c27-16-10-15(12-4-7-20-8-5-12)26-18(23-16)14(11-22-26)19-25-24-17(28-19)9-13-3-1-2-6-21-13/h1-3,6,10-12,20H,4-5,7-9H2,(H,23,27) STHCFVJQKJJNDL-UHFFFAOYSA-N 298075 US10118930, Example 285::7-(piperidin-4-yl)-3-[5-(pyridin-2-ylmethyl)-1,3,4-oxadiazol-2-yl]pyrazolo[1,5-a]pyrimidin-5 (4H)-one trihydrochloride Tissue-type plasminogen activator Human 28.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298075 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298075&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529875 381620907 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571141 Oc1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C13H14N6O3/c20-10-5-9(7-1-3-14-4-2-7)19-11(16-10)8(6-15-19)12-17-18-13(21)22-12/h5-7,14H,1-4H2,(H,16,20)(H,18,21) FRAGXERADYGOLZ-UHFFFAOYSA-N 298076 US10118930, Example 286::3-(5-hydroxy-1,3,4-oxadiazol-2-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 33.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298076 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298076&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137025803 381620908 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571142 NC(=S)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C12H15N5OS/c13-11(19)8-6-15-17-9(5-10(18)16-12(8)17)7-1-3-14-4-2-7/h5-7,14H,1-4H2,(H2,13,19)(H,16,18) DELYWDUDPOEKDG-UHFFFAOYSA-N 298077 US10118930, Example 287::5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carbothioamide hydrochloride Tissue-type plasminogen activator Human 37.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298077 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298077&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018301 381620909 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571143 O=c1cc(C2CCNCC2)n2ncc(-c3nnc(o3)-c3cccs3)c2[nH]1 InChI=1S/C17H16N6O2S/c24-14-8-12(10-3-5-18-6-4-10)23-15(20-14)11(9-19-23)16-21-22-17(25-16)13-2-1-7-26-13/h1-2,7-10,18H,3-6H2,(H,20,24) VBOWIIQRIUPPBR-UHFFFAOYSA-N 298078 US10118930, Example 288::7-(piperidin-4-yl)-3-[5-(thiophen-2-yl)-1,3,4-oxadiazol-2-yl]pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 27.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298078 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298078&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018739 381620910 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571144 FC(F)(F)Cc1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C15H15F3N6O2/c16-15(17,18)6-12-22-23-14(26-12)9-7-20-24-10(5-11(25)21-13(9)24)8-1-3-19-4-2-8/h5,7-8,19H,1-4,6H2,(H,21,25) QYYAVZDMVWTWTB-UHFFFAOYSA-N 298079 US10118930, Example 289::7-(piperidin-4-yl)-3-[5-(2,2,2-trifluoroethyl)-1,3,4-oxadiazol-2-yl]pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 27.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298079 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298079&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018651 381620911 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571145 Clc1ccccc1-c1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H17ClN6O2/c20-14-4-2-1-3-12(14)18-24-25-19(28-18)13-10-22-26-15(9-16(27)23-17(13)26)11-5-7-21-8-6-11/h1-4,9-11,21H,5-8H2,(H,23,27) ZQAZYPSPESSGAS-UHFFFAOYSA-N 298080 US10118930, Example 290::3-[5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 26.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298080 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298080&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529876 381620912 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571146 O=c1cc(C2CCNCC2)n2ncc(-c3nnc(CN4CCCCC4)o3)c2[nH]1 InChI=1S/C19H25N7O2/c27-16-10-15(13-4-6-20-7-5-13)26-18(22-16)14(11-21-26)19-24-23-17(28-19)12-25-8-2-1-3-9-25/h10-11,13,20H,1-9,12H2,(H,22,27) BIKKFYNZDRCRDK-UHFFFAOYSA-N 298081 US10118930, Example 291::7-(piperidin-4-yl)-3-[5-(piperidin-1-ylmethyl)-1,3,4-oxadiazol-2-yl]pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 85.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298081 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298081&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018734 381620913 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571147 O=C1CCCN1Cc1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C18H21N7O3/c26-14-8-13(11-3-5-19-6-4-11)25-17(21-14)12(9-20-25)18-23-22-15(28-18)10-24-7-1-2-16(24)27/h8-9,11,19H,1-7,10H2,(H,21,26) FIAARYKXNQJRPZ-UHFFFAOYSA-N 298082 US10118930, Example 292::3-{5-[(2-oxopyrrolidin-1-yl)methyl]-1,3,4-oxadiazol-2-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298082 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298082&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018742 381620914 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571148 O=c1cc(C2CCNCC2)n2ncc(-c3nnc(o3)C3CCCCC3)c2[nH]1 InChI=1S/C19H24N6O2/c26-16-10-15(12-6-8-20-9-7-12)25-17(22-16)14(11-21-25)19-24-23-18(27-19)13-4-2-1-3-5-13/h10-13,20H,1-9H2,(H,22,26) ILUWVVBEEFCUCZ-UHFFFAOYSA-N 298083 US10118930, Example 293::3-(5-cyclohexyl-1,3,4-oxadiazol-2-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 31.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298083 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298083&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018628 381620915 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571149 O=c1cc(C2CCNCC2)n2ncc(-c3nnc(o3)C3CCC3)c2[nH]1 InChI=1S/C17H20N6O2/c24-14-8-13(10-4-6-18-7-5-10)23-15(20-14)12(9-19-23)17-22-21-16(25-17)11-2-1-3-11/h8-11,18H,1-7H2,(H,20,24) XEMQELGQPNVSHT-UHFFFAOYSA-N 298084 US10118930, Example 294::3-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 37.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298084 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298084&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018646 381620916 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571150 CCCCc1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H22N6O2/c1-2-3-4-15-21-22-17(25-15)12-10-19-23-13(9-14(24)20-16(12)23)11-5-7-18-8-6-11/h9-11,18H,2-8H2,1H3,(H,20,24) SSPAEUKODOHJTK-UHFFFAOYSA-N 298085 US10118930, Example 295::3-(5-butyl-1,3,4-oxadiazol-2-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 35.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298085 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298085&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137026024 381620917 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571151 Cc1nn2c(cc(=O)[nH]c2c1-c1nc(no1)C(C)(C)C)C1CCNCC1 InChI=1S/C18H24N6O2/c1-10-14(16-21-17(23-26-16)18(2,3)4)15-20-13(25)9-12(24(15)22-10)11-5-7-19-8-6-11/h9,11,19H,5-8H2,1-4H3,(H,20,25) KEUUUIZDDPGTDX-UHFFFAOYSA-N 298086 US10118930, Example 296::3-(3-tert-butyl-1,2,4-oxadiazol-5-yl)-2-methyl-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 23.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298086 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298086&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018741 381620918 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571152 COCCc1noc(n1)-c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H22N6O3/c1-10-15(17-19-13(22-26-17)5-8-25-2)16-20-14(24)9-12(23(16)21-10)11-3-6-18-7-4-11/h9,11,18H,3-8H2,1-2H3,(H,20,24) LLSMNSCKHVEJRM-UHFFFAOYSA-N 298087 US10118930, Example 297::3-[3-(2-methoxyethyl)-1,2,4-oxadiazol-5-yl]-2-methyl-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 27.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298087 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298087&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018610 381620919 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571153 CCOC(=O)c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C15H20N4O3/c1-3-22-15(21)13-9(2)18-19-11(8-12(20)17-14(13)19)10-4-6-16-7-5-10/h8,10,16H,3-7H2,1-2H3,(H,17,20) VEMIWYWPSBUQJB-UHFFFAOYSA-N 297784 US10118930, Example 9::Ethyl 2-methyl-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate trifluoroacetate::US10118930, Example 298 Tissue-type plasminogen activator Human 35.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=297784 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=297784&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137025707 381620619 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571154 Cc1nn2c(cc(=O)[nH]c2c1-c1nc(Cc2ccc(F)cc2)no1)C1CCNCC1 InChI=1S/C21H21FN6O2/c1-12-19(21-24-17(27-30-21)10-13-2-4-15(22)5-3-13)20-25-18(29)11-16(28(20)26-12)14-6-8-23-9-7-14/h2-5,11,14,23H,6-10H2,1H3,(H,25,29) FQTLYQVFCYCZJF-UHFFFAOYSA-N 298089 US10118930, Example 299::3-[3-(4-fluorobenzyl)-1,2,4-oxadiazol-5-yl]-2-methyl-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 25.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298089 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298089&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529877 381620920 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571155 CCc1noc(n1)-c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C16H20N6O2/c1-3-12-18-16(24-21-12)14-9(2)20-22-11(8-13(23)19-15(14)22)10-4-6-17-7-5-10/h8,10,17H,3-7H2,1-2H3,(H,19,23) PMQRROGEADXFMI-UHFFFAOYSA-N 298090 US10118930, Example 300::3-(3-ethyl-1,2,4-oxadiazol-5-yl)-2-methyl-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 16.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298090 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298090&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018744 381620921 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571156 CC(C)c1noc(n1)-c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H22N6O2/c1-9(2)15-20-17(25-22-15)14-10(3)21-23-12(8-13(24)19-16(14)23)11-4-6-18-7-5-11/h8-9,11,18H,4-7H2,1-3H3,(H,19,24) NUDDAPYNPGOOAN-UHFFFAOYSA-N 298091 US10118930, Example 301::2-methyl-7-(piperidin-4-yl)-3-[3-(propan-2-yl)-1,2,4-oxadiazol-5-yl]pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 30.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298091 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298091&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018329 381620922 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571157 Cc1nn2c(cc(=O)[nH]c2c1-c1nc(CCOC(C)(C)C)no1)C1CCNCC1 InChI=1S/C20H28N6O3/c1-12-17(19-22-15(25-29-19)7-10-28-20(2,3)4)18-23-16(27)11-14(26(18)24-12)13-5-8-21-9-6-13/h11,13,21H,5-10H2,1-4H3,(H,23,27) WCHZPUAZJXVPDB-UHFFFAOYSA-N 298092 US10118930, Example 302::3-[3-(2-tert-butoxyethyl)-1,2,4-oxadiazol-5-yl]-2-methyl-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 6.00 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298092 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298092&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018446 381620923 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571158 CC(C)(C)CC1CC(CCN1)c1cc(=O)[nH]c2c(cnn12)-c1nc(no1)C(C)(C)C InChI=1S/C22H32N6O2/c1-21(2,3)11-14-9-13(7-8-23-14)16-10-17(29)25-18-15(12-24-28(16)18)19-26-20(27-30-19)22(4,5)6/h10,12-14,23H,7-9,11H2,1-6H3,(H,25,29) ZFWGVMYIAMJNLB-UHFFFAOYSA-N 298093 US10118930, Example 303::3-(3-tert-butyl-1,2,4-oxadiazol-5-yl)-7-[2-(2,2-dimethylpropyl)piperidin-4-yl]pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 38.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298093 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298093&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018429 381620924 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571159 CC(C)CCc1csc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H25N5OS/c1-12(2)3-4-14-11-26-19(22-14)15-10-21-24-16(9-17(25)23-18(15)24)13-5-7-20-8-6-13/h9-13,20H,3-8H2,1-2H3,(H,23,25) JGBIBCCDWBGJCB-UHFFFAOYSA-N 298094 US10118930, Example 304::3-[4-(3-methylbutyl)-1,3-thiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 24.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298094 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298094&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018530 381620925 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571160 COc1ccc(cc1)C1(CC1)c1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C23H24N6O3/c1-31-16-4-2-15(3-5-16)23(8-9-23)22-28-27-21(32-22)17-13-25-29-18(12-19(30)26-20(17)29)14-6-10-24-11-7-14/h2-5,12-14,24H,6-11H2,1H3,(H,26,30) HLCWIGBBULSUQZ-UHFFFAOYSA-N 298095 US10118930, Example 305::3-{5-[1-(4-methoxyphenyl)cyclopropyl]-1,3,4-oxadiazol-2-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 20.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298095 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298095&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529878 381620926 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571161 Cc1nn2c(cc(=O)[nH]c2c1-c1nc(no1)-c1ccc(C)cc1)C1CCNCC1 InChI=1S/C21H22N6O2/c1-12-3-5-15(6-4-12)19-24-21(29-26-19)18-13(2)25-27-16(11-17(28)23-20(18)27)14-7-9-22-10-8-14/h3-6,11,14,22H,7-10H2,1-2H3,(H,23,28) LFFZXQDAUSZSAW-UHFFFAOYSA-N 298096 US10118930, Example 306::2-methyl-3-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 11.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298096 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298096&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529879 381620927 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571162 CC(CF)(CF)c1csc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C18H21F2N5OS/c1-18(9-19,10-20)14-8-27-17(23-14)12-7-22-25-13(6-15(26)24-16(12)25)11-2-4-21-5-3-11/h6-8,11,21H,2-5,9-10H2,1H3,(H,24,26) QTYDRYYBDSMFKS-UHFFFAOYSA-N 298097 US10118930, Example 307::3-[4-(1,3-difluoro-2-methylpropan-2-yl)-1,3-thiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 20.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298097 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298097&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018557 381620928 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571163 CCc1csc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C16H19N5OS/c1-2-11-9-23-16(19-11)12-8-18-21-13(7-14(22)20-15(12)21)10-3-5-17-6-4-10/h7-10,17H,2-6H2,1H3,(H,20,22) PLKPIFPTSOXFOO-UHFFFAOYSA-N 298098 US10118930, Example 308::3-(4-ethyl-1,3-thiazol-2-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 11.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298098 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298098&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137025673 381620929 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571164 Cc1ccc(cc1)-c1csc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C21H21N5OS/c1-13-2-4-14(5-3-13)17-12-28-21(24-17)16-11-23-26-18(10-19(27)25-20(16)26)15-6-8-22-9-7-15/h2-5,10-12,15,22H,6-9H2,1H3,(H,25,27) QGEDFXFKBDSVSX-UHFFFAOYSA-N 298099 US10118930, Example 309::3-[4-(4-methylphenyl)-1,3-thiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 41.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298099 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298099&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529880 381620930 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571165 CC(C)c1csc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H21N5OS/c1-10(2)13-9-24-17(20-13)12-8-19-22-14(7-15(23)21-16(12)22)11-3-5-18-6-4-11/h7-11,18H,3-6H2,1-2H3,(H,21,23) HWORATHISHXLIP-UHFFFAOYSA-N 298100 US10118930, Example 310::7-(piperidin-4-yl)-3-[4-(propan-2-yl)-1,3-thiazol-2-yl]pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 25.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298100 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298100&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137025747 381620931 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571166 O=c1cc(C2CCNCC2)n2ncc(-c3nc(cs3)C3CC3)c2[nH]1 InChI=1S/C17H19N5OS/c23-15-7-14(11-3-5-18-6-4-11)22-16(21-15)12(8-19-22)17-20-13(9-24-17)10-1-2-10/h7-11,18H,1-6H2,(H,21,23) HWXHIFQDBWMKKR-UHFFFAOYSA-N 298101 US10118930, Example 311::3-(4-cyclopropyl-1,3-thiazol-2-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 18.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298101 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298101&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018654 381620932 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571167 Cc1ccc(-c2csc(n2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)c(C)c1 InChI=1S/C22H23N5OS/c1-13-3-4-16(14(2)9-13)18-12-29-22(25-18)17-11-24-27-19(10-20(28)26-21(17)27)15-5-7-23-8-6-15/h3-4,9-12,15,23H,5-8H2,1-2H3,(H,26,28) DSZAENSMFJRQFG-UHFFFAOYSA-N 298102 US10118930, Example 312::3-[4-(2,4-dimethylphenyl)-1,3-thiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 22.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298102 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298102&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529881 381620933 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571168 CC(C)OC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C15H20N4O3/c1-9(2)22-15(21)11-8-17-19-12(7-13(20)18-14(11)19)10-3-5-16-6-4-10/h7-10,16H,3-6H2,1-2H3,(H,18,20) FMJRHXMWIPEWSB-UHFFFAOYSA-N 298103 US10118930, Example 315::Propan-2-yl 5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate hydrochloride Tissue-type plasminogen activator Human 36.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298103 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298103&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018649 381620934 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571169 CN(Cc1cc(C)on1)C(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C18H22N6O3/c1-11-7-13(22-27-11)10-23(2)18(26)14-9-20-24-15(8-16(25)21-17(14)24)12-3-5-19-6-4-12/h7-9,12,19H,3-6,10H2,1-2H3,(H,21,25) AAIIYAWXZTUBMZ-UHFFFAOYSA-N 298104 US10118930, Example 316::N-methyl-N-[(5-methyl-1,2-oxazol-3-yl)methyl]-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxamide hydrochloride Tissue-type plasminogen activator Human 27.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298104 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298104&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018567 381620935 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571170 CCNC(=O)c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C15H21N5O2/c1-3-17-15(22)13-9(2)19-20-11(8-12(21)18-14(13)20)10-4-6-16-7-5-10/h8,10,16H,3-7H2,1-2H3,(H,17,22)(H,18,21) IHTBVFILLRYNIK-UHFFFAOYSA-N 298105 US10118930, Example 317::N-ethyl-2-methyl-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxamide hydrochloride Tissue-type plasminogen activator Human 29.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298105 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298105&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018316 381620936 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571171 CN(Cc1cccnc1)C(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H22N6O2/c1-24(12-13-3-2-6-21-10-13)19(27)15-11-22-25-16(9-17(26)23-18(15)25)14-4-7-20-8-5-14/h2-3,6,9-11,14,20H,4-5,7-8,12H2,1H3,(H,23,26) PGHCEMARCDMHNA-UHFFFAOYSA-N 298106 US10118930, Example 318::N-methyl-5-oxo-7-(piperidin-4-yl)-N-(pyridin-3-ylmethyl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxamide hydrochloride Tissue-type plasminogen activator Human 45.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298106 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298106&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529882 381620937 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571172 CN(C)C(=O)c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C15H21N5O2/c1-9-13(15(22)19(2)3)14-17-12(21)8-11(20(14)18-9)10-4-6-16-7-5-10/h8,10,16H,4-7H2,1-3H3,(H,17,21) MDFMJNDLLULNMA-UHFFFAOYSA-N 298107 US10118930, Example 319::N,N,2-trimethyl-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxamide hydrochloride Tissue-type plasminogen activator Human 75.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298107 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298107&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018405 381620938 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571173 O[C@@H]1CCN(C1)C(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 |r| InChI=1S/C16H21N5O3/c22-11-3-6-20(9-11)16(24)12-8-18-21-13(7-14(23)19-15(12)21)10-1-4-17-5-2-10/h7-8,10-11,17,22H,1-6,9H2,(H,19,23) CHRINXRJJBTHAZ-UHFFFAOYSA-N 298108 US10118930, Example 320::3-{[(3R)-3-hydroxypyrrolidin-1-yl]carbonyl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 82.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298108 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298108&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018422 381620939 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571174 C[C@@H]1CCN(C1)C(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 |r| InChI=1S/C17H23N5O2/c1-11-4-7-21(10-11)17(24)13-9-19-22-14(8-15(23)20-16(13)22)12-2-5-18-6-3-12/h8-9,11-12,18H,2-7,10H2,1H3,(H,20,23) NRHKMXYKUQSEBW-UHFFFAOYSA-N 298109 US10118930, Example 321::3-{[(3R)-3-methylpyrrolidin-1-yl]carbonyl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 82.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298109 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298109&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018455 381620940 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571175 O=C(N1CCCC1)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C16H21N5O2/c22-14-9-13(11-3-5-17-6-4-11)21-15(19-14)12(10-18-21)16(23)20-7-1-2-8-20/h9-11,17H,1-8H2,(H,19,22) GNRKHIKIYFVFMS-UHFFFAOYSA-N 298110 US10118930, Example 322::7-(piperidin-4-yl)-3-(pyrrolidin-1-ylcarbonyl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 36.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298110 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298110&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018535 381620941 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571176 Cc1nn2c(cc(=O)[nH]c2c1C(O)=O)C1CCNCC1 InChI=1S/C13H16N4O3/c1-7-11(13(19)20)12-15-10(18)6-9(17(12)16-7)8-2-4-14-5-3-8/h6,8,14H,2-5H2,1H3,(H,15,18)(H,19,20) BJNSNIXTCNOKGX-UHFFFAOYSA-N 298111 US10118930, Example 323::2-methyl-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylic acid hydrochloride Tissue-type plasminogen activator Human 460 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298111 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298111&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137026061 381620942 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571177 CC1(C)CCN(Cc2cnn3c(cc(=O)[nH]c23)C2CCNCC2)C1 InChI=1S/C18H27N5O/c1-18(2)5-8-22(12-18)11-14-10-20-23-15(9-16(24)21-17(14)23)13-3-6-19-7-4-13/h9-10,13,19H,3-8,11-12H2,1-2H3,(H,21,24) LDGCFOSKHSZJQX-UHFFFAOYSA-N 298112 US10118930, Example 324::3-[(3,3-dimethylpyrrolidin-1-yl)methyl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 150 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298112 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298112&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018323 381620943 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571178 C[C@H]1CCCN1C(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 |r| InChI=1S/C17H23N5O2/c1-11-3-2-8-21(11)17(24)13-10-19-22-14(9-15(23)20-16(13)22)12-4-6-18-7-5-12/h9-12,18H,2-8H2,1H3,(H,20,23) WKMINTYKELLTOA-UHFFFAOYSA-N 298113 US10118930, Example 325::3-{[(2R)-2-methylpyrrolidin-1-yl]carbonyl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 18.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298113 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298113&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018531 381620944 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571179 FC1(F)CN(C1)C(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C15H17F2N5O2/c16-15(17)7-21(8-15)14(24)10-6-19-22-11(5-12(23)20-13(10)22)9-1-3-18-4-2-9/h5-6,9,18H,1-4,7-8H2,(H,20,23) JHXIJHNLAHUGCP-UHFFFAOYSA-N 298114 US10118930, Example 326::3-[(3,3-difluoroazetidin-1-yl)carbonyl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 12.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298114 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298114&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018650 381620945 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571180 O=C(N1CCCCC1)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H23N5O2/c23-15-10-14(12-4-6-18-7-5-12)22-16(20-15)13(11-19-22)17(24)21-8-2-1-3-9-21/h10-12,18H,1-9H2,(H,20,23) LYZODQMOHVNFCO-UHFFFAOYSA-N 298115 US10118930, Example 327::7-(piperidin-4-yl)-3-(piperidin-1-ylcarbonyl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 9.00 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298115 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298115&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018657 381620946 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571181 Cc1nc(sc1C)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C16H19N5OS/c1-9-10(2)23-16(19-9)12-8-18-21-13(7-14(22)20-15(12)21)11-3-5-17-6-4-11/h7-8,11,17H,3-6H2,1-2H3,(H,20,22) KAVDACZUGDHYEK-UHFFFAOYSA-N 298116 US10118930, Example 328::3-(4,5-dimethyl-1,3-thiazol-2-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 21.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298116 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298116&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018367 381620947 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571182 Cc1ccc(C)c(c1)-c1csc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C22H23N5OS/c1-13-3-4-14(2)16(9-13)18-12-29-22(25-18)17-11-24-27-19(10-20(28)26-21(17)27)15-5-7-23-8-6-15/h3-4,9-12,15,23H,5-8H2,1-2H3,(H,26,28) GUNFYOCUZWYBMM-UHFFFAOYSA-N 298117 US10118930, Example 329::3-[4-(2,5-dimethylphenyl)-1,3-thiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 54.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298117 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298117&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529883 381620948 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571183 CC1(C)CN(Cc2cnn3c(cc(=O)[nH]c23)C2CCNCC2)CCO1 InChI=1S/C18H27N5O2/c1-18(2)12-22(7-8-25-18)11-14-10-20-23-15(9-16(24)21-17(14)23)13-3-5-19-6-4-13/h9-10,13,19H,3-8,11-12H2,1-2H3,(H,21,24) GDBNSXXZLNQWMH-UHFFFAOYSA-N 298118 US10118930, Example 330::3-[(2,2-dimethylmorpholin-4-yl)methyl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 110 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298118 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298118&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018666 381620949 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571184 O=c1cc(C2CCNCC2)n2ncc(-c3nnc(Cc4cccnc4)o3)c2[nH]1 InChI=1S/C19H19N7O2/c27-16-9-15(13-3-6-20-7-4-13)26-18(23-16)14(11-22-26)19-25-24-17(28-19)8-12-2-1-5-21-10-12/h1-2,5,9-11,13,20H,3-4,6-8H2,(H,23,27) IHPVALOPQYUXST-UHFFFAOYSA-N 298119 US10118930, Example 331::7-(piperidin-4-yl)-3-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 24.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298119 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298119&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529884 381620950 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571185 CC(C)(C)c1cnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C18H23N5O2/c1-18(2,3)14-10-20-17(25-14)12-9-21-23-13(8-15(24)22-16(12)23)11-4-6-19-7-5-11/h8-11,19H,4-7H2,1-3H3,(H,22,24) AYRAXQIRPOBEEP-UHFFFAOYSA-N 298120 US10118930, Example 332::3-(5-tert-butyl-1,3-oxazol-2-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 26.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298120 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298120&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137025681 381620951 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571186 O=c1cc(C2CCNCC2)n2nc3CCCCc3c2[nH]1 InChI=1S/C15H20N4O/c20-14-9-13(10-5-7-16-8-6-10)19-15(17-14)11-3-1-2-4-12(11)18-19/h9-10,16H,1-8H2,(H,17,20) AVUSASNCWIPWQD-UHFFFAOYSA-N 298121 US10118930, Example 333::4-(piperidin-4-yl)-7,8,9,10-tetrahydropyrimido[1,2-b]indazol-2(1H)-one hydrochloride Tissue-type plasminogen activator Human 370 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298121 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298121&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018656 381620952 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571187 Cc1sc(nc1C(F)(F)F)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C16H16F3N5OS/c1-8-13(16(17,18)19)23-15(26-8)10-7-21-24-11(6-12(25)22-14(10)24)9-2-4-20-5-3-9/h6-7,9,20H,2-5H2,1H3,(H,22,25) KGGJUNJOCOZIPN-UHFFFAOYSA-N 298122 US10118930, Example 334::3-[5-methyl-4-(trifluoromethyl)-1,3-thiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 30.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298122 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298122&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018631 381620953 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571188 O=c1cc(C2CCNCC2)n2ncc(-c3nc(cs3)C3CCCCC3)c2[nH]1 InChI=1S/C20H25N5OS/c26-18-10-17(14-6-8-21-9-7-14)25-19(24-18)15(11-22-25)20-23-16(12-27-20)13-4-2-1-3-5-13/h10-14,21H,1-9H2,(H,24,26) RPOBZXMMUMOCPU-UHFFFAOYSA-N 298123 US10118930, Example 335::3-(4-cyclohexyl-1,3-thiazol-2-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 9.00 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298123 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298123&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018735 381620954 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571189 ClC1(CC1)c1csc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H18ClN5OS/c18-17(3-4-17)13-9-25-16(21-13)11-8-20-23-12(7-14(24)22-15(11)23)10-1-5-19-6-2-10/h7-10,19H,1-6H2,(H,22,24) QSXHRDPCLLRCLS-UHFFFAOYSA-N 298124 US10118930, Example 336::3-[4-(1-chlorocyclopropyl)-1,3-thiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 25.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298124 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298124&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018617 381620955 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571190 FC(F)Oc1ccccc1-c1csc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C21H19F2N5O2S/c22-21(23)30-17-4-2-1-3-13(17)15-11-31-20(26-15)14-10-25-28-16(9-18(29)27-19(14)28)12-5-7-24-8-6-12/h1-4,9-12,21,24H,5-8H2,(H,27,29) LQPRFNYHVJOWLE-UHFFFAOYSA-N 298126 US10118930, Example 337::3-{4-[2-(difluoromethoxy)phenyl]-1,3-thiazol-2-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 30.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298126 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298126&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529886 381620957 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571191 Cc1nn2c(cc(=O)[nH]c2c1-c1nnc(o1)C(C)(C)C)C1CCNCC1 InChI=1S/C18H24N6O2/c1-10-14(16-21-22-17(26-16)18(2,3)4)15-20-13(25)9-12(24(15)23-10)11-5-7-19-8-6-11/h9,11,19H,5-8H2,1-4H3,(H,20,25) BUBFTEVTMRTWON-UHFFFAOYSA-N 298127 US10118930, Example 338::3-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-2-methyl-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 11.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298127 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298127&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018533 381620958 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571192 Cc1noc(n1)-c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C15H18N6O2/c1-8-13(15-17-9(2)20-23-15)14-18-12(22)7-11(21(14)19-8)10-3-5-16-6-4-10/h7,10,16H,3-6H2,1-2H3,(H,18,22) QJBMTWULIWFSBO-UHFFFAOYSA-N 298128 US10118930, Example 339::2-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 28.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298128 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298128&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018660 381620959 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571193 Cc1nn2c(cc(=O)[nH]c2c1-c1nnc(o1)C1CCC1)C1CCNCC1 InChI=1S/C18H22N6O2/c1-10-15(18-22-21-17(26-18)12-3-2-4-12)16-20-14(25)9-13(24(16)23-10)11-5-7-19-8-6-11/h9,11-12,19H,2-8H2,1H3,(H,20,25) WDIUMXRINCQWEP-UHFFFAOYSA-N 298129 US10118930, Example 340::3-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)-2-methyl-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 28.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298129 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298129&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018602 381620960 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571194 Cc1nn2c(cc(=O)[nH]c2c1-c1nc(no1)C(F)(F)F)C1CCNCC1 InChI=1S/C15H15F3N6O2/c1-7-11(13-21-14(23-26-13)15(16,17)18)12-20-10(25)6-9(24(12)22-7)8-2-4-19-5-3-8/h6,8,19H,2-5H2,1H3,(H,20,25) IJMOCCTYELKXOZ-UHFFFAOYSA-N 298130 US10118930, Example 341::2-methyl-7-(piperidin-4-yl)-3-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298130 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298130&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018348 381620961 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571195 CN(C)Cc1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C14H21N5O/c1-18(2)9-11-8-16-19-12(7-13(20)17-14(11)19)10-3-5-15-6-4-10/h7-8,10,15H,3-6,9H2,1-2H3,(H,17,20) UMSDQKQDBODLKD-UHFFFAOYSA-N 298131 US10118930, Example 342::3-[(dimethylamino)methyl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 170 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298131 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298131&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018378 381620962 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571196 O=c1cc(C2CCNCC2)n2ncc(CN3CCCC3)c2[nH]1 InChI=1S/C16H23N5O/c22-15-9-14(12-3-5-17-6-4-12)21-16(19-15)13(10-18-21)11-20-7-1-2-8-20/h9-10,12,17H,1-8,11H2,(H,19,22) DYSUQGLQTBPQHA-UHFFFAOYSA-N 298132 US10118930, Example 343::7-(piperidin-4-yl)-3-(pyrrolidin-1-ylmethyl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 130 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298132 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298132&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018736 381620963 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571197 O=c1cc(C2CCNCC2)n2ncc(C3CC3)c2[nH]1 InChI=1S/C14H18N4O/c19-13-7-12(10-3-5-15-6-4-10)18-14(17-13)11(8-16-18)9-1-2-9/h7-10,15H,1-6H2,(H,17,19) DLUQHQGPIVPRRR-UHFFFAOYSA-N 298133 US10118930, Example 344::3-cyclopropyl-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 120 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298133 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298133&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018448 381620964 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571198 O=c1cc(C2CCNCC2)n2ncc(CN3CCS(=O)(=O)CC3)c2[nH]1 InChI=1S/C16H23N5O3S/c22-15-9-14(12-1-3-17-4-2-12)21-16(19-15)13(10-18-21)11-20-5-7-25(23,24)8-6-20/h9-10,12,17H,1-8,11H2,(H,19,22) PCXNRAORQBMOHH-UHFFFAOYSA-N 298134 US10118930, Example 345::3-[(1,1-dioxidothiomorpholin-4-yl)methyl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 120 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298134 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298134&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018369 381620965 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571199 Cc1nn2c(cc(=O)[nH]c2c1-c1nc(no1)C1CC1(C)C)C1CCNCC1 InChI=1S/C19H24N6O2/c1-10-15(18-22-16(24-27-18)12-9-19(12,2)3)17-21-14(26)8-13(25(17)23-10)11-4-6-20-7-5-11/h8,11-12,20H,4-7,9H2,1-3H3,(H,21,26) UFYGZKSBTKEGQV-UHFFFAOYSA-N 298135 US10118930, Example 346::3-[3-(2,2-dimethylcyclopropyl)-1,2,4-oxadiazol-5-yl]-2-methyl-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 17.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298135 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298135&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018676 381620966 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571200 Cc1nn2c(cc(=O)[nH]c2c1-c1nc(no1)-c1ccccc1OC(F)(F)F)C1CCNCC1 InChI=1S/C21H19F3N6O3/c1-11-17(19-26-16(31)10-14(30(19)28-11)12-6-8-25-9-7-12)20-27-18(29-33-20)13-4-2-3-5-15(13)32-21(22,23)24/h2-5,10,12,25H,6-9H2,1H3,(H,26,31) XIEYHBBOFWZPJR-UHFFFAOYSA-N 298136 US10118930, Example 347::2-methyl-7-(piperidin-4-yl)-3-{3-[2-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 28.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298136 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298136&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529887 381620967 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571201 O=c1cc(C2CCNCC2)n2ncc(CN3CCOCC3)c2[nH]1 InChI=1S/C16H23N5O2/c22-15-9-14(12-1-3-17-4-2-12)21-16(19-15)13(10-18-21)11-20-5-7-23-8-6-20/h9-10,12,17H,1-8,11H2,(H,19,22) CYBORROADRJVAW-UHFFFAOYSA-N 298137 US10118930, Example 348::3-(morpholin-4-ylmethyl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 160 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298137 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298137&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018357 381620968 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571202 CC(C)(C)C[C@@H]1C[C@@H](CCN1)c1cc(=O)[nH]c2c(cnn12)-c1nc(no1)-c1ccccc1F |r| InChI=1S/C24H27FN6O2/c1-24(2,3)12-15-10-14(8-9-26-15)19-11-20(32)28-22-17(13-27-31(19)22)23-29-21(30-33-23)16-6-4-5-7-18(16)25/h4-7,11,13-15,26H,8-10,12H2,1-3H3,(H,28,32) BMYCXLDGAVFUFH-UHFFFAOYSA-N 298138 US10118930, Example 349::7-[(2S,4R)-2-(2,2-dimethylpropyl)piperidin-4-yl]-3-[3-(2-fluorophenyl)-1,2,4-oxadiazol-5-yl]pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 21.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298138 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298138&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529888 381620969 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571203 Cc1nn2c(cc(=O)[nH]c2c1-c1nc(no1)C1CCCCC1)C1CCNCC1 InChI=1S/C20H26N6O2/c1-12-17(20-23-18(25-28-20)14-5-3-2-4-6-14)19-22-16(27)11-15(26(19)24-12)13-7-9-21-10-8-13/h11,13-14,21H,2-10H2,1H3,(H,22,27) JHHXKIHJBLYYOR-UHFFFAOYSA-N 298139 US10118930, Example 350::3-(3-cyclohexyl-1,2,4-oxadiazol-5-yl)-2-methyl-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 20.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298139 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298139&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018717 381620970 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571204 FC(F)(F)c1csc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C15H14F3N5OS/c16-15(17,18)11-7-25-14(21-11)9-6-20-23-10(5-12(24)22-13(9)23)8-1-3-19-4-2-8/h5-8,19H,1-4H2,(H,22,24) OKUOMYWRCDIWNW-UHFFFAOYSA-N 298140 US10118930, Example 351::7-(piperidin-4-yl)-3-[4-(trifluoromethyl)-1,3-thiazol-2-yl]pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 26.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298140 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298140&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018671 381620971 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571205 FCCCOC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C15H19FN4O3/c16-4-1-7-23-15(22)11-9-18-20-12(8-13(21)19-14(11)20)10-2-5-17-6-3-10/h8-10,17H,1-7H2,(H,19,21) YSJANLGWPVEXLP-UHFFFAOYSA-N 298142 US10118930, Example 352::3-fluoropropyl 5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate hydrochloride Tissue-type plasminogen activator Human 44.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298142 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298142&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018395 381620973 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571206 FC(F)COC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C14H16F2N4O3/c15-11(16)7-23-14(22)9-6-18-20-10(5-12(21)19-13(9)20)8-1-3-17-4-2-8/h5-6,8,11,17H,1-4,7H2,(H,19,21) FAVOLPZWVBZOEL-UHFFFAOYSA-N 298146 US10118930, Example 353::2,2-difluoroethyl 5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate hydrochloride Tissue-type plasminogen activator Human 28.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298146 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298146&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018542 381620977 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571207 FC(F)(F)COC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C14H15F3N4O3/c15-14(16,17)7-24-13(23)9-6-19-21-10(5-11(22)20-12(9)21)8-1-3-18-4-2-8/h5-6,8,18H,1-4,7H2,(H,20,22) TUSBXXAIFGHRET-UHFFFAOYSA-N 298147 US10118930, Example 354::2,2,2-trifluoroethyl 5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate hydrochloride Tissue-type plasminogen activator Human 27.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298147 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298147&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018397 381620978 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571208 FC(F)(F)CCOC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C15H17F3N4O3/c16-15(17,18)3-6-25-14(24)10-8-20-22-11(7-12(23)21-13(10)22)9-1-4-19-5-2-9/h7-9,19H,1-6H2,(H,21,23) ONYIUJCUIAKYCB-UHFFFAOYSA-N 298152 US10118930, Example 355::3,3,3-trifluoropropyl 5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate hydrochloride Tissue-type plasminogen activator Human 27.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298152 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298152&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018549 381620983 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571209 O=C(OC1CCC1)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C16H20N4O3/c21-14-8-13(10-4-6-17-7-5-10)20-15(19-14)12(9-18-20)16(22)23-11-2-1-3-11/h8-11,17H,1-7H2,(H,19,21) NRPVONVYCOVDFB-UHFFFAOYSA-N 298153 US10118930, Example 356::Cyclobutyl 5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate hydrochloride Tissue-type plasminogen activator Human 23.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298153 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298153&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018664 381620984 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571210 COC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C13H16N4O3/c1-20-13(19)9-7-15-17-10(6-11(18)16-12(9)17)8-2-4-14-5-3-8/h6-8,14H,2-5H2,1H3,(H,16,18) YUDQJRBREVRORT-UHFFFAOYSA-N 298154 US10118930, Example 357::Methyl 5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate hydrochloride Tissue-type plasminogen activator Human 14.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298154 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298154&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018658 381620985 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571211 CCCOC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C15H20N4O3/c1-2-7-22-15(21)11-9-17-19-12(8-13(20)18-14(11)19)10-3-5-16-6-4-10/h8-10,16H,2-7H2,1H3,(H,18,20) PTEHPDBEEFFPPL-UHFFFAOYSA-N 298155 US10118930, Example 358::Propyl 5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate hydrochloride Tissue-type plasminogen activator Human 24.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298155 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298155&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018472 381620986 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571212 O=C(N1CCC11CCOCC1)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H25N5O3/c25-16-11-15(13-1-6-20-7-2-13)24-17(22-16)14(12-21-24)18(26)23-8-3-19(23)4-9-27-10-5-19/h11-13,20H,1-10H2,(H,22,25) VBXLPJQBNLLECR-UHFFFAOYSA-N 298156 US10118930, Example 359::3-(7-oxa-1-azaspiro[3.5]non-1-ylcarbonyl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one trifluoroacetate Tissue-type plasminogen activator Human 120 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298156 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298156&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018639 381620987 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571213 C[C@H](N(C)C(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1)c1ccccc1 |r| InChI=1S/C21H25N5O2/c1-14(15-6-4-3-5-7-15)25(2)21(28)17-13-23-26-18(12-19(27)24-20(17)26)16-8-10-22-11-9-16/h3-7,12-14,16,22H,8-11H2,1-2H3,(H,24,27) SABKTKDWFVZRRO-UHFFFAOYSA-N 298157 US10118930, Example 360::N-methyl-5-oxo-N-[(1S)-1-phenylethyl]-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxamide hydrochloride Tissue-type plasminogen activator Human 52.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298157 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298157&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529897 381620988 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571214 CN(Cc1ccccn1)C(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H22N6O2/c1-24(12-14-4-2-3-7-21-14)19(27)15-11-22-25-16(10-17(26)23-18(15)25)13-5-8-20-9-6-13/h2-4,7,10-11,13,20H,5-6,8-9,12H2,1H3,(H,23,26) NUOMYEAKBYICIQ-UHFFFAOYSA-N 298158 US10118930, Example 361::N-methyl-5-oxo-7-(piperidin-4-yl)-N-(pyridin-2-ylmethyl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxamide hydrochloride Tissue-type plasminogen activator Human 32.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298158 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298158&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529898 381620989 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571215 FC1(F)CCN(CC1)C(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H21F2N5O2/c18-17(19)3-7-23(8-4-17)16(26)12-10-21-24-13(9-14(25)22-15(12)24)11-1-5-20-6-2-11/h9-11,20H,1-8H2,(H,22,25) SXYOMZIFHSXHFG-UHFFFAOYSA-N 298159 US10118930, Example 362::3-[(4,4-difluoropiperidin-1-yl)carbonyl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 21.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298159 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298159&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018668 381620990 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571216 C[C@H]1CCCN1Cc1cnn2c(cc(=O)[nH]c12)C1CCNCC1 |r| InChI=1S/C17H25N5O/c1-12-3-2-8-21(12)11-14-10-19-22-15(9-16(23)20-17(14)22)13-4-6-18-7-5-13/h9-10,12-13,18H,2-8,11H2,1H3,(H,20,23) HRFKAZFRIONPAJ-UHFFFAOYSA-N 298160 US10118930, Example 363::3-{[(2S)-2-methylpyrrolidin-1-yl]methyl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 130 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298160 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298160&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018659 381620991 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571217 Cc1nn2c(cc(=O)[nH]c2c1C(=O)OC1CCC1)C1CCNCC1 InChI=1S/C17H22N4O3/c1-10-15(17(23)24-12-3-2-4-12)16-19-14(22)9-13(21(16)20-10)11-5-7-18-8-6-11/h9,11-12,18H,2-8H2,1H3,(H,19,22) YAVHJTQPULNBMG-UHFFFAOYSA-N 298161 US10118930, Example 364::Cyclobutyl 2-methyl-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate hydrochloride Tissue-type plasminogen activator Human 11.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298161 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298161&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018665 381620992 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571218 CCCOC(=O)c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C16H22N4O3/c1-3-8-23-16(22)14-10(2)19-20-12(9-13(21)18-15(14)20)11-4-6-17-7-5-11/h9,11,17H,3-8H2,1-2H3,(H,18,21) SZTLNNGVIDCLSK-UHFFFAOYSA-N 298162 US10118930, Example 365::Propyl 2-methyl-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate hydrochloride::US10118930, Example 467 Tissue-type plasminogen activator Human 38.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298162 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298162&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018414 381620993 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571219 CC(C)OC(=O)c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C16H22N4O3/c1-9(2)23-16(22)14-10(3)19-20-12(8-13(21)18-15(14)20)11-4-6-17-7-5-11/h8-9,11,17H,4-7H2,1-3H3,(H,18,21) ZLJKEPAKBQUWGJ-UHFFFAOYSA-N 298163 US10118930, Example 366::Propan-2-yl 2-methyl-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate hydrochloride Tissue-type plasminogen activator Human 27.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298163 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298163&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018304 381620994 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571220 Cc1nn2c(cc(=O)[nH]c2c1C(=O)OCC(F)(F)F)C1CCNCC1 InChI=1S/C15H17F3N4O3/c1-8-12(14(24)25-7-15(16,17)18)13-20-11(23)6-10(22(13)21-8)9-2-4-19-5-3-9/h6,9,19H,2-5,7H2,1H3,(H,20,23) CIVVWNBPEDHZNF-UHFFFAOYSA-N 298164 US10118930, Example 367::2,2,2-trifluoroethyl 2-methyl-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate hydrochloride Tissue-type plasminogen activator Human 25.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298164 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298164&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018439 381620995 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571221 Cc1nn2c(cc(=O)[nH]c2c1C1CC1)C1CCNCC1 InChI=1S/C15H20N4O/c1-9-14(11-2-3-11)15-17-13(20)8-12(19(15)18-9)10-4-6-16-7-5-10/h8,10-11,16H,2-7H2,1H3,(H,17,20) WZCNXWOOHWFVAV-UHFFFAOYSA-N 298165 US10118930, Example 368::3-cyclopropyl-2-methyl-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 390 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298165 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298165&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018693 381620996 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571222 Cc1nc(sc1-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1)-c1ccc(cc1)C(F)(F)F InChI=1S/C22H20F3N5OS/c1-12-19(32-21(28-12)14-2-4-15(5-3-14)22(23,24)25)16-11-27-30-17(10-18(31)29-20(16)30)13-6-8-26-9-7-13/h2-5,10-11,13,26H,6-9H2,1H3,(H,29,31) TWRPSOLTCGUBTI-UHFFFAOYSA-N 298166 US10118930, Example 369::3-{4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 39.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298166 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298166&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529899 381620997 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571223 CC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C13H16N4O2/c1-8(18)10-7-15-17-11(6-12(19)16-13(10)17)9-2-4-14-5-3-9/h6-7,9,14H,2-5H2,1H3,(H,16,19) SOUAJXWZEXNCFJ-UHFFFAOYSA-N 298167 US10118930, Example 370::3-acetyl-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 36.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298167 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298167&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018423 381620998 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571224 CCC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C14H18N4O2/c1-2-12(19)10-8-16-18-11(7-13(20)17-14(10)18)9-3-5-15-6-4-9/h7-9,15H,2-6H2,1H3,(H,17,20) XTIWTDXPIYATRO-UHFFFAOYSA-N 298168 US10118930, Example 371::7-(piperidin-4-yl)-3-propanoylpyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 30.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298168 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298168&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137025660 381620999 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571225 O=c1cc(C2CCNCC2)n2ncc(-c3coc(n3)-c3ccccc3)c2[nH]1 InChI=1S/C20H19N5O2/c26-18-10-17(13-6-8-21-9-7-13)25-19(24-18)15(11-22-25)16-12-27-20(23-16)14-4-2-1-3-5-14/h1-5,10-13,21H,6-9H2,(H,24,26) LEWXMDYDAMNXHX-UHFFFAOYSA-N 298169 US10118930, Example 372::3-(2-phenyl-1,3-oxazol-4-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 22.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298169 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298169&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529900 381621000 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571226 O=c1cc(C2CCNCC2)n2ncc(-c3ccns3)c2[nH]1 InChI=1S/C14H15N5OS/c20-13-7-11(9-1-4-15-5-2-9)19-14(18-13)10(8-16-19)12-3-6-17-21-12/h3,6-9,15H,1-2,4-5H2,(H,18,20) HRDUCODKRUSLHO-UHFFFAOYSA-N 298170 US10118930, Example 373::7-(piperidin-4-yl)-3-(1,2-thiazol-5-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 11.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298170 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298170&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018669 381621001 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571227 Brc1nn2c(cc(=O)[nH]c2c1C#N)C1CCNCC1 InChI=1S/C12H12BrN5O/c13-11-8(6-14)12-16-10(19)5-9(18(12)17-11)7-1-3-15-4-2-7/h5,7,15H,1-4H2,(H,16,19) DBYGQIDFPWTHAN-UHFFFAOYSA-N 298171 US10118930, Example 374::2-bromo-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carbonitrile hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298171 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298171&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018747 381621002 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571228 Cn1nccc1-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C15H18N6O/c1-20-12(4-7-17-20)11-9-18-21-13(8-14(22)19-15(11)21)10-2-5-16-6-3-10/h4,7-10,16H,2-3,5-6H2,1H3,(H,19,22) OJZHTDOXBOTQLL-UHFFFAOYSA-N 298172 US10118930, Example 375::3-(1-methyl-1H-pyrazol-5-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 30.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298172 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298172&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018745 381621003 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571229 O=c1cc(C2CCNCC2)n2ncc(-c3cnc(s3)N3CCOCC3)c2[nH]1 InChI=1S/C18H22N6O2S/c25-16-9-14(12-1-3-19-4-2-12)24-17(22-16)13(10-21-24)15-11-20-18(27-15)23-5-7-26-8-6-23/h9-12,19H,1-8H2,(H,22,25) QOEKXIRQXTWPEO-UHFFFAOYSA-N 298173 US10118930, Example 376::3-[2-(morpholin-4-yl)-1,3-thiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 32.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298173 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298173&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018581 381621004 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571230 CCC(C)(C)C(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H24N4O2/c1-4-17(2,3)15(23)12-10-19-21-13(9-14(22)20-16(12)21)11-5-7-18-8-6-11/h9-11,18H,4-8H2,1-3H3,(H,20,22) MEAGECIPRUWVNI-UHFFFAOYSA-N 298174 US10118930, Example 377::3-(2,2-dimethylbutanoyl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 25.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298174 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298174&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018670 381621005 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571231 CC(C)Cc1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H22N6O2/c1-10(2)7-15-21-16(22-25-15)12-9-19-23-13(8-14(24)20-17(12)23)11-3-5-18-6-4-11/h8-11,18H,3-7H2,1-2H3,(H,20,24) OYQJNGMXWYAENW-UHFFFAOYSA-N 298175 US10118930, Example 378::3-(5-Isobutyl-1,2,4-oxadiazol-3-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 32.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298175 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298175&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018593 381621006 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571232 CCCCCCc1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H26N6O2/c1-2-3-4-5-6-17-23-18(24-27-17)14-12-21-25-15(11-16(26)22-19(14)25)13-7-9-20-10-8-13/h11-13,20H,2-10H2,1H3,(H,22,26) PNAJPSCLUUFKKF-UHFFFAOYSA-N 298176 US10118930, Example 379::3-(5-Hexyl-1,2,4-oxadiazol-3-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 22.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298176 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298176&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018743 381621007 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571233 O=c1cc(C2CCNCC2)n2ncc(-c3noc(n3)C3CC3)c2[nH]1 InChI=1S/C16H18N6O2/c23-13-7-12(9-3-5-17-6-4-9)22-15(19-13)11(8-18-22)14-20-16(24-21-14)10-1-2-10/h7-10,17H,1-6H2,(H,19,23) STAAKQZHJKDIOT-UHFFFAOYSA-N 298177 US10118930, Example 380::3-(5-Cyclopropyl-1,2,4-oxadiazol-3-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 14.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298177 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298177&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018583 381621008 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571234 CC1(CC1)c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H20N6O2/c1-17(4-5-17)16-21-14(22-25-16)11-9-19-23-12(8-13(24)20-15(11)23)10-2-6-18-7-3-10/h8-10,18H,2-7H2,1H3,(H,20,24) DGIURQNLLYSKKD-UHFFFAOYSA-N 298178 US10118930, Example 381::Rac-3-[5-(1-Methylcyclopropyl)-1,2,4-oxadiazol-3-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 29.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298178 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298178&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018680 381621009 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571235 CC1CC1c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H20N6O2/c1-9-6-11(9)17-21-15(22-25-17)12-8-19-23-13(7-14(24)20-16(12)23)10-2-4-18-5-3-10/h7-11,18H,2-6H2,1H3,(H,20,24) QLAFZLZAFUJBHE-UHFFFAOYSA-N 298179 US10118930, Example 382::Rel-3-{5-[(1R,2S)-2-methylcyclopropyl]-1,2,4-oxadiazol-3-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 28.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298179 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298179&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018556 381621010 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571236 CC(C)=Cc1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 |(5.75,5.52,;4.26,5.12,;3.17,6.21,;3.86,3.64,;2.37,3.24,;1.9,1.77,;.36,1.77,;-.12,3.24,;1.13,4.14,;-.73,.68,;-2.26,.84,;-2.89,-.56,;-1.75,-1.59,;-1.75,-3.13,;-.41,-3.9,;.92,-3.13,;2.26,-3.9,;.92,-1.59,;-.41,-.82,;-3.08,-3.9,;-4.41,-3.13,;-5.75,-3.9,;-5.75,-5.44,;-4.41,-6.21,;-3.08,-5.44,)| InChI=1S/C17H20N6O2/c1-10(2)7-15-21-16(22-25-15)12-9-19-23-13(8-14(24)20-17(12)23)11-3-5-18-6-4-11/h7-9,11,18H,3-6H2,1-2H3,(H,20,24) QEENWSUELYZWGF-UHFFFAOYSA-N 298180 US10118930, Example 383::3-[5-(2-Methylprop-1-en-1-yl)-1,2,4-oxadiazol-3-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 15.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298180 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298180&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018711 381621011 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571237 O=c1cc(C2CCNCC2)n2ncc(-c3noc(C=C4CCCC4)n3)c2[nH]1 |(2.27,-4.6,;.93,-3.83,;-.4,-4.6,;-1.73,-3.83,;-3.07,-4.6,;-4.4,-3.83,;-5.73,-4.6,;-5.73,-6.14,;-4.4,-6.91,;-3.07,-6.14,;-1.73,-2.29,;-2.88,-1.26,;-2.25,.14,;-.72,-.02,;.37,1.07,;-.11,2.54,;1.14,3.44,;2.38,2.54,;3.87,2.93,;4.27,4.42,;5.73,4.9,;5.73,6.44,;4.27,6.91,;3.37,5.67,;1.91,1.07,;-.4,-1.52,;.93,-2.29,)| InChI=1S/C19H22N6O2/c26-16-10-15(13-5-7-20-8-6-13)25-19(22-16)14(11-21-25)18-23-17(27-24-18)9-12-3-1-2-4-12/h9-11,13,20H,1-8H2,(H,22,26) PLIIHDUFDHUWRH-UHFFFAOYSA-N 298181 US10118930, Example 384::3-[5-(Cyclopentylidenemethyl)-1,2,4-oxadiazol-3-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 26.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298181 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298181&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018449 381621012 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571238 O=c1cc(C2CCNCC2)n2ncc(-c3noc(n3)C3CCCC3)c2[nH]1 InChI=1S/C18H22N6O2/c25-15-9-14(11-5-7-19-8-6-11)24-17(21-15)13(10-20-24)16-22-18(26-23-16)12-3-1-2-4-12/h9-12,19H,1-8H2,(H,21,25) CUQVNSOHGBGHTK-UHFFFAOYSA-N 298182 US10118930, Example 385::3-(5-Cyclopentyl-1,2,4-oxadiazol-3-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 14.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298182 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298182&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018399 381621013 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571239 CC1(CCCC1)c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H24N6O2/c1-19(6-2-3-7-19)18-23-16(24-27-18)13-11-21-25-14(10-15(26)22-17(13)25)12-4-8-20-9-5-12/h10-12,20H,2-9H2,1H3,(H,22,26) SAQOJLQBBIVJPM-UHFFFAOYSA-N 298183 US10118930, Example 386::Rac-3-[5-(1-Methylcyclopentyl)-1,2,4-oxadiazol-3-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 28.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298183 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298183&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018746 381621014 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571240 CC1CCCC1c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H24N6O2/c1-11-3-2-4-13(11)19-23-17(24-27-19)14-10-21-25-15(9-16(26)22-18(14)25)12-5-7-20-8-6-12/h9-13,20H,2-8H2,1H3,(H,22,26) ATUBYBPXVCJCET-UHFFFAOYSA-N 298184 US10118930, Example 387::Rel-3-{5-[(1R,2S)-2-methylcyclopentyl]-1,2,4-oxadiazol-3-yl}-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 10.00 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298184 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298184&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018344 381621015 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571241 FC(F)(F)Cc1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C15H15F3N6O2/c16-15(17,18)6-12-22-13(23-26-12)9-7-20-24-10(5-11(25)21-14(9)24)8-1-3-19-4-2-8/h5,7-8,19H,1-4,6H2,(H,21,25) IANFUFAEZVMISU-UHFFFAOYSA-N 298185 US10118930, Example 388::7-(Piperidin-4-yl)-3-[5-(2,2,2-trifluoroethyl)-1,2,4-oxadiazol-3-yl]pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 30.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298185 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298185&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018434 381621016 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571242 O=c1cc(C2CCNCC2)n2ncc(-c3noc(n3)C3CCCO3)c2[nH]1 InChI=1S/C17H20N6O3/c24-14-8-12(10-3-5-18-6-4-10)23-16(20-14)11(9-19-23)15-21-17(26-22-15)13-2-1-7-25-13/h8-10,13,18H,1-7H2,(H,20,24) QWKRCVUUGZZFOO-UHFFFAOYSA-N 298186 US10118930, Example 389::Rac-7-(piperidin-4-yl)-3-(5-(tetrahydrofuran-2-yl)-1,2,4-oxadiazol-3-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 30.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298186 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298186&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018755 381621017 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571243 FC(F)(F)c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C14H13F3N6O2/c15-14(16,17)13-21-11(22-25-13)8-6-19-23-9(5-10(24)20-12(8)23)7-1-3-18-4-2-7/h5-7,18H,1-4H2,(H,20,24) KTMJILGVYKZFSM-UHFFFAOYSA-N 298187 US10118930, Example 390::7-(piperidin-4-yl)-3-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298187 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298187&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018754 381621018 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571244 CC(C)(c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1)C(F)(F)F InChI=1S/C17H19F3N6O2/c1-16(2,17(18,19)20)15-24-13(25-28-15)10-8-22-26-11(7-12(27)23-14(10)26)9-3-5-21-6-4-9/h7-9,21H,3-6H2,1-2H3,(H,23,27) FWTWLFIZEUWTDA-UHFFFAOYSA-N 298188 US10118930, Example 391::7-(piperidin-4-yl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2,4-oxadiazol-3-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 30.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298188 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298188&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018475 381621019 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571245 FC1(F)CC(C1)c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H18F2N6O2/c18-17(19)6-10(7-17)16-23-14(24-27-16)11-8-21-25-12(5-13(26)22-15(11)25)9-1-3-20-4-2-9/h5,8-10,20H,1-4,6-7H2,(H,22,26) BEWDXHBBMGJNJM-UHFFFAOYSA-N 298189 US10118930, Example 392::3-(5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 27.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298189 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298189&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018681 381621020 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571246 FC1(F)CCC(CC1)c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H22F2N6O2/c20-19(21)5-1-12(2-6-19)18-25-16(26-29-18)13-10-23-27-14(9-15(28)24-17(13)27)11-3-7-22-8-4-11/h9-12,22H,1-8H2,(H,24,28) ZPZSIYJXDHZUBN-UHFFFAOYSA-N 298190 US10118930, Example 393::3-(5-(4,4-difluorocyclohexyl)-1,2,4-oxadiazol-3-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 30.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298190 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298190&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018596 381621021 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571247 COCc1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C15H18N6O3/c1-23-8-13-19-14(20-24-13)10-7-17-21-11(6-12(22)18-15(10)21)9-2-4-16-5-3-9/h6-7,9,16H,2-5,8H2,1H3,(H,18,22) ALDUYELYZTVDMQ-UHFFFAOYSA-N 298191 US10118930, Example 394::3-(5-(methoxymethyl)-1,2,4-oxadiazol-3-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 29.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298191 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298191&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018695 381621022 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571248 COCCCc1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H22N6O3/c1-25-8-2-3-15-21-16(22-26-15)12-10-19-23-13(9-14(24)20-17(12)23)11-4-6-18-7-5-11/h9-11,18H,2-8H2,1H3,(H,20,24) ZJVCLFOWJGRPRA-UHFFFAOYSA-N 298192 US10118930, Example 395::3-(5-(3-methoxypropyl)-1,2,4-oxadiazol-3-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 27.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298192 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298192&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018709 381621023 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571249 CC1CCCCN1C(=O)c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H27N5O2/c1-12-5-3-4-10-23(12)19(26)17-13(2)22-24-15(11-16(25)21-18(17)24)14-6-8-20-9-7-14/h11-12,14,20H,3-10H2,1-2H3,(H,21,25) AQIMOZGNOXJTRS-UHFFFAOYSA-N 298193 US10118930, Example 396::Ethyl 2-methyl-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate hydrochloride Tissue-type plasminogen activator Human 40.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298193 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298193&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018597 381621024 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571250 Cc1nn2c(cc(=O)[nH]c2c1C(=O)N1CCSCC1)C1CCNCC1 InChI=1S/C17H23N5O2S/c1-11-15(17(24)21-6-8-25-9-7-21)16-19-14(23)10-13(22(16)20-11)12-2-4-18-5-3-12/h10,12,18H,2-9H2,1H3,(H,19,23) VONVMRKIJLWEGF-UHFFFAOYSA-N 298194 US10118930, Example 397::2-methyl-7- (piperidin-4-yl)-3- (thiomorpholin-4- ylcarbonyl)pyrazolo [1,5-a]pyrimidin- 5(4H)-one hydrochloride Tissue-type plasminogen activator Human 36.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298194 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298194&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018410 381621025 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571251 COC[C@@H]1CCCN1C(=O)c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 |r| InChI=1S/C19H27N5O3/c1-12-17(19(26)23-9-3-4-14(23)11-27-2)18-21-16(25)10-15(24(18)22-12)13-5-7-20-8-6-13/h10,13-14,20H,3-9,11H2,1-2H3,(H,21,25) ANJCKUVTEGMEEE-UHFFFAOYSA-N 298195 US10118930, Example 398::3-{[(2S)-2- (methoxymethyl) pyrrolidin-1-yl] carbonyl}-2- methyl-7- (piperidin-4-yl) pyrazolo[1,5-a] pyrimidin-5(4H)- one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298195 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298195&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018411 381621026 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571252 Cc1nn2c(cc(=O)[nH]c2c1C(=O)N1CCCCC1)C1CCNCC1 InChI=1S/C18H25N5O2/c1-12-16(18(25)22-9-3-2-4-10-22)17-20-15(24)11-14(23(17)21-12)13-5-7-19-8-6-13/h11,13,19H,2-10H2,1H3,(H,20,24) JLWYOHNPYWGYEX-UHFFFAOYSA-N 298196 US10118930, Example 399::2-methyl-7- (piperidin-4-yl)- 3-(piperidin-1- ylcarbonyl) pyrazolo[1,5-a] pyrimidin-5(4H)- one hydrochloride Tissue-type plasminogen activator Human 42.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298196 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298196&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018415 381621027 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571253 CCN(C1CC1)C(=O)c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C18H25N5O2/c1-3-22(13-4-5-13)18(25)16-11(2)21-23-14(10-15(24)20-17(16)23)12-6-8-19-9-7-12/h10,12-13,19H,3-9H2,1-2H3,(H,20,24) DRLZUVJFTBIQCT-UHFFFAOYSA-N 298197 US10118930, Example 400::N-cyclopropyl- N-ethyl-2- methyl-5-oxo- 7-(piperidin-4- yl)-4,5-dihydro- pyrazolo[1,5-a] pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 32.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298197 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298197&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018413 381621028 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571254 CN(C1CCC1)C(=O)c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C18H25N5O2/c1-11-16(18(25)22(2)13-4-3-5-13)17-20-15(24)10-14(23(17)21-11)12-6-8-19-9-7-12/h10,12-13,19H,3-9H2,1-2H3,(H,20,24) IJJZNCMSLLMITL-UHFFFAOYSA-N 298198 US10118930, Example 401::N-cyclobutyl- N,2-dimethyl- 5-oxo-7- (piperidin-4-yl)- 4,5-dihydro- pyrazolo[1,5-a] pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298198 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298198&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018408 381621029 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571255 COCC1CCCN(C1)C(=O)c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H29N5O3/c1-13-18(20(27)24-9-3-4-14(11-24)12-28-2)19-22-17(26)10-16(25(19)23-13)15-5-7-21-8-6-15/h10,14-15,21H,3-9,11-12H2,1-2H3,(H,22,26) WTSTVRNFKSOEOM-UHFFFAOYSA-N 298199 US10118930, Example 402::3-{[3- (methoxymethyl) piperidin-1-yl] carbonyl}-2- methyl-7- (piperidin-4-yl) pyrazolo[1,5-a] pyrimidin-5(4H)- one hydrochloride Tissue-type plasminogen activator Human 40.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298199 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298199&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018686 381621030 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571256 COC1CCN(CC1)C(=O)c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H27N5O3/c1-12-17(19(26)23-9-5-14(27-2)6-10-23)18-21-16(25)11-15(24(18)22-12)13-3-7-20-8-4-13/h11,13-14,20H,3-10H2,1-2H3,(H,21,25) GCZSPLKKKACOOC-UHFFFAOYSA-N 298200 US10118930, Example 403::3-[(4- methoxypiperidin- 1-yl)carbonyl]-2- methyl-7- (piperidin-4-yl) pyrazolo[1,5-a] pyrimidin-5(4H)- one hydrochloride Tissue-type plasminogen activator Human 36.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298200 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298200&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018687 381621031 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571257 Cc1nn2c(cc(=O)[nH]c2c1C(=O)N1CCCc2ccccc12)C1CCNCC1 InChI=1S/C22H25N5O2/c1-14-20(22(29)26-12-4-6-15-5-2-3-7-17(15)26)21-24-19(28)13-18(27(21)25-14)16-8-10-23-11-9-16/h2-3,5,7,13,16,23H,4,6,8-12H2,1H3,(H,24,28) JGSGMVRJUXWKFW-UHFFFAOYSA-N 298201 US10118930, Example 404::3-(3,4- dihydroquinolin- 1(2H)-ylcarbonyl)- 2-methyl-7- (piperidin-4-yl) pyrazolo[1,5-a] pyrimidin-5(4H)- one hydrochloride Tissue-type plasminogen activator Human 30.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298201 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298201&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529901 381621032 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571258 Cc1nn2c(cc(=O)[nH]c2c1C(=O)N1CCC2CCCCC2C1)C1CCNCC1 InChI=1S/C22H31N5O2/c1-14-20(22(29)26-11-8-15-4-2-3-5-17(15)13-26)21-24-19(28)12-18(27(21)25-14)16-6-9-23-10-7-16/h12,15-17,23H,2-11,13H2,1H3,(H,24,28) NRGSYVSLMKEXEB-UHFFFAOYSA-N 298203 US10118930, Example 405::2-methyl-3- (octahydro- isoquinolin-2(1H)- ylcarbonyl)-7- (piperidin-4-yl) pyrazolo[1,5-a] pyrimidin-5(4H)- one hydrochloride Tissue-type plasminogen activator Human 37.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298203 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298203&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018690 381621034 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571259 CCCN(CC1CC1)C(=O)c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H29N5O2/c1-3-10-24(12-14-4-5-14)20(27)18-13(2)23-25-16(11-17(26)22-19(18)25)15-6-8-21-9-7-15/h11,14-15,21H,3-10,12H2,1-2H3,(H,22,26) GBGQNQNKKZDOSN-UHFFFAOYSA-N 298204 US10118930, Example 406::N-(cyclopropyl- methyl)-2- methyl-5-oxo- 7-(piperidin-4-yl)- N-propyl-4,5- dihydropyrazolo [1,5-a]pyrimidine- 3-carboxamide hydrochloride Tissue-type plasminogen activator Human 37.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298204 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298204&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018751 381621035 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571260 Cc1nn2c(cc(=O)[nH]c2c1C(=O)NC(C)(C)C)C1CCNCC1 InChI=1S/C17H25N5O2/c1-10-14(16(24)20-17(2,3)4)15-19-13(23)9-12(22(15)21-10)11-5-7-18-8-6-11/h9,11,18H,5-8H2,1-4H3,(H,19,23)(H,20,24) KLCXXMUMQALLCG-UHFFFAOYSA-N 298205 US10118930, Example 407::N-tert-butyl-2- methyl-5-oxo- 7-(piperidin-4- yl)-4,5- dihydropyrazolo [1,5-a] pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298205 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298205&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018748 381621036 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571261 CC(C)C1CCCN(C1)C(=O)c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C21H31N5O2/c1-13(2)16-5-4-10-25(12-16)21(28)19-14(3)24-26-17(11-18(27)23-20(19)26)15-6-8-22-9-7-15/h11,13,15-16,22H,4-10,12H2,1-3H3,(H,23,27) SKUPDSKCGNRSKW-UHFFFAOYSA-N 298206 US10118930, Example 408::3-[(3- isopropyl- piperidin-1-yl) carbonyl]-2- methyl-7- (piperidin-4-yl) pyrazolo[1,5-a] pyrimidin-5(4H)- one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298206 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298206&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018752 381621037 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571262 Cc1nn2c(cc(=O)[nH]c2c1C(=O)N1CCCC2(CC2)C1)C1CCNCC1 InChI=1S/C20H27N5O2/c1-13-17(19(27)24-10-2-5-20(12-24)6-7-20)18-22-16(26)11-15(25(18)23-13)14-3-8-21-9-4-14/h11,14,21H,2-10,12H2,1H3,(H,22,26) CMSJDEUGDWBUCZ-UHFFFAOYSA-N 298207 US10118930, Example 409::3-(5-azaspiro [2.5]oct-5- ylcarbonyl)-2- methyl-7- (piperidin-4-yl) pyrazolo[1,5-a] pyrimidin-5(4H)- one hydrochloride Tissue-type plasminogen activator Human 46.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298207 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298207&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018753 381621038 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571263 Cc1nn2c(cc(=O)[nH]c2c1C(=O)N1Cc2ccccc2C1)C1CCNCC1 InChI=1S/C21H23N5O2/c1-13-19(21(28)25-11-15-4-2-3-5-16(15)12-25)20-23-18(27)10-17(26(20)24-13)14-6-8-22-9-7-14/h2-5,10,14,22H,6-9,11-12H2,1H3,(H,23,27) MMHGGGODTAMYDP-UHFFFAOYSA-N 298208 US10118930, Example 410::3-(1,3-dihydro- 2H-isoindol-2- ylcarbonyl)-2- methyl-7- (piperidin-4-yl) pyrazolo[1,5-a] pyrimidin-5(4H)- one hydrochloride Tissue-type plasminogen activator Human 45.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298208 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298208&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529903 381621039 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571264 Cc1nn2c(cc(=O)[nH]c2c1C(=O)N1CCN2CCCC2C1)C1CCNCC1 InChI=1S/C20H28N6O2/c1-13-18(20(28)25-10-9-24-8-2-3-15(24)12-25)19-22-17(27)11-16(26(19)23-13)14-4-6-21-7-5-14/h11,14-15,21H,2-10,12H2,1H3,(H,22,27) DHCOORNJISRCFN-UHFFFAOYSA-N 298209 US10118930, Example 411::3-(hexahydro- pyrrolo[1,2-a] pyrazin-2(1H)- ylcarbonyl)-2- methyl-7- (piperidin-4-yl) pyrazolo[1,5-a] pyrimidin-5(4H)- one hydrochloride Tissue-type plasminogen activator Human 540 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298209 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298209&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018463 381621040 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571265 Cc1nn2c(cc(=O)[nH]c2c1C(=O)N1CCc2ccccc12)C1CCNCC1 InChI=1S/C21H23N5O2/c1-13-19(21(28)25-11-8-14-4-2-3-5-16(14)25)20-23-18(27)12-17(26(20)24-13)15-6-9-22-10-7-15/h2-5,12,15,22H,6-11H2,1H3,(H,23,27) RVQPMAIQBALQOL-UHFFFAOYSA-N 298210 US10118930, Example 412::3-(2,3-dihydro- 1H-indol-1- ylcarbonyl)-2- methyl-7- (piperidin-4-yl) pyrazolo[1,5-a] pyrimidin-5(4H)- one hydrochloride Tissue-type plasminogen activator Human 33.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298210 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298210&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529904 381621041 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571266 Cc1nn2c(cc(=O)[nH]c2c1C(=O)N1CC2CCCCC2C1)C1CCNCC1 InChI=1S/C21H29N5O2/c1-13-19(21(28)25-11-15-4-2-3-5-16(15)12-25)20-23-18(27)10-17(26(20)24-13)14-6-8-22-9-7-14/h10,14-16,22H,2-9,11-12H2,1H3,(H,23,27) FKJFLNLVLIPJIG-UHFFFAOYSA-N 298211 US10118930, Example 413::2-methyl-3- (octahydro-2H- isoindol-2- ylcarbonyl)-7- (piperidin-4-yl) pyrazolo[1,5-a] pyrimidin-5(4H)- one hydrochloride Tissue-type plasminogen activator Human 35.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298211 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298211&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018465 381621042 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571267 Cc1nn2c(cc(=O)[nH]c2c1C(=O)N1CCc2ccccc2C1)C1CCNCC1 InChI=1S/C22H25N5O2/c1-14-20(22(29)26-11-8-15-4-2-3-5-17(15)13-26)21-24-19(28)12-18(27(21)25-14)16-6-9-23-10-7-16/h2-5,12,16,23H,6-11,13H2,1H3,(H,24,28) RVANXRDILDAEKX-UHFFFAOYSA-N 298212 US10118930, Example 414::3-(3,4-dihydro- isoquinolin-2(1H)- ylcarbonyl)-2- methyl-7- (piperidin-4-yl) pyrazolo[1,5-a] pyrimidin-5(4H)- one hydrochloride Tissue-type plasminogen activator Human 35.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298212 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298212&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529905 381621043 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571268 Cc1nn2c(cc(=O)[nH]c2c1C(=O)N1CCCC1)C1CCNCC1 InChI=1S/C17H23N5O2/c1-11-15(17(24)21-8-2-3-9-21)16-19-14(23)10-13(22(16)20-11)12-4-6-18-7-5-12/h10,12,18H,2-9H2,1H3,(H,19,23) UZGKYCHRYRPYJH-UHFFFAOYSA-N 298213 US10118930, Example 415::2-methyl-7- (piperidin-4-yl)- 3-(pyrrolidin-1- ylcarbonyl) pyrazolo[1,5-a] pyrimidin-5(4H)- one hydrochloride Tissue-type plasminogen activator Human 61.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298213 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298213&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018760 381621044 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571269 CC1CCN(CC1)C(=O)c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H27N5O2/c1-12-5-9-23(10-6-12)19(26)17-13(2)22-24-15(11-16(25)21-18(17)24)14-3-7-20-8-4-14/h11-12,14,20H,3-10H2,1-2H3,(H,21,25) XUPKSAMCAVOYOO-UHFFFAOYSA-N 298215 US10118930, Example 416::2-methyl-3- [(4-methyl- piperidin-1-yl) carbonyl]-7- (piperidin-4-yl) pyrazolo[1,5-a] pyrimidin-5(4H)- one hydrochloride Tissue-type plasminogen activator Human 31.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298215 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298215&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018762 381621046 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571270 Cc1nn2c(cc(=O)[nH]c2c1C(=O)NC1CCCC1)C1CCNCC1 InChI=1S/C18H25N5O2/c1-11-16(18(25)20-13-4-2-3-5-13)17-21-15(24)10-14(23(17)22-11)12-6-8-19-9-7-12/h10,12-13,19H,2-9H2,1H3,(H,20,25)(H,21,24) BAICKGLDORZQAE-UHFFFAOYSA-N 298216 US10118930, Example 417::N-cyclopentyl- 2-methyl-5- oxo-7- (piperidin-4-yl)- 4,5-dihydro- pyrazolo[1,5-a] pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 24.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298216 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298216&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018758 381621047 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571271 CC(C)CNC(=O)c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H25N5O2/c1-10(2)9-19-17(24)15-11(3)21-22-13(8-14(23)20-16(15)22)12-4-6-18-7-5-12/h8,10,12,18H,4-7,9H2,1-3H3,(H,19,24)(H,20,23) HLBKQAMGXHBBIZ-UHFFFAOYSA-N 298217 US10118930, Example 418::N-isobutyl-2- methyl-5-oxo-7- (piperidin-4-yl)- 4,5-dihydro- pyrazolo[1,5-a] pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 31.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298217 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298217&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018759 381621048 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571272 CC1CN(CC(C)O1)C(=O)c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H27N5O3/c1-11-9-23(10-12(2)27-11)19(26)17-13(3)22-24-15(8-16(25)21-18(17)24)14-4-6-20-7-5-14/h8,11-12,14,20H,4-7,9-10H2,1-3H3,(H,21,25) VKSUVKQGZZHEMZ-UHFFFAOYSA-N 298218 US10118930, Example 419::3-[(2,6- dimethyl- morpholin-4-yl) carbonyl]-2- methyl-7- (piperidin-4-yl) pyrazolo[1,5-a] pyrimidin-5(4H)- one hydrochloride Tissue-type plasminogen activator Human 35.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298218 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298218&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018361 381621049 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571273 Cc1nn2c(cc(=O)[nH]c2c1C(=O)N1CCCC(C)(C)C1)C1CCNCC1 InChI=1S/C20H29N5O2/c1-13-17(19(27)24-10-4-7-20(2,3)12-24)18-22-16(26)11-15(25(18)23-13)14-5-8-21-9-6-14/h11,14,21H,4-10,12H2,1-3H3,(H,22,26) AVYFSNLPBQPERV-UHFFFAOYSA-N 298219 US10118930, Example 420::3-[(3,3- dimethyl- piperidin-1-yl) carbonyl]-2- methyl-7- (piperidin-4-yl) pyrazolo[1,5-a] pyrimidin-5(4H)- one hydrochloride Tissue-type plasminogen activator Human 47.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298219 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298219&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018362 381621050 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571274 CC1CC(C)CN(C1)C(=O)c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H29N5O2/c1-12-8-13(2)11-24(10-12)20(27)18-14(3)23-25-16(9-17(26)22-19(18)25)15-4-6-21-7-5-15/h9,12-13,15,21H,4-8,10-11H2,1-3H3,(H,22,26) XKZFJMVEXNXDTP-UHFFFAOYSA-N 298220 US10118930, Example 421::3-[(3,5- dimethyl- piperidin-1-yl) carbonyl]-2- methyl-7- (piperidin-4-yl) pyrazolo[1,5-a] pyrimidin-5(4H)- one hydrochloride Tissue-type plasminogen activator Human 30.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298220 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298220&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018363 381621051 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571275 Cc1nn2c(cc(=O)[nH]c2c1C(=O)NC1CCC1)C1CCNCC1 InChI=1S/C17H23N5O2/c1-10-15(17(24)19-12-3-2-4-12)16-20-14(23)9-13(22(16)21-10)11-5-7-18-8-6-11/h9,11-12,18H,2-8H2,1H3,(H,19,24)(H,20,23) GWHVFANZUJOUFF-UHFFFAOYSA-N 298221 US10118930, Example 422::N-cyclobutyl- 2-methyl-5- oxo-7- (piperidin-4-yl)- 4,5-dihydro- pyrazolo[1,5-a] pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 23.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298221 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298221&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018364 381621052 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571276 CCN(Cc1ccccc1)C(=O)c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C22H27N5O2/c1-3-26(14-16-7-5-4-6-8-16)22(29)20-15(2)25-27-18(13-19(28)24-21(20)27)17-9-11-23-12-10-17/h4-8,13,17,23H,3,9-12,14H2,1-2H3,(H,24,28) QQADOUQMMMYTPW-UHFFFAOYSA-N 298222 US10118930, Example 423::N-benzyl-N- ethyl-2-methyl- 5-oxo-7- (piperidin-4-yl)- 4,5-dihydro- pyrazolo[1,5-a] pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 33.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298222 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298222&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529906 381621053 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571277 CCN(C)C(=O)c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C16H23N5O2/c1-4-20(3)16(23)14-10(2)19-21-12(9-13(22)18-15(14)21)11-5-7-17-8-6-11/h9,11,17H,4-8H2,1-3H3,(H,18,22) HMZQHZHMFJWOJM-UHFFFAOYSA-N 298223 US10118930, Example 424::N-ethyl-N,2- dimethyl- 5-oxo-7- (piperidin-4-yl)- 4,5-dihydro- pyrazolo[1,5-a] pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 78.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298223 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298223&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018621 381621054 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571278 CN(CC1CC1)C(=O)c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C18H25N5O2/c1-11-16(18(25)22(2)10-12-3-4-12)17-20-15(24)9-14(23(17)21-11)13-5-7-19-8-6-13/h9,12-13,19H,3-8,10H2,1-2H3,(H,20,24) IATDPUZYDDXYQF-UHFFFAOYSA-N 298224 US10118930, Example 425::N-(cyclopropyl- methyl)-N,2- dimethyl- 5-oxo-7- (piperidin-4-yl)- 4,5-dihydro- pyrazolo[1,5-a] pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 37.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298224 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298224&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018622 381621055 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571279 Cc1nn2c(cc(=O)[nH]c2c1C(=O)N1CCOC(C)(C)C1)C1CCNCC1 InChI=1S/C19H27N5O3/c1-12-16(18(26)23-8-9-27-19(2,3)11-23)17-21-15(25)10-14(24(17)22-12)13-4-6-20-7-5-13/h10,13,20H,4-9,11H2,1-3H3,(H,21,25) AYPCLFKKVMSDHO-UHFFFAOYSA-N 298225 US10118930, Example 426::3-[(2,2- dimethyl- morpholin-4-yl) carbonyl]-2- methyl-7- (piperidin-4-yl) pyrazolo[1,5-a] pyrimidin- 5(4H)-one hydrochloride Tissue-type plasminogen activator Human 56.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298225 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298225&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018624 381621056 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571280 Cc1nn2c(cc(=O)[nH]c2c1C(=O)N1CCOCC1(C)C)C1CCNCC1 InChI=1S/C19H27N5O3/c1-12-16(18(26)23-8-9-27-11-19(23,2)3)17-21-15(25)10-14(24(17)22-12)13-4-6-20-7-5-13/h10,13,20H,4-9,11H2,1-3H3,(H,21,25) FEVDMGJEHOQSHQ-UHFFFAOYSA-N 298226 US10118930, Example 427::3-[(3,3- dimethyl- morpholin-4-yl) carbonyl]-2- methyl-7- (piperidin-4-yl) pyrazolo[1,5-a] pyrimidin- 5(4H)-one hydrochloride Tissue-type plasminogen activator Human 23.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298226 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298226&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018586 381621057 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571281 CN(Cc1ccccn1)C(=O)c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C20H24N6O2/c1-13-18(20(28)25(2)12-15-5-3-4-8-22-15)19-23-17(27)11-16(26(19)24-13)14-6-9-21-10-7-14/h3-5,8,11,14,21H,6-7,9-10,12H2,1-2H3,(H,23,27) KQBLDUAUJPTYDV-UHFFFAOYSA-N 298227 US10118930, Example 428::N,2-dimethyl- 5-oxo-7- (piperidin-4-yl)- N-(pyridin-2- ylmethyl)-4,5- dihydro- pyrazolo[1,5-a] pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 29.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298227 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298227&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529907 381621058 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571282 Cc1nn2c(cc(=O)[nH]c2c1C(=O)N1CCC(F)(F)C1)C1CCNCC1 InChI=1S/C17H21F2N5O2/c1-10-14(16(26)23-7-4-17(18,19)9-23)15-21-13(25)8-12(24(15)22-10)11-2-5-20-6-3-11/h8,11,20H,2-7,9H2,1H3,(H,21,25) UKTQWECUJLYVRZ-UHFFFAOYSA-N 298228 US10118930, Example 429::3-[(3,3- difluoro- pyrrolidin-1-yl) carbonyl]-2- methyl-7- (piperidin-4-yl) pyrazolo[1,5-a] pyrimidin- 5(4H)-one hydrochloride Tissue-type plasminogen activator Human 30.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298228 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298228&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018588 381621059 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571283 Cc1nn2c(cc(=O)[nH]c2c1C(=O)N1CCNC(=O)CC1)C1CCNCC1 InChI=1S/C18H24N6O3/c1-11-16(18(27)23-8-4-14(25)20-7-9-23)17-21-15(26)10-13(24(17)22-11)12-2-5-19-6-3-12/h10,12,19H,2-9H2,1H3,(H,20,25)(H,21,26) BCOHZAOKXIAUBA-UHFFFAOYSA-N 298230 US10118930, Example 430::2-methyl-3- [(5-oxo-1,4- diazepan-1-yl) carbonyl]-7- (piperidin-4-yl) pyrazolo[1,5-a] pyrimidin- 5(4H)-one hydrochloride Tissue-type plasminogen activator Human 120 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298230 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298230&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018589 381621061 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571284 CN(C(=O)c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1)c1ccccc1C InChI=1S/C21H25N5O2/c1-13-6-4-5-7-16(13)25(3)21(28)19-14(2)24-26-17(12-18(27)23-20(19)26)15-8-10-22-11-9-15/h4-7,12,15,22H,8-11H2,1-3H3,(H,23,27) KAXIQHQNIDKKOA-UHFFFAOYSA-N 298231 US10118930, Example 431::N,2-dimethyl- N-(2-methyl- phenyl)-5- oxo-7- (piperidin-4-yl)- 4,5-dihydro- pyrazolo[1,5-a] pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 28.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298231 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298231&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529909 381621062 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571285 CCCN(CC)C(=O)c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C18H27N5O2/c1-4-10-22(5-2)18(25)16-12(3)21-23-14(11-15(24)20-17(16)23)13-6-8-19-9-7-13/h11,13,19H,4-10H2,1-3H3,(H,20,24) OLOGFXMXWNZBSJ-UHFFFAOYSA-N 298232 US10118930, Example 432::N-ethyl-2- methyl-5- oxo-7- (piperidin-4-yl)- N-propyl-4,5- dihydro- pyrazolo[1,5-a] pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 120 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298232 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298232&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018384 381621063 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571286 CN(Cc1ccccc1C)C(=O)c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C22H27N5O2/c1-14-6-4-5-7-17(14)13-26(3)22(29)20-15(2)25-27-18(12-19(28)24-21(20)27)16-8-10-23-11-9-16/h4-7,12,16,23H,8-11,13H2,1-3H3,(H,24,28) HDFXWPDZUBVVHW-UHFFFAOYSA-N 298233 US10118930, Example 433::N,2-dimethyl- N-(2-methyl- benzyl)-5- oxo-7- (piperidin-4-yl)- 4,5-dihydro- pyrazolo[1,5-a] pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 31.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298233 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298233&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529910 381621064 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571287 Cc1nn2c(cc(=O)[nH]c2c1C(=O)N1CCC(C)(C)CC1)C1CCNCC1 InChI=1S/C20H29N5O2/c1-13-17(19(27)24-10-6-20(2,3)7-11-24)18-22-16(26)12-15(25(18)23-13)14-4-8-21-9-5-14/h12,14,21H,4-11H2,1-3H3,(H,22,26) ZCYGPLZRHAGLQO-UHFFFAOYSA-N 298234 US10118930, Example 434::3-[(4,4- dimethyl- piperidin-1-yl) carbonyl]-2- methyl-7- (piperidin-4-yl) pyrazolo[1,5-a] pyrimidin- 5(4H)-one hydrochloride Tissue-type plasminogen activator Human 32.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298234 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298234&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018387 381621065 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571288 CN(C1CCCC1)C(=O)c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H27N5O2/c1-12-17(19(26)23(2)14-5-3-4-6-14)18-21-16(25)11-15(24(18)22-12)13-7-9-20-10-8-13/h11,13-14,20H,3-10H2,1-2H3,(H,21,25) MMQPCAPKJRIKOT-UHFFFAOYSA-N 298235 US10118930, Example 435::N-cyclopentyl- N,2-dimethyl- 5-oxo-7- (piperidin-4-yl)- 4,5-dihydro- pyrazolo[1,5-a] pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 42.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298235 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298235&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018684 381621066 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571289 CN(Cc1ccccc1)C(=O)c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C21H25N5O2/c1-14-19(21(28)25(2)13-15-6-4-3-5-7-15)20-23-18(27)12-17(26(20)24-14)16-8-10-22-11-9-16/h3-7,12,16,22H,8-11,13H2,1-2H3,(H,23,27) OXMNQDDAIATZIY-UHFFFAOYSA-N 298236 US10118930, Example 436::N-benzyl-N,2- dimethyl- 5-oxo-7- (piperidin-4-yl)- 4,5-dihydro- pyrazolo[1,5-a] pyrimidine-3- carboxamide hydrochloride Tissue-type plasminogen activator Human 39.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298236 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298236&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529911 381621067 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571290 COc1ccccc1-c1noc(n1)-c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C21H22N6O3/c1-12-18(21-24-19(26-30-21)14-5-3-4-6-16(14)29-2)20-23-17(28)11-15(27(20)25-12)13-7-9-22-10-8-13/h3-6,11,13,22H,7-10H2,1-2H3,(H,23,28) RSJFJIPQLYPDLS-UHFFFAOYSA-N 298237 US10118930, Example 437::3-[3-(2-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-2-methyl-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 10.00 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298237 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298237&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529912 381621068 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571291 Cc1nn2c(cc(=O)[nH]c2c1-c1nc(no1)-c1ccccc1F)C1CCNCC1 InChI=1S/C20H19FN6O2/c1-11-17(20-24-18(26-29-20)13-4-2-3-5-14(13)21)19-23-16(28)10-15(27(19)25-11)12-6-8-22-9-7-12/h2-5,10,12,22H,6-9H2,1H3,(H,23,28) DBIITXFEPSAGDP-UHFFFAOYSA-N 298238 US10118930, Example 438::3-[3-(2-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-methyl-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 12.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298238 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298238&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529913 381621069 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571292 Cc1nn2c(cc(=O)[nH]c2c1-c1nc(Cc2ccccc2Cl)no1)C1CCNCC1 InChI=1S/C21H21ClN6O2/c1-12-19(21-24-17(27-30-21)10-14-4-2-3-5-15(14)22)20-25-18(29)11-16(28(20)26-12)13-6-8-23-9-7-13/h2-5,11,13,23H,6-10H2,1H3,(H,25,29) WINUCURUYDLAOM-UHFFFAOYSA-N 298239 US10118930, Example 439::3-[3-(2-chlorobenzyl)-1,2,4-oxadiazol-5-yl]-2-methyl-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 26.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298239 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298239&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529914 381621070 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571293 Cc1nn2c(cc(=O)[nH]c2c1-c1nc(no1)-c1ccccc1C)C1CCNCC1 InChI=1S/C21H22N6O2/c1-12-5-3-4-6-15(12)19-24-21(29-26-19)18-13(2)25-27-16(11-17(28)23-20(18)27)14-7-9-22-10-8-14/h3-6,11,14,22H,7-10H2,1-2H3,(H,23,28) USBJNCQUCVBWDH-UHFFFAOYSA-N 298240 US10118930, Example 440::2-methyl-3-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 23.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298240 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298240&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529915 381621071 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571294 Cc1nn2c(cc(=O)[nH]c2c1-c1nc(no1)-c1cccc(Cl)c1)C1CCNCC1 InChI=1S/C20H19ClN6O2/c1-11-17(20-24-18(26-29-20)13-3-2-4-14(21)9-13)19-23-16(28)10-15(27(19)25-11)12-5-7-22-8-6-12/h2-4,9-10,12,22H,5-8H2,1H3,(H,23,28) WXIKAPKWQIBVEM-UHFFFAOYSA-N 298241 US10118930, Example 441::3-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]-2-methyl-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 29.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298241 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298241&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529916 381621072 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571295 Cc1nn2c(cc(=O)[nH]c2c1-c1nc(no1)-c1ccc(cc1)C(F)(F)F)C1CCNCC1 InChI=1S/C21H19F3N6O2/c1-11-17(19-26-16(31)10-15(30(19)28-11)12-6-8-25-9-7-12)20-27-18(29-32-20)13-2-4-14(5-3-13)21(22,23)24/h2-5,10,12,25H,6-9H2,1H3,(H,26,31) YMZSQCYTDSACBD-UHFFFAOYSA-N 298242 US10118930, Example 442::2-methyl-7-(piperidin-4-yl)-3-{3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 27.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298242 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298242&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529917 381621073 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571296 CC(C)Cc1sc(nc1C)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C19H25N5OS/c1-11(2)8-16-12(3)22-19(26-16)14-10-21-24-15(9-17(25)23-18(14)24)13-4-6-20-7-5-13/h9-11,13,20H,4-8H2,1-3H3,(H,23,25) ZQBDBJSJBKHEKS-UHFFFAOYSA-N 298243 US10118930, Example 443::3-[4-methyl-5-(2-methylpropyl)-1,3-thiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 23.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298243 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298243&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018697 381621074 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571297 COc1c(F)cc(Cc2nnc(o2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)cc1F InChI=1S/C21H20F2N6O3/c1-31-19-14(22)6-11(7-15(19)23)8-18-27-28-21(32-18)13-10-25-29-16(9-17(30)26-20(13)29)12-2-4-24-5-3-12/h6-7,9-10,12,24H,2-5,8H2,1H3,(H,26,30) FTZCLWYYHMQNCU-UHFFFAOYSA-N 298244 US10118930, Example 444::3-[5-(3,5-difluoro-4-methoxybenzyl)-1,3,4-oxadiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 17.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298244 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298244&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529918 381621075 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571298 Cc1nn2c(cc(=O)[nH]c2c1-c1nnc(o1)-c1ccccc1F)C1CCNCC1 InChI=1S/C20H19FN6O2/c1-11-17(20-25-24-19(29-20)13-4-2-3-5-14(13)21)18-23-16(28)10-15(27(18)26-11)12-6-8-22-9-7-12/h2-5,10,12,22H,6-9H2,1H3,(H,23,28) IGDAOCZTFYZASP-UHFFFAOYSA-N 298245 US10118930, Example 445::3-[5-(2-fluorophenyl)-1,3,4-oxadiazol-2-yl]-2-methyl-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 56.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298245 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298245&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529919 381621076 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571299 Cc1nn2c(cc(=O)[nH]c2c1-c1nc(Cc2ccc(O)cc2)no1)C1CCNCC1 InChI=1S/C21H22N6O3/c1-12-19(21-23-17(26-30-21)10-13-2-4-15(28)5-3-13)20-24-18(29)11-16(27(20)25-12)14-6-8-22-9-7-14/h2-5,11,14,22,28H,6-10H2,1H3,(H,24,29) AYIHHIXWWFKKSO-UHFFFAOYSA-N 298246 US10118930, Example 446::3-[3-(4-hydroxybenzyl)-1,2,4-oxadiazol-5-yl]-2-methyl-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 10.00 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298246 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298246&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529920 381621077 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571300 COc1ccc(Cc2nnc(o2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)cc1F InChI=1S/C21H21FN6O3/c1-30-17-3-2-12(8-15(17)22)9-19-26-27-21(31-19)14-11-24-28-16(10-18(29)25-20(14)28)13-4-6-23-7-5-13/h2-3,8,10-11,13,23H,4-7,9H2,1H3,(H,25,29) FCORDQOPJFOUQN-UHFFFAOYSA-N 298247 US10118930, Example 447::3-[5-(3-fluoro-4-methoxybenzyl)-1,3,4-oxadiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 14.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298247 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298247&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529921 381621078 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571301 Cc1ccccc1-c1csc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C21H21N5OS/c1-13-4-2-3-5-15(13)17-12-28-21(24-17)16-11-23-26-18(10-19(27)25-20(16)26)14-6-8-22-9-7-14/h2-5,10-12,14,22H,6-9H2,1H3,(H,25,27) PVFFPOQOEANRPV-UHFFFAOYSA-N 298062 US10118930, Example 448::3-[4-(2-methylphenyl)-1,3-thiazol-2-yl]-7-(piperidin-4-yl)pyrazolo[1,5-c]pyrimidin-5(4H)-one hydrochloride::US10118930, Example 273 Tissue-type plasminogen activator Human 30.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298062 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298062&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529866 381620894 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571302 CC(=C)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C14H18N4O/c1-9(2)11-8-16-18-12(7-13(19)17-14(11)18)10-3-5-15-6-4-10/h7-8,10,15H,1,3-6H2,2H3,(H,17,19) VCMGWBJFLUHCAZ-UHFFFAOYSA-N 298251 US10118930, Example 449::7-(piperidin-4-yl)-3-(prop-1-en-2-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 55.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298251 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298251&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018714 381621081 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571303 Cc1sc(nc1-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1)-c1ccccc1 InChI=1S/C21H21N5OS/c1-13-19(25-21(28-13)15-5-3-2-4-6-15)16-12-23-26-17(11-18(27)24-20(16)26)14-7-9-22-10-8-14/h2-6,11-12,14,22H,7-10H2,1H3,(H,24,27) GCLOMXHZKTXOCO-UHFFFAOYSA-N 298252 US10118930, Example 450::3-(5-methyl-2-phenyl-1,3-thiazol-4-yl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 360 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298252 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298252&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137529923 381621082 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571304 O=C(C1CCCC1)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C17H22N4O2/c22-15-9-14(11-5-7-18-8-6-11)21-17(20-15)13(10-19-21)16(23)12-3-1-2-4-12/h9-12,18H,1-8H2,(H,20,22) WITRIFQIQNHSLW-UHFFFAOYSA-N 298253 US10118930, Example 451::3-(cyclopentylcarbonyl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 11.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298253 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298253&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018713 381621083 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571305 CCC(C)C(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C16H22N4O2/c1-3-10(2)15(22)12-9-18-20-13(8-14(21)19-16(12)20)11-4-6-17-7-5-11/h8-11,17H,3-7H2,1-2H3,(H,19,21) YGPBFOIHDMNOGN-UHFFFAOYSA-N 298254 US10118930, Example 452::3-(2-methylbutanoyl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 8.00 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298254 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298254&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018609 381621084 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571306 O=C(C1CC1)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C15H18N4O2/c20-13-7-12(9-3-5-16-6-4-9)19-15(18-13)11(8-17-19)14(21)10-1-2-10/h7-10,16H,1-6H2,(H,18,20) CCIASDKSHIIWPW-UHFFFAOYSA-N 298255 US10118930, Example 453::3-(cyclopropylcarbonyl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 8.00 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298255 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298255&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018757 381621085 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571307 COC(=O)c1c(nn2c(cc(=O)[nH]c12)C1CCNCC1)C(F)(F)F InChI=1S/C14H15F3N4O3/c1-24-13(23)10-11(14(15,16)17)20-21-8(6-9(22)19-12(10)21)7-2-4-18-5-3-7/h6-7,18H,2-5H2,1H3,(H,19,22) LYUYSIFYJPTUDJ-UHFFFAOYSA-N 298257 US10118930, Example 454::Methyl 5-oxo-7-(piperidin-4-yl)-2-(trifluoromethyl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298257 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298257&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018702 381621087 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571308 CCOC(=O)c1c(SC)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C15H20N4O3S/c1-3-22-15(21)12-13-17-11(20)8-10(9-4-6-16-7-5-9)19(13)18-14(12)23-2/h8-9,16H,3-7H2,1-2H3,(H,17,20) YUBFXGQKAZHZBN-UHFFFAOYSA-N 298258 US10118930, Example 455::Ethyl 2-(methylsulfanyl)-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate hydrochloride Tissue-type plasminogen activator Human 36.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298258 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298258&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018484 381621088 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571309 CC(C)(C)C(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C16H22N4O2/c1-16(2,3)14(22)11-9-18-20-12(8-13(21)19-15(11)20)10-4-6-17-7-5-10/h8-10,17H,4-7H2,1-3H3,(H,19,21) CZYYJUQSYRDVRT-UHFFFAOYSA-N 298259 US10118930, Example 456::3-(2,2-dimethylpropanoyl)-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5(4H)-one hydrochloride Tissue-type plasminogen activator Human 39.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298259 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298259&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018611 381621089 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571310 OC(=O)c1c(nn2c(cc(=O)[nH]c12)C1CCNCC1)C(F)(F)F InChI=1S/C13H13F3N4O3/c14-13(15,16)10-9(12(22)23)11-18-8(21)5-7(20(11)19-10)6-1-3-17-4-2-6/h5-6,17H,1-4H2,(H,18,21)(H,22,23) ARUSINHYQRYCHI-UHFFFAOYSA-N 298260 US10118930, Example 457::5-oxo-7-(piperidin-4-yl)-2-(trifluoromethyl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylic acid hydrochloride Tissue-type plasminogen activator Human 85.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298260 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298260&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018477 381621090 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571311 CCOC(=O)c1c(nn2c(cc(=O)[nH]c12)C1CCNCC1)C(F)(F)F InChI=1S/C15H17F3N4O3/c1-2-25-14(24)11-12(15(16,17)18)21-22-9(7-10(23)20-13(11)22)8-3-5-19-6-4-8/h7-8,19H,2-6H2,1H3,(H,20,23) LFEWXEPTGJGWLF-UHFFFAOYSA-N 298261 US10118930, Example 458::Ethyl 5-oxo-7-(piperidin-4-yl)-2-(trifluoromethyl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate hydrochloride Tissue-type plasminogen activator Human 130 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298261 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298261&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018404 381621091 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571312 CCCOC(=O)c1c(nn2c(cc(=O)[nH]c12)C1CCNCC1)C(F)(F)F InChI=1S/C16H19F3N4O3/c1-2-7-26-15(25)12-13(16(17,18)19)22-23-10(8-11(24)21-14(12)23)9-3-5-20-6-4-9/h8-9,20H,2-7H2,1H3,(H,21,24) KXSVKSAPBNJIQR-UHFFFAOYSA-N 298262 US10118930, Example 459::Propyl 5-oxo-7-(piperidin-4-yl)-2-(trifluoromethyl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate hydrochloride Tissue-type plasminogen activator Human 83.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298262 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298262&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018703 381621092 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571313 CC(C)OC(=O)c1c(nn2c(cc(=O)[nH]c12)C1CCNCC1)C(F)(F)F InChI=1S/C16H19F3N4O3/c1-8(2)26-15(25)12-13(16(17,18)19)22-23-10(7-11(24)21-14(12)23)9-3-5-20-6-4-9/h7-9,20H,3-6H2,1-2H3,(H,21,24) RSFSCEQPTAODIB-UHFFFAOYSA-N 298263 US10118930, Example 460::Propan-2-yl 5-oxo-7-(piperidin-4-yl)-2-(trifluoromethyl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate hydrochloride Tissue-type plasminogen activator Human 59.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298263 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298263&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137025689 381621093 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571314 Cc1nn2c(cc(=O)[nH]c2c1C(=O)OCC(C)(F)F)C1CCNCC1 InChI=1S/C16H20F2N4O3/c1-9-13(15(24)25-8-16(2,17)18)14-20-12(23)7-11(22(14)21-9)10-3-5-19-6-4-10/h7,10,19H,3-6,8H2,1-2H3,(H,20,23) WGNMMVPUZWDTLQ-UHFFFAOYSA-N 298264 US10118930, Example 461::2,2-difluoropropyl 2-methyl-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate hydrochloride Tissue-type plasminogen activator Human 61.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298264 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298264&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018487 381621094 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571315 CC1(C)CCN(C1)C(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C18H25N5O2/c1-18(2)5-8-22(11-18)17(25)13-10-20-23-14(9-15(24)21-16(13)23)12-3-6-19-7-4-12/h9-10,12,19H,3-8,11H2,1-2H3,(H,21,24) FCZPHFWUFMWQTQ-UHFFFAOYSA-N 298265 US10118930, Example 462::3-[(3,3-dimethylpyrrolidin-1-yl)carbonyl]-7-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidin-5 (4H)-one hydrochloride Tissue-type plasminogen activator Human 34.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298265 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298265&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018618 381621095 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571316 CC(F)(F)COC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C15H18F2N4O3/c1-15(16,17)8-24-14(23)10-7-19-21-11(6-12(22)20-13(10)21)9-2-4-18-5-3-9/h6-7,9,18H,2-5,8H2,1H3,(H,20,22) DQUIGOHPBKXUTF-UHFFFAOYSA-N 298266 US10118930, Example 463::2,2-difluoropropyl 5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate hydrochloride Tissue-type plasminogen activator Human 51.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298266 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298266&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018607 381621096 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571317 Cc1nn2c(cc(=O)[nH]c2c1C(=O)OCCCF)C1CCNCC1 InChI=1S/C16H21FN4O3/c1-10-14(16(23)24-8-2-5-17)15-19-13(22)9-12(21(15)20-10)11-3-6-18-7-4-11/h9,11,18H,2-8H2,1H3,(H,19,22) QBSKSPJTXZWVQK-UHFFFAOYSA-N 298267 US10118930, Example 464::3-fluoropropyl 2-methyl-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate hydrochloride Tissue-type plasminogen activator Human 130 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298267 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298267&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018756 381621097 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571318 Cc1nn2c(cc(=O)[nH]c2c1C(=O)OCC(F)F)C1CCNCC1 InChI=1S/C15H18F2N4O3/c1-8-13(15(23)24-7-11(16)17)14-19-12(22)6-10(21(14)20-8)9-2-4-18-5-3-9/h6,9,11,18H,2-5,7H2,1H3,(H,19,22) SQSFEGVHVCZZQS-UHFFFAOYSA-N 298268 US10118930, Example 465::2,2-difluoroethyl 2-methyl-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate hydrochloride Tissue-type plasminogen activator Human 40.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298268 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298268&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018619 381621098 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571319 Cc1nn2c(cc(=O)[nH]c2c1C(=O)OCCC(F)(F)F)C1CCNCC1 InChI=1S/C16H19F3N4O3/c1-9-13(15(25)26-7-4-16(17,18)19)14-21-12(24)8-11(23(14)22-9)10-2-5-20-6-3-10/h8,10,20H,2-7H2,1H3,(H,21,24) RESFUYYGDXVUNI-UHFFFAOYSA-N 298269 US10118930, Example 466::3,3,3-trifluoropropyl 2-methyl-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate hydrochloride Tissue-type plasminogen activator Human 85.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298269 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298269&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018636 381621099 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571320 CCCOC(=O)c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C16H22N4O3/c1-3-8-23-16(22)14-10(2)19-20-12(9-13(21)18-15(14)20)11-4-6-17-7-5-11/h9,11,17H,3-8H2,1-2H3,(H,18,21) SZTLNNGVIDCLSK-UHFFFAOYSA-N 298162 US10118930, Example 365::Propyl 2-methyl-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate hydrochloride::US10118930, Example 467 Tissue-type plasminogen activator Human 38.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298162 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298162&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018414 381620993 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571321 Cc1nn2c(cc(=O)[nH]c2c1C(=O)OC(C)(C)C)C1CCNCC1 InChI=1S/C17H24N4O3/c1-10-14(16(23)24-17(2,3)4)15-19-13(22)9-12(21(15)20-10)11-5-7-18-8-6-11/h9,11,18H,5-8H2,1-4H3,(H,19,22) DIJAKUDLFWWOHD-UHFFFAOYSA-N 298272 US10118930, Example 468::Tert-butyl 2-methyl-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate hydrochloride Tissue-type plasminogen activator Human 39.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298272 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298272&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018474 381621101 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571322 CSc1nn2c(cc(=O)[nH]c2c1C(O)=O)C1CCNCC1 InChI=1S/C13H16N4O3S/c1-21-12-10(13(19)20)11-15-9(18)6-8(17(11)16-12)7-2-4-14-5-3-7/h6-7,14H,2-5H2,1H3,(H,15,18)(H,19,20) UFARDYFNWMYGOT-UHFFFAOYSA-N 298273 US10118930, Example 469::2-(methylsulfanyl)-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylic acid hydrochloride Tissue-type plasminogen activator Human 160 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298273 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298273&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018715 381621102 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1 571323 CCCOC(=O)c1c(SC)nn2c(cc(=O)[nH]c12)C1CCNCC1 InChI=1S/C16H22N4O3S/c1-3-8-23-16(22)13-14-18-12(21)9-11(10-4-6-17-7-5-10)20(14)19-15(13)24-2/h9-10,17H,3-8H2,1-2H3,(H,18,21) YLCUCSSEIRMCBX-UHFFFAOYSA-N 298274 US10118930, Example 470::Propyl 2-(methylsulfanyl)-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate hydrochloride Tissue-type plasminogen activator Human 25.0 US Patent 10.7270/Q2QC05J5 aid1795999 US10118930 Ellermann, M; Valot, G; Cancho Grande, Y; Hasfeld, J; Kinzel, T; Kobberling, J; Beyer, K; Rohrig, S; Sperzel, M; Stampfus, J; Meyer, I; Kollnberger, M; Burkhardt, N; Schlemmer, K; Stegmann, C; Schuhmacher, J; Werner, M; Heiermann, J; Hengeveld, WJ 11/6/2018 3/11/2019 Bayer Pharma Aktiengesellschaft http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=298274 http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1517&target=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=298274&enzyme=Tissue-type+plasminogen+activator&column=ki&startPg=0&Increment=50&submit=Search 137018712 381621103 1 MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP 1BDA,1RTF,1A5H,1PK2,1TPK,1PML Tissue-type plasminogen activator TPA_HUMAN P00750 A8K022 B2R8E8 Q15103 Q503B0 Q6PJA5 Q7Z7N2 Q86YK8 Q9BU99 Q9BZW1